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Abstract 
 
Convulsive Status Epilepticus (CSE) is the most common medical neurological emergency in 
children. Prolonged seizures are associated with brain injury in both animal models and humans and 
there is concern about longer term outcomes. A qualitative difference between prolonged and 
shorter seizures is apparent, but information about the longer term prognosis of CSE remains scarce.  
Retrospective studies have linked the commonest form of childhood CSE, prolonged febrile 
seizures (PFS), and temporal lobe epilepsy due to mesial temporal sclerosis (TLE-MTS). This study 
aimed to prospectively follow a population-representative cohort of children following CSE and look 
for signs of evolving MTS or other brain injury. Magnetic resonance imaging (MRI) was used to 
visualise underlying brain abnormalities and identify early signs of injury. To investigate the 
longitudinal evolution of any injury, MRI investigations were repeated at 6 and 12 months post-CSE 
and the child’s clinical status monitored throughout. 
31.2% of children had an abnormal MRI scan post-CSE. Most of these abnormalities pre-dated 
the episode of CSE and no clinically significant abnormalities were found in children with PFS.   
Mean hippocampal volumes were only reduced in the group of children with symptomatic 
CSE; however 20-30% of all children showed loss of hippocampal volume during the year following 
CSE. This could represent a precursor to TLE-MTS.  
Further abnormalities were shown on diffusion tensor imaging in children with PFS. 
Hippocampal mean diffusivity did not show the usual age dependency and widespread reductions in 
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fractional anisotropy were seen across major white matter tracts. These reductions were apparent 
at 1 and 6 months post-PFS, but resolved by 1 year.  
These findings form important evidence that children with non-PFS CSE are also at risk of 
long-term hippocampal damage and that children with PFS appear to have extensive extra-
hippocampal abnormalities. These will be further explored in the body of this thesis. 
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Chapter 1: Background 
 
1.1 Epileptic Seizures 
 
 Epilepsy is a paroxysmal disorder characterised by spontaneous and recurrent epileptic 
seizures(1). A seizure consists of a discrete episode of abnormal neuronal discharge combined with 
the clinical manifestation of that discharge, usually a change in behaviour.  
It is the change in the electrical behaviour of the brain from normal background activity to 
epileptic discharges that has come to be the defining hallmark of an epileptic seizure.  The work on 
this thesis concentrates on status epilepticus, but prior to discussing CSE I will provide some 
background on the electrical aspects of seizures.  
1.1.1 The pathophysiology of a seizure 
 
 Normal neuronal activity as recorded on a typical scalp electroencephalogram (EEG) consists 
of asynchronous oscillations with a typical amplitude of around 10-100µV (Figure 1.1). The EEG 
measures the localised electrical potential at points on the surface of the scalp around each 
electrode. The aggregate signal received is thought to reflect the summated activity of large 
populations (105-107) of cortical neurons. Due to the complex nature of this activity it is difficult to 
separate out the relative contributions of different neuronal phenomena to the EEG signal, however 
experiments with simultaneous recording from scalp EEG and intracranial electrodes have shown 
that the best correlation is with the summation of multiple excitatory post-synaptic membrane 
potentials (EPSPs) across the dendritic spines of cortical neurons.  
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Figure 1-1: Normal EEG (eyes closed) 
 An EEG recorded during a seizure will show synchronised, rhythmic activity across a number 
of different electrodes (depending on seizure location and focality) as seen in Figure 1.2. This activity 
appears to be self-sustaining in the short term and capable of spreading from one brain region to 
another. Conceptually a seizure can be divided into three phases: initiation, propagation and 
termination(2).  
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Figure 1-2: EEG showing seizure activity 
1.1.2 Initiation 
 
 For a seizure to occur the activity in the brain must make a transition from the normal, low-
amplitude unsynchronised activity (Figure 1-1), to the synchronised, rhythmic discharge typical of a 
seizure (Figure 1-2)(3). The initial phase of this process is known as initiation.  
It is hypothesised that this initial transition usually takes place in a discrete, anatomically 
localised group of neurons(4). Burst-generating cells capable of high frequency discharges are 
thought to play an important role in this process. Pyramidal cells in the hippocampus and neocortex 
have been shown to be capable of this behaviour (5;6).  Localised excitation of these cells leads to 
rapid recruitment of a larger population of neurons, synchronisation of neuronal firing and the 
beginning of a self-sustaining cycle of increasing excitatory activity. 
Changes in the brain that make neurons more excitable tend to promote seizure initiation 
and changes that suppress brain activity inhibit it. These changes can be global, such as a global 
metabolic disturbance like hypocalcaemia; or local, such as a localised infarction or stroke. Genetic 
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mutations, especially those involving ion channels and structural brain abnormalities such as cortical 
dysplasias or areas of infarction are also known to lower the seizure threshold.  
1.1.3 Propagation 
 
Once a seizure has been initiated, the abnormal discharge needs to spread beyond the initial 
group of neurons to involve a wider area of the brain (should it fail to do this, it would not normally 
be classified as a clinical “seizure”). This is termed propagation and takes place along multiple 
routes, depending on the existing neuronal projections of the axons of the affected neurons. Focal 
seizures tend to involve predominantly local spread to adjacent brain regions(7), whereas it is 
thought that generalised seizures occur when sub-cortical structures are excited by the initial 
discharge(8) enabling the subsequent rapid recruitment of wide areas of cortex. As more brain 
structures are recruited, this causes the loss of consciousness associated with generalised seizures. 
1.1.4 Termination 
 
Thus far the seizure has been viewed in isolation: the abnormal burst of excitatory activity 
will tend to create more excitation in a self-sustaining loop.  However, this process is counter-
balanced by inhibitory mechanisms within the brain, which will act to try and terminate this activity. 
This termination step is considered to be the key to limiting seizure duration - with failure of 
termination being the basic cause of status epilepticus. 
 Normal activity in the brain is carefully balanced between excitation and inhibition.  In the 
adult brain the main excitatory neurotransmitter is glutamate and the main inhibitory 
neurotransmitter is γ-aminobutyric acid (GABA). GABA inhibits action potential generation by 
binding to specific GABAA receptors on the surface of neurons, opening a chloride specific ion 
channel and increasing the chloride conductance of the cell membrane. Under normal physiological 
conditions this has the effect of hyperpolarising the neuron and inhibiting the generation of new 
action potentials. While this is an important mechanism of action for many antiepileptic drugs, it 
does not appear to be involved in physiological seizure termination(9).  
 Rather it is thought a combination of other mechanisms is primarily responsible for seizure 
termination in the majority of seizures. It has long been known that ongoing seizure activity causes a 
rapid local decrease in tissue pH (10;11) and recently pH sensitive ion channels have been shown to 
play an important role in seizure termination in a transgenic mouse model (12). Other changes that 
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have been hypothesised to contribute to seizure termination include energy failure(13), hypoxia(14), 
and adenosine release(15). Failure of these mechanisms leads to status epilepticus; the emphasis of 
the work presented in this thesis.  
1.2 Convulsive Status Epilepticus 
  
 Status epilepticus is important as it is associated with mortality and important morbidity. 
Early observations suggested that longer seizure durations were associated with an increased risk of 
death: “A severe epileptic fit may kill the patient …. especially… if the disease extends into the 
second day” (Caelius Aurelianus, Morb chron.). Since then, numerous case studies have documented 
patients who are thought to have died from uncontrolled seizures (16-19). There are also other 
associations between extended seizure duration and adverse outcomes, such as brain injury and 
epilepsy, which will be discussed in more detail later.  
The phrase “status epilepticus” to refer to such prolonged, unremitting seizures was first 
coined in 1868(20). Conceived as the “maximum expression” of epilepsy(21), Status Epilepticus came 
to be defined any seizure as “persists for a sufficient length of time or is repeated frequently enough 
to produce a fixed or enduring condition”(22). Before this the term was generally held to be 
restricted to overt convulsive seizures - convulsive status epilepticus (CSE) - and while it was 
extended to include electrical seizures without overt convulsive activity - non-convulsive status 
epilepticus (NCSE)(20) - the majority of research and debate has focused around CSE as it is both 
easier to define and observe; and has a greater association with adverse outcomes. In keeping with 
this, this thesis will focus mostly on CSE.  
1.2.1 Definition  
 
 There have been many attempts to draw up a formal definition of CSE. Ultimately the 
definition used depends largely on the purpose to hand. The initial theoretical formulation of CSE as 
a seizure which will not terminate without outside intervention, while intellectually appealing, 
proves unwieldy in practice as there is no way to tell in a living organism when a seizure has crossed 
into this category. Most definitions therefore, use time based criteria to differentiate CSE from other 
seizures. The standard definition used for most scientific studies is a cut off of 30 minutes, based on 
ILAE guidelines(1). The reasoning behind this definition is that 30 minutes of seizure activity appears 
to be a cut-off in animal models, after which the risk of brain injury rises markedly(23).  
20 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
While 30 minutes is typically the definition used for epidemiological studies, there has been 
a recent move towards a shorter definition for clinical use(24). If the risk of brain injury and 
benzodiazepine resistance increase with seizure duration then it is desirable to initiate interventions 
to terminate the seizure as soon as it becomes clear it will not stop on its own. Analysis of seizure 
duration has shown that most afebrile seizures are short and self-terminating, with a mean duration 
of 3.1 minutes(25). However there exists a sub-population that has a much longer mean duration of 
over 30 minutes. Models constructed from this data show that those seizures which last longer than 
7 minutes are more likely to belong to this second group and become prolonged if intervention is 
not initiated(25). Recent analysis of children with febrile seizures reports a similar bi-modal 
distribution of durations(26). From a clinical point of view therefore, defining CSE as any seizure over 
10 minutes will help ensure timely initiation of treatment while minimising the risk of unnecessary 
treatment(27). 
Pragmatically then, there are two definitions in widespread use today,  30 minutes, in order 
to study the risk of brain injury and  10 minutes for the initiation of anti-convulsive medication. For 
the purposes of this thesis, the following definition of CSE will be used, unless otherwise stated: 
“A convulsive seizure, or series of seizures without recovery of consciousness in between, 
lasting in total longer than 30 minutes”  
1.2.2 Aetiology 
 
There are as many causes of CSE as there are of convulsive seizures. Typically CSE is spilt into 
several aetiological groupings, each with their own subset of causes. A definition of some of the 
aetiological groups that were used in this study to classify CSE is given in Table 1-1 below. 
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Aetiological group Definition Possible causes of CSE 
Prolonged Febrile Seizure 
CSE occurring in a previously 
neurologically normal child with 
no history of central nervous 
system infection and associated 
with a temperature > 38.0C 
Febrile Seizure 
Acute Symptomatic 
CSE occurring in a previously 
neurologically normal child with 
an acute neurological insult 
within the past 24 hours 
Bacterial meningitis 
Viral encephalitis 
Hypoglycaemia 
Hypocalcaemia 
Hypo/hypernatraemia 
Head injury 
Cerebrovascular accident (CVA) 
Remote Symptomatic 
CSE occurring in a child with a 
previously known neurological 
disorder occurring over 24 
hours previously. Also includes 
genetic causes for seizures. 
Cortical dysplasia 
Tuberous sclerosis 
SCN1a mutation 
Previous Hypoxic Ischaemic 
Encephalopathy 
Previous CVA or head injury 
Mesial Temporal Sclerosis 
Acute on Remote Symptomatic 
As above with an additional 
acute neurological insult in the 
past 24 hours. 
 
Idiopathic Epilepsy 
CSE in a child with idiopathic 
epilepsy and no other acute 
cause for the seizure 
Idiopathic epilepsy 
Cryptogenic Epilepsy 
CSE in a child with cryptogenic 
epilepsy and no other acute 
cause for the seizure 
Cryptogenic epilepsy 
Unclassified All other CSE  
Table 1-1: Aetiological classification of CSE (Adapted from Chin et al.(28))  
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1.2.3 Epidemiology 
 
CSE is one of the most common medical neurological emergencies. Epidemiological studies 
have shown that it has an incidence of 6.8-61/100,000 persons/year and a bi-modal distribution, 
with peaks at the two extremes of the age spectrum: in children under 1 year and in the elderly 
(29;30) (Figure 1-3).  
 
Figure 1-3: Age specific incidence of CSE (Adapted from Hesdorffer et al(30)) 
 
It is apparent that the main aetiologies and outcomes of CSE differ between children and 
adults and hence need to be considered separately. The findings of the main studies investigating 
the aetiology of CSE in children are summarised in table 1-2:  
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Due to methodological differences, and changes in classification systems, it is difficult to 
compare these studies directly. Overall an incidence of around 20-30/100,000 persons/year is 
reported, highest in children under 1 year and falling with age(33). There is also a low reported 
mortality rate, of the order of 1-3% (32;34). However the mixture of aetiologies appears to differ 
significantly between studies, which may represent a combination of the different approaches used 
to identify and classify cases of CSE, as well as true variability between the populations under study. 
In the two studies that reported it separately, the most common cause of CSE was prolonged febrile 
seizure (see table 1-1 for definitions), forming up to one third of cases. Many children who have an 
episode of CSE have underlying neurological abnormalities (remote/acute on remote symptomatic 
seizures) suggesting that CSE is more common in children with other neurological problems.  
  
1.2.4 Pathophysiology 
 
 As previously mentioned, CSE is viewed as a failure of seizure termination. This implies that 
the ongoing seizure activity itself is similar to other epileptic seizures and that it is the failure of the 
normal inhibitory mechanisms that differentiates CSE. As there are many possible causes for 
seizures, there is unlikely to be a common mechanism for this failure of inhibition that is applicable 
to all cases of CSE. However if, as is commonly believed, seizures represent a final common pathway 
for the expression of multiple underlying pathologies, then there may be expected to be similarities 
in the physiological and pathological changes occurring during and after CSE.  
Authors Year Number 
of 
children 
Incidence (per 
100,000 
children/yr) 
Prolonged 
febrile 
seizure 
Acute 
symptomatic 
Remote 
symptomatic 
Acute on 
remote 
Idiopathic/ 
Cryptogenic 
epilepsy/Other 
Chin et 
al.(28) 
2006 176 17-23 32% 17% 16% 16% 19% 
Coeytaux 
et al(31) 
2000 64 21 66% 25% - 9% 
Hesdorffer 
et al(30) 
1998 69 24 23% 46% 18% - 13% 
DeLorenzo 
et al.(29) 
1996 29 38 52% 39% - 5% 
Table 1-2: The epidemiology of childhood CSE (adapted from Raspall-Chaure et al(32)) 
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As a seizure progresses, changes occur in neuronal receptors and the neuronal environment 
that appear to contribute to the establishment of a fixed and recurrent state of seizure activity. One 
change that is known to occur is a reduction in the number and efficacy of GABAA receptors on 
neurones with increasing seizure duration (Figure 1-4) (35-37). This leads to a reduction in 
interneuronal activity, which is predominantly GABAA mediated and may contribute towards the 
failure of inhibition. Other changes which occur during a seizure include increased cerebral blood 
flow and neuronal energy consumption(38;39) leading to lactic acidosis(40), cerebral pH changes(10) 
and increased extracellular glutamate concentrations(41). Intractable seizures lasting hours to days 
have been shown to lead to brain oedema and death with atrophy and demonstrable cell loss visible 
at post mortem in numerous case studies in both adults and children(17;42-44). 
 
Figure 1-4: Changes during status epilepticus showing increased endocytosis of GABAA receptors resulting in lower 
membrane population and decreased inhibition 
Evidence of the deleterious effect of less severe CSE is scarcer; magnetic resonance imaging 
(MRI) studies looking at children in the first few days after an episode of CSE have shown changes 
suggestive of hippocampal swelling and oedema (45-47) implying that some degree of acute injury 
occurs with even with shorter CSE, however the majority of our knowledge comes from animal 
models.  
Initial work by Meldrum et al (39;48) showed that prolonged seizures in both baboons and 
rats were associated with neuronal loss and other evidence of brain damage following seizure 
induction by intracerebral injection of bicuculline. Similar findings have been found in other animal 
models of epilepsy (49-51), with cell loss and subsequent gliosis (52;53) being widely reported 
following the induction of CSE. It is thought that this damage is due to a combination of ischaemic 
damage from hypoxia during the seizure(54), followed by later glutamate-mediated excitotoxic 
damage(55). Seizure duration appears to be an important determinant of neuronal damage, with 
more severe and more extensive injury being reported with increasing seizure duration (23;56). 
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There is therefore strong evidence from animal models to suspect that CSE is harmful to brain tissue.
   
1.2.5 Treatment 
 
Although the mechanism generating CSE may differ between individuals, the acute 
treatment of CSE is fairly well established. Guidelines on the treatment of paediatric CSE are widely 
available in several countries(57-61) and, while they differ in some particulars depending on the 
local availability of medication, they uniformly place an emphasis on early treatment with 
anticonvulsive medication(62). Neuronal inhibition is the mainstay of treatment, with 
benzodiazepines being the generally accepted first line drug of choice. Since the risk of injury 
appears to be related to seizure duration(56), and the fact that as a seizure progresses, 
benzodiazepines become less effective(63), early and, if possible, pre-hospital treatment is 
important.  
 Second line treatment with non-benzodiazepine agents such as phenytoin, phenobarbitone 
or sodium valproate is recommended if two doses of benzodiazepines do not achieve seizure 
termination(64) due to the increased risk of respiratory depression and reduced efficacy of further 
doses, although it is recognised that the evidence-base to support particular second or third line 
treatments is poor(65;66). After the failure of two different medications then CSE can be considered 
to be “refractory”(67). Opinions vary as to whether the optimal treatment in this case is for the trial 
of a further conventional anti-epileptic treatment (68;69), or for anaesthetic treatment with 
continuous infusions of agents such as thiopental, propofol and midazolam (70;71). Regardless, it is 
recognised that treatment of such seizures is difficult and the use of general anaesthesia to obtain 
seizure control should be considered in a timely fashion(72).  
In the absence of any recognised neuroprotective agents suitable for use in humans, the 
treatment of CSE remains purely symptomatic. There are currently no recommendations for 
prophylactic or protective treatments besides what may be necessary to treat the underlying cause 
(73).  
1.2.6 Outcome 
 
A variety of adverse outcomes have been associated with CSE, including increases in short 
and long-term mortality, subsequent epilepsy and delayed neurodevelopment. However the 
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reported risks are highly variable between different studies and populations(34). The immediate and 
short term mortality of CSE in children has been shown to be low, with death predominantly caused 
by the underlying aetiology rather than the seizure(74). Almost all immediate deaths occur in 
children with significant symptomatic causes for their CSE, whether an acute neurological insult or a 
progressive neurological condition(75). Children with prolonged febrile seizures have been shown to 
have minimal mortality from their CSE(76).   
In adults it has been shown that the long term mortality rate of survivors of CSE is increased, 
with a cumulative 10 year-mortality of 43% (standardized mortality ratio 2.8)(77). However this 
appears to be predominantly due to increased mortality after symptomatic CSE, with the mortality 
rate after idiopathic/cryptogenic CSE or PFS not significantly different from the general population. 
Long term mortality for children with CSE is likewise increased, mainly as an effect of deaths in 
children with a symptomatic aetiology for their CSE, such as cerebral palsy or bacterial meningitis. By 
comparison, the mortality rate after idiopathic/cryptogenic CSE or PFS does not appear to be 
significantly different from the general population (78;79) 
While some studies have reported a possible effect of age(75;80) and seizure duration(81) 
on outcome, this is difficult to disentangle from the fact that children with more serious causes for 
their CSE may have longer seizures which are more difficult to control(82) and that younger children 
are more likely to have a serious acute symptomatic cause for their CSE(83). An additional factor 
may be improvements to medical treatment, with older studies, prior to the widespread 
introduction of aggressive treatment of CSE reporting longer seizure durations and poorer 
outcomes. 
Despite the lack of evidence for a specific effect of CSE itself on mortality, concerns remain 
that there may be significant associated brain injury attributable to the CSE itself. From a clinical 
context, there have been varying reports as to the long term risks of cognitive impairment, 
subsequent epilepsy or other neurological impairment following CSE(34). Partly this is due to the 
heterogeneous nature of the published literature and partly due to the difficulty of controlling for 
the influence of the underlying cause of the seizure.  
There is a 37% risk of further unprovoked seizures within the first 2 years following a first 
unprovoked seizure(84;85) and prolonged duration does not appear to significantly alter this(76;82). 
This is not necessarily the case in children with acute or remote symptomatic CSE however, who 
have a greater than 50% risk of further seizures and subsequent epilepsy (76;86;87). For children 
with a pre-existing diagnosis of epilepsy, the occurrence of CSE does not appear to significantly alter 
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the natural course of the disease, as seizure frequency following an episode of CSE has not been 
shown to increase(88).  Although an increased incidence of epilepsy in children with complex febrile 
convulsions has been reported (87;89;90), there is some controversy over these findings. A 
population-based study by Verity et al. found a significantly increased risk of further afebrile seizures 
in the group of children with febrile seizures over 30 min duration compared to those with shorter 
febrile seizures (21% vs. 3.4%)(87). Similarly a larger but earlier cohort study by Nelson et al. found 
an increased risk of 5.4%, but this did not attain statistical criteria for significance(91). In many 
studies, prolonged duration was only one of the possible criteria used to define complex febrile 
convulsions(89;90) and some multi-variable analyses have suggested that prolonged duration on its 
own is not associated with a higher risk of epilepsy(92;93). 
While there is evidence that neurodevelopment can be impaired following CSE (86;94), very 
few studies report data from formalised neurocognitive assessments (34;95). Verity et al(87) found 
cognitive impairment on the British Ability Scales in 10/37 children with CSE, however 8 of these had 
evidence of a neurological or developmental condition prior to CSE and one had suspected previous 
hypoxic-ischaemic injury at birth. Only one child had cognitive impairment following PFS. Further 
evidence of the relatively benign impact of PFS comes from a study by Ellenberg et al(96), who 
showed that children with PFS did not have an IQ deficit compared to sibling pairs. In contrast Kolfen 
et al.(97) found significant deficits in non-verbal IQ in children with PFS compared to both healthy 
controls and children with short febrile seizures and a recent report from Hesdorffer et al.(26) 
suggests that children with PFS may have a degree of motor impairment and delayed motor 
milestones, although overall cognitive scores remain intact.  
1.3 The Hippocampus 
1.3.1 Anatomical location 
 
 The hippocampus is an archicortical structure located within the 
temporal lobe, sitting in the wall of the lateral ventricle. One of the most 
topologically complex structures in the brain, it appears as a slightly 
curved, “seahorse” shaped structure (Figure 1-5), which can be divided 
into three anatomical components: the anterior head; the middle body; 
and the posterior tail. The head is the widest part, with a transverse 
diameter of 1-2cm in an adult, the hippocampus then narrows to around 
Tail 
Body 
Head 
Figure 1-5: Human 
hippocampus preparation 
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1cm in the body and tail.  
 
 Anteriorly, the head of the hippocampus projects into the lateral ventricle before curving 
back on itself medially to form the uncus. The anterior limit of the hippocampus can be difficult to 
accurately delineate, as it is bounded by a thin section of the lateral ventricle. Therefore, particularly 
in the medial portions, it can be difficult to accurately separate from the ambient gyrus and 
amygdala anteriorly. Laterally the head of the hippocampus is bordered by the temporal horn of the 
lateral ventricle and superiorly, by the amygdala, with the alveus separating the two. Medially the 
relations of the hippocampal head are complex. It is bounded by the ambient gyrus, the 
parahippocampal gyrus and cerebrospinal fluid in the transverse fissure. The inferior border is also 
made up of several structures, including the parahippocampal gyrus and the uncal sulcus. 
Moving posteriorly into the body of the hippocampus, here it takes up its classic oval 
appearance, with the lateral ventricle laterally and superiorly, parahippocampal gyrus and 
prosubiculum inferiorly, and transverse fissure medially. 
 Finally, the hippocampal tail begins to merge superiorly with the crus of the fornix. It 
continues to be bounded inferiorly by the parahippocampal gyrus. It forms part of the floor of the 
lateral ventricle and this forms the lateral border. Medially the border is the transverse fissure and 
posteriorly it merges with the subsplenial gyrus.   
1.3.2 Internal structure 
 
 The internal structure of the hippocampus 
consists of two, interlocking and interconnected 
structures named the Cornu Ammonis and the 
Gyrus Dentatus. The Cornu Ammonis is the more 
complex and consists of 6 cell layers (Figure 1-6). 
It can be divided into four subregions - CA1, 2, 3 
and 4, which are arranged around the radius of 
the hippocampus in coronal section (Figure 1-7). 
In the human CA1 is relatively large and contains 
an extensive pyramidal layer with triangular cell 
bodies. CA2 has a much smaller pyramidal layer, 
Figure 1-6: Hippocampal cell layers in the cornu 
ammonis 
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with rounder, more densely packed cells. The unique feature of CA3 is that it contains unmyelinated 
mossy fibres that project from the dentate gyrus and synapse onto pyramidal cells. CA4 sits within 
the dentate gyrus and contains relatively few, large pyramidal cells with myelinated mossy fibres 
projecting from the dentate gyrus. 
The Gyrus Dentatus, or dentate gyrus, curves around the end of CA4 and extends medially 
below the fimbria. It is a three layered structure made up mostly of granule cells (stratum 
granulosum), and their dendritic trees and axonal projections with few interneurons. Most axons 
project to CA3 and CA4 as mossy fibres. 
There are thought to be two main neuronal systems within the hippocampus: the perforant 
pathway, an evolutionarily older polysynaptic pathway running through all fields of the 
hippocampus; and the direct pathway, running from entorhinal cortex straight to CA1. 
The perforant pathway runs from layer 2 of the entorhinal cortex through the subiculum to 
synapse within the molecular layer of the dentate gyrus. These cells then project excitatory mossy 
fibres to pyramidal neurons in CA3 and CA4. Those neurons send axons into the alveus and fimbria, 
with back projections (Schaffer collaterals) to cells in CA1. From the alveus collaterals are sent to the 
subiculum and thence back into the alveus and fimbria, ultimately running back to the anterior 
thalamic nuclei. The direct pathway sends axons from layer 3 of entorhinal cortex directly to CA1 
Figure 1-7: Histology of normal hippocampus showing hippocampal subfields (LFB staining) 
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pyramidal neurons. These then project into the subiculum and synapse there onto neurons that 
project directly back to entorhinal cortex.  
1.3.3 From structure to function 
 
The functions of the hippocampus have been the subject of much research and discussion 
for over 50 years. A full enumeration of the field is beyond the scope of this thesis, so what follows 
will be confined to a brief overview. 
The earliest clinical evidence for the role of the hippocampus came from observational 
studies of patients with hippocampal lesions. Many patients (most famously H.M.) displayed 
profound short term memory loss and the inability to form new memories following surgical removal 
of both hippocampi(98). Further studies in humans with bilateral hippocampal damage have shown 
that in addition to this anterograde amnesia, a degree of retrograde memory loss, thought to be 
related to the extent of the associated extra-hippocampal damage can be found(99). A large body of 
data from both humans and animals, has now highlighted the important role of the hippocampus in 
the formation and retrieval of specific types of memory, including episodic memory(100), spatial 
learning (101) and contextual fear(102). Disruption of the hippocampus, whether temporary or 
permanent, impairs performance on many memory dependant tasks.  
In addition to memory, there is also a link between the hippocampus and emotional 
processing. The hippocampus occupies a prominent position in the limbic circuitry thought to control 
emotion and affect. Connections exist between the hippocampus and the hypothalamic-pituitary-
adrenal (HPA) axis that controls the stress response as well as other emotional processing areas such 
as the amygdala. Psychological disorders involving abnormalities of the stress response, such as 
post-traumatic stress disorder(103) (PTSD) and depression(104;105) have been linked to changes in 
hippocampal volume and altered hippocampal function. Furthermore, successful treatment of these 
conditions has been shown to reverse many of these changes suggesting that there is an intimate 
connection between the hippocampus and emotion. 
The hippocampus therefore is involved in at least two distinct brain functions. Differential 
gene expression and  differential connectivity between ventral and dorsal portions of the 
hippocampus may provide a basis for the segregation of these(106), but for practical purposes they 
remain closely linked, both anatomically and functionally for many activities.  
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1.3.4 Mesial Temporal Sclerosis 
 
 Of particular relevance to the study of epilepsy is a condition known as hippocampal 
sclerosis or mesial temporal sclerosis (MTS). This is an abnormality of the hippocampus that has a 
characteristic histological and radiological appearance. It is thought to be an acquired lesion, 
possibly linked to the result of epileptic seizures. Although it has occasionally been reported in 
people without clinical seizures(107;108), it is most frequently found in people with temporal lobe 
epilepsy (TLE) and is almost never found as an incidental finding in people having MRI scans for 
other reasons(109;110). It is generally considered, therefore, that MTS is a highly epileptogenic 
lesion and its occurrence likely to signify a very high risk of spontaneous seizures and TLE. 
The first description of MTS was made by Sommer in 1880(111). He noticed a common 
pattern of cell loss within the hippocampi of patients with epilepsy at post-mortem. There was a loss 
of neurons in CA1 and CA4 sub-fields with a relative sparing of the cells in CA2. These changes were 
at first thought to be restricted to the hippocampus, but it soon became clear that there was a 
spectrum of changes, ranging from very subtle cell loss in CA1 to widespread sclerosis involving 
amygdala, parahippocampal gyrus and temporal neocortex(112). Other histological features of MTS 
that have been recognised include gliosis of the end folium and dispersion of the granule cells in the 
dentate gyrus. An example of hippocampal sclerosis can be seen in Figure 1-8. 
 
Figure 1-8: Histological specimen showing hippocampal sclerosis (LFB staining) 
  
32 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
 With the advent of Magnetic Resonance Imaging (MRI), non-invasive visualisation of brain 
structures became possible. The atrophy and cell loss associated with MTS can be visualised with 
MRI as a loss of volume in the hippocampus (Figure 1-9A), as well as increased signal intensity on T2 
weighted scans (Figure 1-9B). Other techniques such as T2 relaxometry or hippocampal volumetry 
can also be used to increase sensitivity. Taken together, these defining features have been shown to 
correlate well with the eventual histological findings in patients who go on to have surgical removal 
of the affected hippocampus as well as predicting outcome (113;114). 
 
Figure 1-9: MRI appearance of Mesial Temporal Sclerosis 
Since hippocampal atrophy as shown on MRI is reliably detectable using an optimised 
scanning protocol(115), and this correlates very well with histological MTS, MRI has become the 
“gold-standard” method of pre-surgical diagnosis. This is usually done by visual inspection by a 
neuroradiologist, which has been shown to reliably detect a unilateral reduction in hippocampal 
volume of around 30%(116). Quantitative measurement of hippocampal volume may be preferred 
due to improved sensitivity where the atrophy is less than this, or if bilateral symmetrical atrophy is 
suspected(117).  
 
1.4 Temporal Lobe Epilepsy 
1.4.1 Overview 
 
 The clinical importance of MTS lies in its association with TLE. TLE is a form of epilepsy where 
the initial seizure focus is localised in one of the temporal lobes. Typically this presents with simple 
and complex partial seizures with and without secondary generalisation. The simple partial seizures 
often take the form of an aura, either sensory (classically olfactory or gustatory), psychic (such as 
déjà vu or jamais vu) or autonomic. This may then be followed by a complex partial seizure with 
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behavioural arrest, complex automatisms and post-ictal confusion. These seizures typically last 1-2 
minutes and may progress to a secondarily generalised tonic-clonic seizure(118).  TLE is arguably the 
most common single epilepsy syndrome and is often difficult to treat with medical management 
alone, with 70-80% eventually proving refractory to medical treatment (119). Chronic TLE also 
carries with it a recognised risk of cognitive impairment and psychological co-morbidity (120).  
1.4.2 Natural History 
 
 The natural history of TLE is little understood(121). Since the diagnosis is mostly made in 
patients with intractable epilepsy being considered for surgical treatment, the true incidence of TLE 
is in the general population is unknown, as patients whose epilepsy is well controlled or not thought 
suitable for surgery may never receive a definitive diagnosis. Studies of patients receiving surgical 
treatment for TLE show that there is usually a long delay before the first seizure and the referral for 
surgery(122). This may be because it can be difficult to recognise temporal seizures in younger 
children(123) or because there is often a good initial response to anti-epileptic medication, with the 
epilepsy only becoming intractable in later childhood or adolescence(124).  
 The commonest cause of TLE is MTS, accounting for around 65% of cases overall(125), 
although this may be slightly reduced for childhood-onset TLE, as a greater proportion of cases with 
extra-hippocampal temporal lobe lesions, such as cortical dysplasia or other developmental 
abnormalities are reported in some studies(126-128). As extra-hippocampal TLE is a heterogeneous 
group of conditions, with prognosis and outcome dependent on the aetiology of the lesion(129), this 
thesis will focus almost exclusively on TLE-MTS. 
It is difficult to accurately ascertain the age of onset of TLE-MTS, as most data is from 
retrospective, hospital-based case series, limiting the conclusions that can be drawn. It is possible 
that milder cases of TLE may not be diagnosed as such or may not be referred to tertiary centres, 
especially if they are following a benign course and hence hospital-based studies are likely to 
overestimate disease severity(130). Case series of patients referred for epilepsy surgery suggest that 
the mean age of onset of TLE-MTS in these patients is between 4-16 years(125). Studies of adult 
patients frequently report mean ages of onset of over 14 years(131;132), while those with a 
paediatric cohort usually report lower ages of onset of between 5-8 years(128;133;134). It has been 
suggested that TLE has multiple incidence peaks in childhood, adolescence and early 
adulthood(135), which may be one explanation for this discrepancy. 
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After onset of epilepsy the course of TLE-MTS is rarely smooth and often follows a relapsing 
and remitting course. Many children will have a good initial response to anti-epileptic medication 
(62% in a study by Dlugos et al.(136)), but subsequently seizures often become increasingly difficult 
to control. After 10 years of follow-up, Spooner et al. found 43/62 (69%) children with TLE continued 
to have seizures despite anti-epileptic medication with 21/62 (33%) progressing to epilepsy surgery 
(137). Despite this, many of the children who were later diagnosed with intractable seizures had had 
seizure-free periods of over 1 year during the course of their epilepsy. Similar findings were shown 
by Berg et al. in their study of 333 patients with intractable focal epilepsy (138): the median time to 
failure of the second anti-epileptic drug (and hence designation of intractability) for those patients 
with TLE-MTS was 8.0 years, and 51/178 (28.7%) had had seizure remissions of 1 year or more 
before they were seen for evaluation.  
Although medical treatment frequently fails, the surgical treatment of TLE-MTS enjoys one 
of the highest success rates out of all the epilepsies(139). In patients with an identified hippocampal 
abnormality, congruent with the electrographic seizure focus, there is around a 60-70% chance of 
seizure freedom following temporal lobectomy (140). The relatively high success rate combined with 
the frequent medical intractability mean that TLE-MTS is the type of epilepsy most frequently 
referred for surgical management. 
Along with difficulties with seizure control, there are also frequently reported co-morbidities 
in TLE. In their cohort of children with TLE, Spooner et al showed that there is a high rate of 
psychological co-morbidity in chronic TLE, with high rates of depression and anxiety disorders (141), 
although achieving seizure freedom appears to improve this. Cognitive impairment is also frequently 
reported, with memory and executive function being particularly affected in children(120) although 
an additional decrease in global IQ has been reported in adults(142). 
TLE is frequently linked with an unfavourable prognosis. Although the seizures can be 
treated successfully in the majority of cases, this often requires surgical intervention, which is not 
without its consequences (143). As MTS is the most common cause of TLE and has some of the 
characteristics of an acquired lesion, it is worthwhile probing this association further in order to 
determine if this is the case and identify possible strategies for its prevention. 
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1.5 Linking TLE, MTS and PFS 
 
The long-standing hypothesis proposing a causal link between TLE, MTS and PFS was first 
articulated by Sommer in 1880(111) but has yet to be definitively confirmed or refuted. That MTS 
can cause TLE is rarely disputed(144): MTS is the most common lesion found in TLE and, unless there 
is dual pathology, removal of the affected hippocampus and temporal lobe has a high chance of 
eliminating the seizures(113;114). Furthermore MTS is rarely found in people without seizures 
(110;145), suggesting that the presence of MTS can be used as a marker for TLE, even in the absence 
of reported clinical seizures. 
One of the first observations about patients having surgery for TLE-MTS was that a high 
proportion of them had prolonged febrile seizures in childhood(146). In some series up to 50% of 
patients with TLE-MTS were shown to have a history of PFS (147;148). The incidence of febrile 
convulsions in the general population is around 2-5%(149), of which up to 5% will be prolonged(89). 
There is therefore a strong association between PFS and TLE-MTS and has led to extensive debate as 
to a possible causal relationship. 
1.5.1 Experimental evidence 
 
Supporting evidence for a causal link between PFS and TLE-MTS comes from both animal 
models and human data. As mentioned previously, several different animal models of CSE have now 
shown a causal relationship between induced status epilepticus and subsequent brain injury. The 
hippocampus appears to be particularly vulnerable to injury and is the most commonly affected 
brain structure. The changes which are seen in the hippocampus following seizure induction with 
lithium-pilocarpine or kainic acid resemble human MTS in many ways, with subsequent neuronal 
death, gliosis and volume loss (49;50). Serial MRI after CSE has shown early hippocampal changes 
suggestive of cytotoxic oedema that are predictive of the eventual degree of volume loss(150).  
Models of febrile seizures, using hyperthermia-induced CSE in immature rats, have shown 
transient neuronal injury52, particularly in CA1 and CA3, but no evidence of subsequent neuronal 
death (151;152). They have however shown that experimentally induced febrile seizures can lead to 
later spontaneous limbic seizures(152-154) and cognitive deficits(155). 
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A number of isolated case reports of children following PFS have shown that the 
pathological sequence leading from PFS to TLE-MTS does occur(156-158), but cannot provide 
information on how common this is or what factors are involved in this progression. 
There have now been a number of studies that have addressed this more systematically. 
VanLandingham et al. and Scott et al. have studied children immediately following a PFS and 
consistently shown that in the first 2 days after PFS there is enlarged hippocampal volume and 
increased signal on T2 scans (45;47). This has been interpreted as evidence of acute hippocampal 
oedema and appears to have resolved by 5 days post-PFS.  
Follow-up of 14 patients from their original study by Scott et al. showed that the initial 
changes resolve over the following months, but that an increased degree of hippocampal asymmetry 
was detectable at 4-8 months in 5/14 patients(46). None of these children met criteria for MTS and 
no children had received a diagnosis of TLE by the end of the follow-up period. Finally a more recent 
longitudinal study of 11 children by Provenzale et al. with an initial MRI scan within 72 hours of PFS 
and follow-up between 3-23 months later found unilateral hippocampal volume loss in 5 children 
and bilateral changes in 2 more children(159). They found evidence of MTS and TLE in 2 children and 
complex-partial seizures of uncertain origin in a further 4 children, however, the rate of epilepsy 
seems high when compared to other, population-based, studies of prolonged febrile seizures. 
Furthermore as the MRI sequences used in their study were not optimised for the accurate 
measurements of hippocampal volumes, the validity of the diagnostic criteria they used to define 
MTS (any reduction in hippocampal volume over the study period) can be called into question. 
Both of these studies contrast with a 10 year follow-up study by Tarkka et al. who performed 
MRI scanning on 24 children with previous PFS 10-20 years after the initial event (160). They did not 
find any cases of clinical MTS and absolute left and right hippocampal volumes were not statistically 
different between patients with previous PFS and control subjects with simple febrile seizures only. 
They did find a significant reduction in right-left volume differences in patients with PFS compared to 
control subjects and in 3 patients the right-left volume difference was more than 2 standard 
deviations less than the mean of control subjects. They do not report on any other measures of 
asymmetry and were unable to comment on growth, so this is not necessarily in contradiction to the 
previous studies mentioned above; if progression to MTS only occurs in a minority of cases, 
increases in asymmetry or impairment of hippocampal growth may occur in these patients without 
significantly altering mean hippocampal volumes on a group level, especially with small study sizes. 
Alternatively there may be recovery after the initial injury, with resumed growth and a return to 
normality. 
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1.5.2 Epidemiological evidence 
 
In contrast to the strong associations found in retrospective studies of surgical cohorts and 
the growing amount of mechanistic evidence from animal studies and prospective imaging studies of 
children with PFS, there is limited epidemiological evidence for a causal link between PFS and TLE-
MTS. Some early case-control studies looking at risk factors for TLE-MTS found PFS to be a significant 
risk factor(161;162), but other, population-based studies of children with PFS, have not shown an 
increased risk of focal epilepsy such as TLE(163;164). While there is an increased rate of epilepsy in 
children with PFS, this does not appear to be specific to TLE-MTS, with PFS also being a risk factor for 
other types of epilepsy (165;166).  
1.5.3 Advancing the hypothesis 
  
In light of the existing literature, there are several plausible explanations for the association 
between TLE-MTS and PFS. Some of the most commonly advanced are: 
1. PFS occur in a normal brain and produces an acute hippocampal injury, which over time 
develops into mesial temporal sclerosis and causes temporal lobe epilepsy 
 
2. MTS is a developmental disorder or caused by an early neurological insult and pre-dates the 
PFS. PFS is caused by MTS and is merely the first clinical manifestation, later ones being 
temporal lobe seizures. 
 
3. An underlying brain abnormality, possibly genetic or developmental in origin predisposes 
children to both PFS and later TLE-MTS. PFS may or may not hasten the ultimate 
development of MTS and TLE. 
 
Since the peak ages for febrile seizures are 1-3 years (91;167) and TLE-MTS is only diagnosed 
after 5-8 years, if not later, this time lag of several years makes direct investigation difficult. In the 
study by Maher et al, epilepsy only developed a mean of 12 years after the initial febrile 
convulsion(162), therefore using TLE as an end-point would necessitate a study duration of over a 
decade. It is therefore more practical to use surrogate end points that can be studied over a shorter 
time period.  
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While alterations in hippocampal volumes have been shown following PFS, the long term 
evolution of these changes remains uncertain. Specifically whether they continue to progress to MTS 
or whether they normalise with time.  
1.6 PFS and other forms of epilepsy 
 
 TLE is not the only form of epilepsy that is associated with a history of childhood prolonged 
febrile seizures. In particular, children with epilepsy syndromes such as Dravet syndrome (Severe 
Myoclonic Epilepsy of Infancy)(168) and Generalised Epilepsy with Febrile Seizures Plus (GEFS+)(169) 
may initially present with febrile seizures. Although these children may not be distinguishable at the 
initial presentation, continued febrile seizures beyond the age of 6 years(170), evolving 
developmental problems or the emergence of other seizure types would be reasons to suspect these 
diagnoses.  
SMEI has been estimated to occur in around 1 per 40,000 children(171) and while the 
prevalence of GEFS+ is likely to be higher, the prevalence of febrile seizures is around 1,800 per 
40,000(172).  If 5% of these are prolonged(89), even if all children SMEI/GEFS+ presented with CSE, 
only a small minority of children (<1%) with PFS will have a diagnosis of SMEI or GEFS+. Even though, 
as previously alluded to in Section 1.5.2, PFS may be a risk factor for the subsequent development of 
epilepsy, it seems apparent that the majority of children with PFS will not develop epilepsy 
subsequently.   
1.7 Summary and hypothesis formulation 
 
 In this chapter the basic physiology behind a seizure has been reviewed as well as the factors 
that differentiate CSE. After discussion of the epidemiology, pathophysiology and prognosis of CSE, it 
is clear that CSE is associated with adverse outcomes, but it is also clear that the underlying cause 
and the child’s previous neurological/developmental status are the predominant determinants of 
mortality and morbidity. None the less, it is difficult to rule out a harmful effect of CSE per se from 
the existing data.  
In particular it would be useful to assess neurodevelopment after CSE using modern 
standardised tests, in order to rigorously assess the risks of developmental problems. There are 
conflicting reports about children with PFS, who are otherwise thought to be neurologically and 
developmentally normal; their risk of cognitive deficits following CSE and their risk of further afebrile 
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seizures/epilepsy need to be clarified. The postulated link between PFS and TLE-MTS also merits 
further investigation as this important hypothesis continues to resist either proof or falsification.  
The aim of this doctoral project was to characterise the clinical, cognitive and structural 
outcomes after an episode of childhood CSE with a view to clarifying the short-medium term 
outcome. Since children at this age are growing and developing rapidly, longitudinal studies are 
essential to detect deviation from normal developmental trajectories. MRI investigations and formal 
cognitive testing were performed at multiple time points following CSE to capture the children’s 
performance over time and track the evolution of any CSE associated changes in both brain structure 
and cognitive performance. In order to characterise the structural consequences of CSE, quantitative 
MRI techniques such as hippocampal volumetry and DTI, that have been shown to be abnormal in 
established MTS were used in addition to standard clinical reporting to investigate structural 
changes that may be precursors to clinical TLE-MTS. Results from the neuropsychological 
assessments undertaken during this project have already been reported by Dr Marina Martinos and 
form the basis of her PhD thesis “The consequences of convulsive status epilepticus”(173). They will 
therefore only be dealt with in summary in this thesis and the main part of this thesis will 
concentrate on presenting our findings related to the clinical and MRI investigations undertaken. 
The overall theory underlying this project is that CSE can cause brain injury with long lasting 
consequences. In particular we hypothesise that the hippocampus is selectively vulnerable to CSE 
induced injury and a certain proportion of children will sustain sufficient hippocampal injury that 
develops over time into TLE-MTS. We further hypothesise that injury of this nature is related to PFS 
and not other forms of CSE. Clinical seizures and cognitive deficits will be associated with the degree 
of post-CSE brain injury. Specific hypotheses that will be advanced in this thesis are: 
1) Clinical outcome and the immediate findings on structural MRI will largely be 
determined by the aetiology behind the episode of CSE. As previously demonstrated in 
other studies, children with symptomatic CSE (acute or remote) will have worse clinical, 
structural and cognitive outcomes than children with epilepsy-related CSE or children 
with PFS. 
2) There is a specific effect of PFS on the hippocampus and a proportion of children with 
PFS will sustain hippocampal injury leading to the development of MTS. Disruption of 
normal hippocampal growth and development will be detectable on MRI within the 
follow-up period. The effect of other forms of CSE on hippocampal parameters will not 
be as profound or widespread. 
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3) Structural brain damage following CSE, in particular hippocampal damage will have a 
functional impact and children showing signs of hippocampal damage post-CSE will show 
reduced performance on cognitive testing. 
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 CHAPTER 2: MAGNETIC RESONANCE IMAGING 
 
Since its discovery in 1945, the principle of nuclear magnetic resonance (NMR) has led to the 
invention of a number of techniques of non-invasively imaging the internal structure of the human 
body that are collectively known as magnetic resonance imaging (MRI). This has revolutionised many 
areas of medicine, and led to many advances in the study of neurology and epilepsy in particular. 
The principles of NMR and MRI have been well described in a number of textbooks and will only be 
covered here in summary. 
2.1 Basic MRI theory 
 
 Although NMR is at heart a quantum mechanical phenomenon, when considering the overall 
behaviour of large numbers of molecules, as when imaging the body in an MRI experiment, classical 
Newtonian mechanics provides a simpler and still adequate description. Therefore, in this 
description of NMR a combination of both the classical and quantum mechanical approaches will be 
used as appropriate. 
All MRI techniques rely on measuring the magnetic energy of atomic nuclei within a 
magnetic field. This is possible because in quantum mechanics all atomic nuclei have a property 
known as “spin”, which varies in half-integer levels according to the composition of each nucleus and 
is denoted by the spin quantum number I. The simplest and most commonly measured nucleus in 
human imaging is the hydrogen nucleus, which consists of a single proton and has a spin of +½.  
A spinning nucleus possesses angular momentum (p), which is described by the following 
equation: 
p = ħ (I(I+1)  (ħ = h (Planck’s constant)/2π) 
This is also quantised, both in magnitude and direction. Each nucleus also has a second 
quantum number associated with it, m, the magnetic quantum number, which can take the values 
from +I to –I in integer steps. Hence for hydrogen, m = +½ or –½. The z component of p along an 
arbitrarily defined z-axis is therefore: 
 pz = mħ 
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 As with any other moving charge, the spinning nucleus generates an apparent magnetic 
dipole field. This magnetic moment μ is related to the angular momentum by the gyromagnetic 
ratio, γ, which is a constant unique to each nucleus. Thus: 
μz = γpz = mγħ 
In the absence of any external forces, the energy states of each value of m are equal, so 
there will be an equal population of nuclei with m = +½ and m = -½, and hence no overall net 
magnetic moment. When placed in a fixed magnetic field B0, however, this is no longer the case and 
the energy levels separate such that the difference between the low-energy state, aligned with the 
field (“spin-up”) and the high-energy state, anti-aligned (“spin-down”) is ΔE (Figure 2-1) 
 
 
 
Figure 2-1: Energy levels in a fixed magnetic field 
 
The energy level of each state is given by the equation: 
E = - B0..μ = - μzB0  (taking the z-axis to be aligned with B0) 
 = - mγħB0 
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This implies that for hydrogen nuclei: 
ΔE = γħB0 (as the two possible values for m are +/- ½) 
This energy difference is what is used to create the NMR signal. The frequency associated 
with this energy difference is also related to ΔE by ħ and hence we can derive the following 
equation: 
ħω0 = γħB0 
ω0 = γB0 
This is called the Larmor equation.  
If we now consider each nucleus as a rotating particle within a static magnetic field, 
possessing a magnetic moment, μ and angular momentum, p, since μ is at an angle to the static 
field, the magnetic moment of any individual nucleus will experience a torque and hence tend to 
precess around the axis of the static field at the Larmor frequency. 
 Taking B0 to be along the z-axis, at equilibrium these moments will tend to be equally spread 
around the x-y plane and so the net magnetic moment from all the nuclei at one position, M, will be 
parallel to B0.  
To generate the signal used for MRI, M is rotated towards the x-y plane by a radiofrequency 
(RF) pulse rotating around the z-axis at the Larmor frequency. Although this field is much weaker 
than B0, because it resonates at the Larmor frequency M will move out of alignment with B0 and into 
the x-y plane. Once the RF pulse has been turned off, then a process of relaxation will take place as 
M shifts back to its equilibrium position along B0. The changes in M during this relaxation generate 
the NMR signal as a reciprocal current in a receiving coil which is then analysed to generate the MRI 
image.  
2.2 T1 and T2 weighting 
 
Once the NMR signal has been generated, in order for this to provide useful information, the 
signal needs to alter depending on properties of the tissue being probed. The most commonly used 
mechanisms that exist to generate this contrast in the NMR signal between different tissuesare 
called T1 and T2 after the two main processes at work during the relaxation phase. 
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T1 relaxation is known as spin-lattice relaxation. After M has been rotated into the x-y plane 
by the RF pulse, Mz will be zero. Once the RF pulse is switched off, protons start to interact with the 
surrounding molecules and give up energy. When they do this they will move from the high energy 
state (anti-aligned) to the lower energy state (aligned with B0) and hence M will shift back towards 
the z-axis. The time taken for Mz to recover by ~63% is known as T1 (Figure 2-2).  
 
Figure 2-2: T1 relaxation as spins re-align with the z-axis 
The other process at work is known as T2 relaxation, or spin-spin relaxation. This occurs 
because once M has been rotated into the x-y plane, it will continue to precess (or rotate) around 
the z-axis in the x-y plane at the Larmor frequency. However, each proton generates its own 
magnetic field, which will add or subtract from the main B0 field in its nearby vicinity. Therefore 
protons each experience a slightly different magnetic field, depending on their position and that of 
their neighbours. This means that each will have a slightly different Larmor frequency and, over time 
they will become out of phase with each other. As this happens, Mxy, which is the vector sum of their 
magnetic moments in the x-y plane, will decay exponentially (Figure 2-3). The time taken for the 
signal to decay by ~63% is known as T2.  
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Figure 2-3: T2 relaxation from de-phasing of spins 
In vivo T1 and T2 depend on the composition of surrounding tissues and occur 
simultaneously. Because they occur on different timescales and directions by varying the time 
intervals between pulses (TE and TR) the relative contribution to the NMR signal (weighting) can be 
adjusted and used to create contrast between different structures in the human body. The effects of 
this are summarised in Table 2-1 below. For example, tissues that are mostly free water, such as 
cerebrospinal fluid (CSF) have a long T1 and a long T2 and will be bright on a T2 weighted scan and 
dark on a T1 weighted scan; fat has a short T1 but a longer T2 and is bright on a T1 weighted scan and 
grey on a T2 weighted one. 
 Short TR Long TR 
Short TE T1-weighted image Proton Density Image 
Long TE Noise T2-weighted image 
Table 2-1: The effects of varying TE and TR on image contrast 
 
 A typical MRI experiment will use additional pulses and different pulse sequences to 
generate spatial information, optimise signal to noise ratio, reduce scanning time and avoid artefacts 
but a full consideration of these is beyond the scope of this thesis.  
46 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
2.3 Diffusion Tensor Imaging 
 
One of the consequences of using hydrogen nuclei is that by far the largest component of 
the NMR signal comes from hydrogen bound in water molecules. In a free solution water molecules 
are constantly in motion. Biological systems however are rarely completely free solutions and so 
water diffusion is often restricted by other tissue structures. This means that the magnitude and 
direction of water diffusion can be used to give us important information about underlying tissue 
structure that may not be apparent on standard T1/T2 –weighted imaging(174;175). The process of 
making an MRI sensitive to diffusion information is known as diffusion-weighting.  
In order to make a scan sensitive to diffusion, information from the NMR signal must be 
made sensitive to the small molecular movement from randomised diffusion. This is done by 
applying “diffusion gradients” in opposing directions along a plane after the initial depolarising 
pulse. The first diffusion pulse will tend to pull the spins out of phase with each other as nuclei at 
different relative positions on the plane experience different fields. Since the second diffusion pulse 
is equal and opposite to the first one, it should have the effect of refocusing the spins and reversing 
the effect of the first. However since diffusion is constantly taking place, in the short time interval 
between the pulses some water molecules will have moved within the plane and hence experience a 
slightly different field the second time. So molecules which have moved due to diffusion will not 
completely refocus and hence their signal will be attenuated. The effect of this is to sensitise the 
scan to incoherent molecular movement such as diffusion in the direction of the plane the diffusion 
gradients are applied along. Areas with a high amount of diffusion will give low signal intensity and 
those with little diffusion will give a stronger signal(176).  
 The underlying structure of the brain is not uniform. Axons are commonly bundled together 
into tracts and run in specific directions. Myelin, cell membranes and cytoskeletal structures all 
provide barriers to the free diffusion of water. Water diffuses more easily along rather than across 
white matter tracts, axonal filaments and cell membranes. This means that water diffusion within 
the brain is anisotropic and reflects the underlying brain structure. This being the case, it is not 
sufficient to measure diffusion in only one direction as the measurements will differ depending on 
whether the direction chosen is perpendicular or parallel to the main direction of water diffusion in 
that voxel(177).  
In order to fully describe diffusion in an anisotropic system at least 6 measurements along 
different directions are required(178). Using these measurements, it is then possible to calculate the 
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diffusion tensor for any particular voxel. This 3x3 matrix describes the magnitude of the diffusion 
within that voxel along each of 3 orthogonal axes. The diffusion tensor itself is rarely analysed 
directly and instead scalar metrics such as mean diffusivity and fractional anisotropy are more 
commonly derived from the tensor for further comparisons(176;179;180).  
Mean diffusivity is a directionally averaged measure of diffusion within a voxel. It is 
calculated by taking the magnitude of the three eigenvalues of the diffusion tensor and averaging 
them. MD is thought to reflect how free the water molecules within a voxel are to move around. It is 
increased by the presence of fluid, such as in oedema and inflammation and reduced by any barriers 
to diffusion, such as cell membranes and solid structures.  
Fractional anisotropy is a measure of how isotropic diffusion within a voxel is.  
It is calculated according to the following equation, where λ1-3 are the 3 eigenvalues of the diffusion 
tensor matrix and λ is the mean diffusivity in that voxel. 
 
 
 
FA ranges from 0, in a free solution where diffusion is equal in all directions, to 1, where 
diffusion is only possible in one direction. The average distance a water molecule travels during a 
diffusion-weighted scan is of the order of 4-15μm, so structures that alter FA must be smaller than 
this. In the brain these are thought to be cell membranes, myelin sheaths and protein filaments. 
Hence FA is thought to be a measure of the underlying structure present within a voxel, especially 
white matter tracts.  
2.4 Quantitative MRI techniques 
2.4.1 Hippocampal volumetry 
 
Quantitative hippocampal volumetry is one method of improving the sensitivity to subtle 
volume changes over simple inspection. There have been a variety of automated techniques 
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developed for measuring the hippocampal volume from a suitable MRI scan(181;182), but to date 
the gold standard remains manual tracing of the hippocampus to create a region of interest.  
Detailed descriptions of how to delineate the hippocampus have been given by a number of 
sources(183). While slight differences in anatomical landmarks and scanning sequences used 
between different studies(184), as well as idiosyncrasies of individual MRI scanners mean that the 
absolute value for the hippocampal volume may not be comparable between studies, it has been 
shown that relative values can be obtained with good consistency from one centre using a well-
defined method(185). 
2.4.2 Diffusion measures in the hippocampus 
 
In order to study changes in water diffusion within the hippocampus, such as are 
hypothesised to occur following acute hippocampal injury and in MTS, the usual technique is to first 
generate MD and FA maps from diffusion weighted scans and then create a region of interest (ROI) 
within the hippocampus. Different methods of ROI placement have been used by different groups, 
ranging from small fixed size ROIs placed on the MD map(186), to full masks of the anterior 
hippocampus drawn on the MD(187;188) or the b0 images(189).  
In subjects with diagnosed TLE-MTS, there have been consistent findings of significantly 
increased MD in the abnormal hippocampus(186-189). When considering FA however, while some 
groups have found a significant decrease in the abnormal hippocampus(188;189), others have 
not(186;187).  
This discrepancy is most likely due to methodological differences, both in terms of the 
degree of diffusion weighting and pulse sequence used and in the method used to place the ROI in 
the hippocampus. A summary of the results obtained and methods used are shown in Table 2-1 
below: 
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 Subjects  No diffusion 
directions 
ROI placement Mean 
diffusivity 
Fractional 
anisotropy 
Wieshmann et 
al. (1999)(188) 
20 3 ROI drawn on b0 scan 
to cover entire 
hippocampus 
Increased 
ipsilaterally 
- 
Assaf et al 
(2002)(186) 
12 6 4x8mm ROI placed on 
MD map 
Increased 
ipsilaterally 
No significant 
change 
Thivard et al 
(2005)(187) 
35 23 ROI drawn on MD map 
to cover entire 
hippocampus 
Increased 
ipsilaterally 
No significant 
change 
Salmenpera et 
al (2006)(189) 
7 60 Elliptical ROI drawn on 
4 consecutive slices on 
b0 image 
Increased 
ipsilaterally 
Decreased 
ipsilaterally 
Kimiwada et al 
(2006)(190) 
14 6 ROI drawn on b0 scan 
to cover entire 
hippocampus 
Increased 
ipsilaterally 
Decreased 
bilaterally  
Knake et al 
(2009)(191) 
12 6 4mm diameter 
spherical ROI placed on 
b0 scan 
- Decreased 
compared to 
contralateral 
hippocampus 
Table 2-2: Published studies of hippocampal MD/FA in TLE-MTS 
 
As well as these chronic changes in established MTS, there have also been documented 
acute changes in MD and FA immediately following seizures in both animals(50;192) and 
humans(193;194). This suggests that diffusion parameters may offer another modality to track 
hippocampal changes following CSE in addition to hippocampal volumetry, however an optimal 
methodology for measuring hippocampal MD and FA needs to be established. This will be 
considered further in Chapter 7. 
2.4.3 Automated methods of MRI analysis 
  
 In addition to manual measurements of hippocampal volume, MD and FA, there exist a 
number of complementary techniques that compare MRI scans between subjects on a voxel-by-
voxel basis across wider areas of the brain. This avoids the subjective elements associated with 
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region selection and ROI placement. The most widely used of these automated techniques are voxel 
based morphometry (VBM)(195) and tract-based spatial statistics (TBSS)(196).  
 VBM compares grey matter concentrations and/or volume between groups of subjects. It 
relies firstly on the automated segmentation of each individuals MRI scan into grey matter, white 
matter and CSF containing voxels and secondly on the accurate co-registration of each individual to a 
common template, thereby ensuring that the voxel-by-voxel comparison is comparing the same area 
of brain in each subject. Because the technique was initially developed for use on adults, there are a 
number of difficulties that need to be considered when it is applied in younger subjects. Particularly 
in children under 1 year of age, the appearance of grey and white matter on a T1-weighted scan is 
different: whereas in adults white matter appears bright on a T1-weighted image, grey matter 
darker and CSF the darkest of all, in neonates, because of the unmyelinated nature of large portions 
of the brain and the relatively higher water content, grey matter appears brighter and white matter 
appears dark on T1-weighted images. As the brain matures then the relative intensities reverse and 
trend towards adult values, but during at least the first years of life this appearance is different 
enough to cause trouble with automated image analysis techniques. Co-registration of images relies 
to some extent on the contrast between the MRI signal from different areas of brain and therefore 
co-registration of infant MRI requires different parameters than that of older children. Furthermore, 
the automated segmentation of grey and white matter also requires specialised algorithms and 
hence it is very difficult to apply VBM to groups containing a mixture of ages.  
 TBSS is a separate technique for the automated voxel-by-voxel analysis of diffusion data 
along a white matter skeleton. It has a number of advantages to VBM, particularly as regards the 
robustness of co-registration and will be described in further detail in Chapter 8. The disadvantage 
to TBSS is that it can only detect differences along the major white matter tracts and does not 
compare areas of grey matter or smaller tracts.  
TBSS will be preferred for the voxel-wise analysis presented in Chapter 8 because of the 
difficulties in applying VBM techniques to cohorts over this age range alluded to above. 
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Chapter 3: Materials and Methods 
 
3.1 Definitions 
 
For the purposes of this thesis, CSE was defined as: 
 “A single convulsive seizure lasting more than 30 minutes in total (continuous CSE), or a 
series of convulsive seizures without recovery of consciousness in between, lasting in total longer 
than 30 minutes (intermittent CSE).” 
3.2 Patient recruitment and ethics 
 
 The aim of this study was to recruit a population representative cohort of children 
with CSE. To this end, a multi-tiered approach, successfully used in previous epidemiological studies 
of CSE and epilepsy in infancy (28;197) was used. Children aged between 1 month and 16 years were 
recruited from hospitals in North London (for a list of participating local hospitals, see Appendix A), 
following an episode of CSE. Recruitment began on 1st March 2007 and finished on 1st March 2010. 
Children were identified using a previously established clinical network, covering 18 hospitals with 
24hr paediatric accident and emergency services, five paediatric intensive care units (PICU) and the 
regional centralised paediatric intensive care retrieval service (CATS). Eligible children with CSE were 
notified to a centralised research team by their admitting local paediatrician or CATS. Local hospitals, 
CATS and local PICU were also regularly contacted to see if any eligible children had been seen. Basic 
demographic details and contact information were recorded and each family was contacted by the 
research team and invited to take part in the Status Epilepticus Imaging and Neurocognitive study 
(STEPIN). Those that agreed to participate were invited to have a brain MRI scan and 
developmental/clinical assessment at Great Ormond Street Hospital (GOSH) within 12 weeks after 
the episode of CSE.   
STEPIN was approved by the Local Research Ethics Committee at Great Ormond Street 
Hospital.  Local Research and Development registration was obtained at all referring hospitals. 
Informed written consent to participate in the study and for each procedure involved was obtained 
from each patient and or family at their initial assessment.   
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3.3 Assessment timeline 
 
 Patients were invited to attend Great Ormond Street Hospital for their initial assessment 4-
12 weeks following their episode of CSE. The initial assessment comprised of the collection of a 
clinical history from the child and his/her parents of the episode of CSE and any previous medical or 
developmental problems; neurological examination by a paediatric neurology trainee (Dr M Yoong) 
under the supervision of a consultant paediatric neurologist (Dr RC Scott/Dr RF Chin/Prof B Neville); 
MRI investigations as detailed below; and neurocognitive assessment as also detailed below. If 
possible all parts of the initial assessment were completed on the first visit. On occasion this proved 
impractical because of the sedation required for the MRI scan and in these cases a further 
appointment was required to complete the assessment as soon as possible after the initial visit. 
 Families were re-contacted 4 months after their initial assessment and invited to attend 
GOSH for further MRI investigations. Families were contacted again at 12 months after the initial 
assessment and invited for a final set of MRI investigations and repeat neurocognitive testing. The 
presence or absence of recurrent seizures and CSE, as well as what anti-epileptic medication the 
child was taking was recorded at each follow-up appointment. 
3.4 Patient classification 
 
 Patients were assigned to one of 7 aetiological groups (as previously mentioned in Chapter 
1.2.2) using information from the clinical history and neurological examination recorded at their 
initial assessment. This included details of any previous neuroimaging the child had had, but not the 
results of the MRIs performed during this project. Assignment was done independently by two 
paediatric neurologists (Dr RC Scott and Dr RF Chin) and disagreements resolved by consensus 
discussion.  
 For some analyses, in order to increase the statistical power, aetiological groups were 
combined into 3 categories: prolonged febrile seizures; symptomatic CSE (including acute, remote 
and acute on remote symptomatic CSE); and other CSE (including idiopathic/cryptogenic epilepsy 
and unclassified CSE).  
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3.5 MRI protocol 
 
 All children received MRI investigations on the same Siemens Avanto 1.5T whole-body MRI 
scanner based at Great Ormond Street Hospital. An imaging protocol used for the evaluation of 
children with epilepsy and optimised for the visualisation of mesial temporal structures was carried 
out. Additional diffusion weighted sequences were added to this for diffusion tensor imaging (DTI). A 
copy of the full MRI protocol in available in Appendix B. The same MRI investigations were 
performed at the initial assessment and at each follow-up. 
 MRI investigations were performed where possible with the child awake and lying still in the 
scanner or when they were in a natural sleep. This was successful for most children under 6 months 
and those over 6 years. Where this was judged not possible, or after an initial failed attempt, either 
due to the chronological age of the child or their developmental status, sedative medication was 
offered to increase the chances of the child staying still for the scan. Sedative medication was 
administered by the sedation nursing team at Great Ormond Street after assessment of the child for 
safety and with parental consent. A copy of the protocol used to assess children and prescribe 
medication is available in Appendix C.  
3.6 MRI processing pipeline 
  
 Raw DICOM files were downloaded from the MRI scanner, anonymised, and archived to CD. 
Files were transferred to an encrypted hard disc and stored using a unique random number 
generated by the scanner. TractoR scripts (http://code.google.com/p/tractor/, Clayden, UCL) were 
used to sort the DICOM files into directories for each MRI sequence and dicom2nii 
(http://www.cabiatl.com/mricro/mricron/index.html, Rorden, GeorgiaTech Centre for Advanced 
Brain Imaging) used to convert the DICOM files for each sequence into NIfTI format. 
 Further processing of the diffusion datasets was performed using TractoR to generate the FA 
and MD maps according to a standard script. 
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3.7 Neurocognitive assessment 
 
 Standardised neurocognitive assessment was performed on each child by a psychologist (Dr 
M Martinos). 3 different neurocognitive batteries were used, depending on the chronological age of 
the child: 
1. Children under the age of 42 months were assessed using the Bayley scales of infant and 
toddler development (3rd edition). 
2. Children aged between 42 and 84 months were assessed using the Wechsler Preschool and 
Primary Scale of Intelligence (WPPSI-3rd UK edition). 
3. Children over the age of 84 months were assessed using the Wechsler Intelligence Scale for 
Children-Revised (WISC-4th UK edition). 
 Each test was scored to provide an overall measure of full scale IQ (for the WPPSI and WISC) 
or overall cognitive development (for the Bayley) with mean 100 and standard deviation 15. Results 
from these composite scores were used to compare children for analysis. 
In addition to these, children aged between 5 and 16 years were administered the Children’s 
Memory Scale (CMS) and parents were given a number of questionnaires to complete: the Social-
Emotional and Adaptive Behaviour questionnaire (children under 42 months age); the 
Communication and Symbolic Behaviour Scales Developmental profile (6 -24 months age); and the 
Strengths and Difficulties questionnaire (3-16 years age). Results from these have been previously 
reported on by Dr Martinos(173) and will not be presented in this thesis. 
3.8 Recruitment of control subjects 
 
Children were recruited from a number of different sources, including personal contacts, playgroups, 
hospital clinics and university e-mail lists, to act as control subjects for this project: 
1) Volunteers with no history of seizures, developmental delay or neurological problems 
 These had to be able to complete an MRI scan without sedation, either during 
natural sleep or awake and watching a video 
2) Children having an MRI scan under sedation for other clinical reasons with no history of 
seizures 
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 The main clinical indication for these scans was for further assessment of skin and 
soft tissue abnormalities such as haemangiomas or dermoid cysts requested by the 
Ophthalmology department and for children with sensorineural hearing loss 
undergoing pre-assessment for the cochlear implant program.  
 All of these children had normal neurological examinations and normal 
developmental history except for isolated hearing loss with speech delay in some 
children.  
 If the MRI scan was reported as showing any intracranial abnormalities then these 
children were not used as controls 
Informed consent was obtained from parents by the research team before their 
participation in the project. Controls underwent the same set of neurocognitive and MRI 
investigations as patients; for the MRI the 3D-FLASH sequence was performed first, followed by the 
DTI sequences and then the T2 relaxometry. This was done in order to maximise the useful 
information obtained from the MRI, as some children did not tolerate the entire scan. All MRI scans 
performed were reviewed later by a neuroradiologist (KC/RC) who assessed them for any structural 
abnormalities. Children who had an intracranial structural abnormality present on their MRI scan 
were excluded from our group of control subjects. Any abnormalities found were notified either to 
the paediatrician responsible for the care of that child or the General Practitioner (GP) for those 
children who were not under a named paediatrician. The results of the neurocognitive tests were 
also notified to the child’s GP to pass onto the parents. 
 
3.9 Statistical analysis 
 
Except where otherwise stated, all statistical analysis was performed with the aid of SPSS for 
Windows version 17.0-20.0 (Chicago). p < 0.05 was taken as the cut-off for significance and 
appropriate corrections for multiple comparisons were made as stated in individual chapters.  
 
Having presented the overall clinical and scientific methodology that was used for the 
studies set forth in this thesis, the following chapters will advance the findings and results of each 
study comprising this overall project, with further explanation of the methodology used for each 
individual portion as required. 
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Chapter 4: Characterisation of patient cohort 
 
4.1: Patient cohort at enrolment 
4.1.1 Demographics 
 
 During the period December 2006 - March 2010 225 children were notified to our study. Of 
these, a total of 86 children were recruited and underwent at least one assessment. A summary of 
the demographic details of the patients enrolled in the study is given in Table 4-1 and their age 
distribution shown in Figure 4-1. 
 Not entered Recruited 
Median Age at CSE (years) (range) 2.43 (0.10 – 15.29) 1.98 (0.10 - 15.44) 
Mean Gestational age (weeks) (s.d.) 36.94 (4.94) 37.90 (3.92) 
Male:Female ratio 80:59 44:42 
Table 4-1: Demographic details of initial patient cohort at enrolment 
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Figure 4-1 Histogram of CSE incidence by age and aetiology 
Children were seen for assessment a mean of 31.78 days after their episode of CSE (Range 5 
– 90). Amongst those that were not enrolled, 35 children were uncontactable due to missing or 
incorrect contact details; 32 children were unsuitable for MRI under sedation due to the instability of 
their clinical condition/co-morbidities; 48 children declined to take part in the study; 15 children 
lived far from the study area and were not willing to visit our centre; and 7 children died during their 
acute hospital admission. A further 2 children agreed to take part but did not attend their 
appointments. 
4.1.2 Aetiology 
 
As reported earlier, each child was assigned to an aetiological group (see Chapter 1), 
depending on the reported cause of their episode of CSE and their previous medical and 
developmental history. The most common cause of CSE in our cohort was PFC and a breakdown of 
our cohort by aetiology is given in Figure 4-2. As numbers in some groups were small, groups were 
merged into 3 categories - PFC, symptomatic CSE and other CSE - for the majority of our analyses. A 
summary of the demographic details of each group is given in Table 4-2. 
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Figure 4-2: Aetiology of CSE within STEP IN 
 
 
 
Table 4-2: Demographic details of patient cohort by aetiology 
 
4.1.3 Semiology and medical history 
 
 The clinical characteristics of each episode of CSE are summarised in Table 4-3 and the 
previous medical history in Table 4-4. 
  
 PFC (n=34) 
Symptomatic CSE 
(n=29) 
Other CSE (n=23) 
Age at CSE (s.d.) 1.92 (0.945) 3.35 (3.048) 4.99 (4.370) 
Gestational age 
(weeks) (range) 
38.44 (30 – 41) 36.21 (24 – 41) 39.22 (33 – 40) 
Male:Female ratio 11:23 22:7 11:12 
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 PFC (n=34) 
Symptomatic CSE 
(n=29) 
Other CSE (n=23) Overall (n=86) 
Focal onset 5(14.7%) 7(24.1%) 12(52.2%) 24 (27.9%) 
Continuous seizure 
activity 
21 (61.8%) 17 (58.6%) 13 (56.5%) 51 (59.3%) 
Intermittent seizure 
activity 
13 (38.2%) 12 (41.4%) 10 (43.5%) 35 (40.7%) 
Semiology 
Tonic 5 (14.7%) 2 (6.9%) 7 (30.4%) 14 (16.3%) 
Clonic 1 (2.9%) 3 (10.3%) 2 (8.7%) 6 (6.9%) 
Tonic-
Clonic 
28 (82.4%) 24 (82.8%) 14 (60.9%) 66 (76.7%) 
Mean seizure 
duration in minutes 
(range) 
72.21 (30 – 190) 73.03 (30 – 265) 69.17 (30 – 190) 71.69 (30 – 265) 
Table 4-3: Seizure characteristics of CSE by aetiology 
 
 PFC (n=34) 
Symptomatic CSE 
(n=29) 
Other CSE (n=23) Overall (n=86) 
Previous seizures 13 (38.2%) 19 (65.6%) 18 (78.3%) 50 (58.1%) 
Previous episode 
CSE 
2 (5.9%) 8 (27.4%) 11 (47.8%) 21 (24.4%) 
Taking AED at 
time of CSE 
0 (0%) 14 (52%) 16 (61%) 29 (33.7%) 
Previous Hx 
developmental 
delay 
5 (14.7%) 16 (55.2%) 6 (26.1%) 27 (31.3%) 
FHx Epilepsy 7 (21%) 8 (30%) 8 (35%) 23 (27%) 
AED: Anti-epileptic drugs 
CSE: Convulsive Status Epilepticus 
Hx: History 
FHx: Family History 
 
Table 4-4: Previous medical history of patient cohort 
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4.2: Patient cohort at follow-up 
 
Children and their families were contacted after their initial episode of CSE and were seen an 
average of 31 days post-CSE for their initial set of investigations. Not all children received the full set 
of investigations, as some were unsuitable for MRI scans or had parents refuse consent. Inevitably 
there was some loss to follow-up, with families moving away or being unwilling to undergo further 
MRI investigations. An overview of the cohort is given in Table 4-5 and Figure 4-3 shows which 
children attended which assessments.  
 
Figure 4-3: Flowchart of patient recruitment and follow-up 
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Table 4-5: Patient numbers at each follow-up assessment 
The median time after the initial episode of CSE to the first assessment was 31.6 days and 
this varied from between 5 and 90 days. A summary can be seen in Table 4-6. 
 Median time after CSE in days (range) 
 PFS Symptomatic CSE Other CSE Overall 
1st MRI scan 37 (5 - 90) 33 (11 - 57) 19 (7 - 66) 29.5 (5 - 90) 
Initial developmental 
test 
37 (10 - 254) 30 (11 - 66) 19 (8 - 99) 29 (8 - 254) 
2nd MRI scan 180 (124 - 280) 167 (116 - 221) 
158.5 (123 - 
210) 
169.5 (116 - 
280) 
3rd MRI scan 427 (255 - 699) 394 (268 - 515) 386 (275 - 582) 391 (255 - 699) 
Follow-up 
developmental test 
427 (255 - 949) 402-5 (268 - 536) 386 (275 - 679) 398 (255 - 949) 
Table 4-6: Timing of follow-up assessments 
At each follow-up appointment patients were asked if they had had any further seizures 
(including both febrile and non-febrile seizures) since they were last seen. The results of this are 
given in Table 4-7. 
 
 
 PFS Symptomatic CSE Other CSE Overall 
1st MRI scan 33 24 23 80 
Initial 
developmental 
test 
33 25 20 78 
2nd MRI scan 21 15 14 50 
3rd MRI scan 21 15 13 46 
Follow-up 
developmental 
test 
26 18 13 57 
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 PFS (n=34) 
Symptomatic 
CSE (n=29) 
Other CSE (n=23) Overall (n=86) 
Further seizures by 4 
months 
8 (23.5%) 11 (37.9%) 12 (52.2%) 31 (36.0%) 
Further seizures between 4 
and 12 months 
5 (14.7%) 12 (41.4%) 10 (43.5%) 27 (31.4%) 
Cumulative incidence of 
further seizures by 1 year 
post CSE 
10 (29.4%) 14 (48.3%) 14 (60.9%) 38 (44.2%) 
Cumulative incidence of 
recurrent CSE by 1 year post 
CSE 
1 (2.9%) 1 (3.4%) 4 (17.4%) 6 (7.0%) 
Table 4-7: Incidence of recurrent seizures during first 12 months post-CSE 
4.3 Analysis of Patient Cohort 
 
Patients were recruited to our study in a prospective manner following an episode of CSE. 
This was intended to produce a population representative cohort for further study. In order to 
screen for potential biases in our patient population, basic demographic data on patients who were 
notified to our study, but declined or were unable to take part in the assessments was also collected 
anonymously. Data collected at notification by the local hospital or the Children’s Acute Transport 
Service (CATS) was used to classify patients that were not seen by the research team to an 
aetiological group and to confirm that our cohort was representative of the overall population 
presenting with CSE. Sufficient detail was available to attempt this for 120/145 children who were 
not entered into the study. The index of multiple deprivation (IMD) score was also obtained for each 
child from their home postcode and this was used as a measure of socioeconomic status and 
compared between participants and non-participants. 
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 Children notified but not 
entered into study 
Children entered into study 
Number 139 86 
Male:Female 80:59 44:42 
Median age in years (range) 2.43 (0.10 – 15.29) 1.98 (0.10 – 15.44) 
Mean Gestational age in weeks 
(range) 
36.94 (22 – 41) 37.90 (24 – 41) 
Mean seizure duration in mins 
(s.d.) 
75.26 (73.71) 71.94 (42.73) 
Median Index of Multiple 
Deprivation (range) 
29.45 (3.38 - 62.51) 23.44 (5.28 - 61.38) 
A
e
ti
o
lo
gy
 o
f 
C
SE
 (
%
) 
Prolonged febrile seizure 34(24.5%) 34 (39.5%) 
Acute symptomatic CSE 22 (15.8%) 3 (3.5%) 
Remote symptomatic CSE 24 (17.3%) 9 (10.5%) 
Acute on Remote 
symptomatic CSE 
22 (15.8%) 17 (19.8%) 
Idiopathic Epilepsy 
Related 
4 (2.9%) 8 (9.3%) 
Cryptogenic epilepsy 
related 
7 (5.0%) 11 (12.8%) 
Unclassified 7 (5.0%) 4 (4.7%) 
Unknown 19 (13.7%) - 
Table 4-8: Comparison of entered children with non-participating children 
 Independent sample t-tests were used to compare each group for age (p = 0.175), gestation 
(p = 0.250) and seizure duration (p = 0.720), there was no significant difference in any of these 
factors. A Chi-squared test was used to compare the proportion of children with each aetiology in 
both groups, this showed that the composition of the children entered into our study was 
significantly different from those referred (p < 0.001). A Mann-Whitney U test was used to compare 
IMD between each group and found no significant difference (p = 0.130). 
One further difference between the patients initially notified to the study and those who 
were eventually recruited was the number of male patients with PFS. The initial PFS cohort consisted 
of 44.9% boys, but a disproportionate number of these families declined to take part in any further 
assessments, meaning that our eventual starting cohort had a female predominance, with only 
32.4% boys. 
By comparing our cohort to a previous epidemiological study of CSE done in the same 
geographic area (NLSTEPSS(28)), we were able to see how representative was of the general 
population of children with CSE (Figure 4-4). There were differences between the patients recruited 
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to this current study and those presenting to NLSTEPSS - in particular, less children with 
symptomatic CSE were recruited to this study than were found in NLSTEPSS. As the proportions of 
each aetiological group originally notified to our study were similar to NLSTEPSS, this appears to be 
mainly because a disproportionate number of patients with acute/remote symptomatic CSE declined 
consent for further investigations or were not able to take part despite initial parental consent as 
sedation for MRI was judged to be unsafe.  
 
Figure 4-4: Comparison of STEP IN with NLSTEPSS 
 
Other than these two differences, our cohort was broadly similar to the population of 
children notified to us and to those identified in NLSTEPSS.  
Logistic regression was used to investigate how clinical factors and CSE semiology varied 
between the groups. Previous seizure history, seizure focality, history of developmental problems, 
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age at CSE and AED use were all significantly different between children with PFS and those with 
symptomatic or other CSE. Children with PFS were more likely to be younger at the time of CSE (p = 
0.009), not have had previous CSE (p = 0.042), not be on any AED (p = 0.003) and have no history of 
pre-existing developmental problems (p = 0.025). The overall seizure semiology reported was similar 
to that seen in NLSTEPSS. 
The age distribution of our cohort did not follow a normal distribution, with a skew towards 
younger children. This is similar to other reported studies of CSE, which show a bi-modal distribution 
with peaks in early infancy and old age (29). 
Age to first scan was significantly associated with aetiology (ANOVA, p = 0.004), with 
children with PFS taking on average, 6 days longer to be seen for their initial MRI investigation and 
assessment. There was no difference between the times the groups were seen for any of the other 
assessments and there were similar drop-out rates between the 3 groups. 
All groups had relatively high incidences of recurrent seizures during the first 12 months 
post-CSE. Seizure recurrence at 4 months did not differ between the groups (Chi-squared p = 0.058) 
however by 1 year, the recurrence rates were different (p = 0.032) with fewer recurrent seizures in 
the PFS group. 
4.4 Demographics of control children 
 
A total of 31 children were recruited as healthy control subjects. No control subjects had a 
major abnormality on their MRI scan. Demographic details are given in Table 4-9 and the age 
distribution is shown in Figure 4-5 below. 
 Had any MRI Tolerated DTI Tolerated T2 maps 
 
Age 
(range) 
Number 
(Male: 
Female) 
Age 
(range) 
Number 
Age 
(range) 
Number 
Children having scans 
for other clinical 
reasons 
4.04 (0.21 
– 12.69) 
19 
(7:12) 
3.82 (0.62 
– 11.70) 
15 
(6:9) 
3.80 (0.62 
– 12.69) 
11 
(5:6) 
Normal volunteers 
3.75 (0.26 
– 9.23) 
12 
(5:7) 
3.84 (0.26 
– 9.23) 
7 
(3:4) 
5.11 (2.28 
– 9.23) 
7 
(2:5) 
Total 
3.93 (0.21 
– 12.69) 
31 
(12:19) 
3.82 (0.26 
– 11.70) 
22 
(9:13) 
4.31 (0.62 
– 12.69) 
18 
(7:11) 
Table 4-9: Demographics of control subjects 
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Figure 4-5: Histogram of ages of control subjects 
19 of the children recruited as control subjects were having MRI scans for other clinical 
reasons, which are summarised in Table 4-10, and 12 were healthy volunteers. All control subjects 
had no previous history of seizures, neurological disease (other than that mentioned) or diagnosed 
developmental delay.  
Indication for MRI scan Number of patients 
MRI scan for cochlear implant assessment 3 
Abnormal visual function tests, MRI for assessment of optic nerve 
hypoplasia 
3 
Dermoid cyst 2 
Facial haemangioma, assessment for Sturge-Weber syndrome 3 
Non-intracranial tumour 2 
Headache 2 
Marcus-Gunn phenomena 1 
Congenital nystagmus 1 
Ptosis 1 
Lymphangioma 1 
Table 4-10: MRI indications for control subjects 
  
67 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
4.5 Cognition 
  
 Standardised cognitive scores for each patient group are reported in Table 4-11. These data 
have been previously reported and analysed by Dr M Martinos in her PhD thesis(173) and are 
included here for illustrative purposes only.  
 Controls PFS Symptomatic CSE Other CSE 
Mean (s.d.) 127.38 (11.55) 95.32 (13.97) 75.68 (22.09) 85.14 (21.15) 
Range 110 - 144 65 – 120 55-123 41 - 130 
Table 4-11: Standardised cognitive scores across each patient group at study entry 
4.6 Discussion 
 
When compared with previous epidemiological studies of CSE such the NLSTEPSS study, 
which covered a similar geographical area, children with symptomatic CSE are underrepresented in 
our sample. The reasons for this have been discussed and do have implications as to the power of 
our study to reach conclusions regarding children with symptomatic CSE, particularly those with 
more severe neurodisabilities, who were more likely to be unsuitable for sedation and to decline 
consent due to a high burden from existing multiple hospital appointments. Although there was 
some gender bias in our PFS group, there is no known gender association with PFS aetiology or 
prognosis, so this seems unlikely to significantly bias the results of this study.  
As noted in previous studies, the aetiology of CSE changes with age. PFS is the commonest 
aetiology in the youngest age group, but declines after the age of 3 years. There is a lesser peak of 
symptomatic and other CSE in infancy, but they are then evenly distributed throughout childhood 
and adolescence. 
 Analysis of the clinical factors associated with the initial episode of CSE showed that children 
with PFS were less likely to have had a previous episode of CSE or developmental problems. This is in 
line with the aetiological definition and consistent with other studies. Likewise, studies have 
reported a rate of recurrent seizures within the first year of between 3-56%(34). Our overall 
recurrence rate of 46% falls at the upper end of this range. This risk is highest for those children with 
Other CSE or symptomatic CSE and lower for those with PFS, again in line with that found in previous 
studies(28).  Of note, all recurrent seizures in children with PFS were febrile seizures and no children 
with PFS had had afebrile seizures by the end of the follow-up period. 
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In conclusion, other than those factors mentioned, our study population appears to be 
broadly similar to other reported studies of children with CSE in terms of demographics, medical 
history and seizure semiology. It therefore provides a reasonable foundation for investigating the 
outcome of CSE reaching conclusions applicable to the general population. 
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 CHAPTER 5: CLINICAL MRI FINDINGS 
 
5.1 Summary 
 
The yield of brain MRI following CSE has not been fully investigated and uncertainty remains 
over the best use of neuroimaging after an episode of CSE. Using the data available from our cohort 
of children with CSE we found that around 30% had abnormalities on MRI. Regression analysis 
identified non-PFS aetiology, continuous CSE and persistent abnormal neurological examination as 
independent risk factors for an abnormal MRI scan.  
5.2 Introduction 
 
Following the successful termination of an acute episode of CSE, there is often a dilemma 
concerning the subsequent management and follow-up of the child. In particular, one investigation 
that is frequently considered is the need for neuroimaging and what type of neuroimaging this 
should be. Since outcome is largely dependent on aetiology(28;34), determining the correct 
underlying diagnosis is important both for treatment and prognosis and neuroimaging may be useful 
in this. Current guidelines on the acute management of CSE(62) focus on drug therapy(198) and the 
achievement of seizure termination, but guidance for the optimal use of follow-up investigations 
remains unclear(73) . 
Based on historical data, a minimum yield of detectable lesions of 7.8% has been estimated 
if all children with CSE underwent neuroimaging(73). In practice this may be a conservative 
estimate,particularly if imaging can be restricted to children at particular risk of structural brain 
lesions. It would be beneficial to determine the yield in the general population of children with CSE 
and identify risk factors for the presence of structural lesions so that both unnecessary imaging can 
be avoided and those children who are likely to benefit are treated appropriately. 
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5.3 Methodology 
5.3.1 Patient cohort and classification 
 
 The initial scans of the 80 patients within the STEP IN cohort who successfully underwent 
brain MRI were used for this part of the project. Their clinical details have been previously described 
in Chapter 4. All sequences were available to be used for the MRI classification and clinical factors 
were identified from the initial history and examination as described in Chapter 3. 
5.3.2 MRI classification 
 
Each MRI scan was evaluated by a paediatric radiology trainee (MC) and reviewed by a 
consultant paediatric neuroradiologist (W-KC), for abnormalities. Each scan was assigned  to one of 
four diagnostic groups: normal (no abnormal features detected); normal-variant (some unusual 
feature detected, thought to be a variation of the normal range with no functional significance); 
minor abnormality (abnormal feature thought to be either unrelated to this episode of CSE or of no 
functional significance); or major abnormality (abnormal feature likely to have significant impact on 
the child and/or represent a cause for this episode of CSE.). Scans were also assessed for the 
presence of hippocampal malrotation (HIMAL)(199), which has been reported to be associated with 
seizures(200;201). This was performed blind to the clinical history of the child.  
Four factors were used to identify HIMAL: 
 Incomplete inversion of the hippocampus 
 Blurred internal structure 
 Abnormal position of the collateral sulcus 
 Downwards displacement of the fornix on one side 
Patients with all 4 features were considered to meet full criteria for HIMAL and those with 3 
features were considered to meet partial criteria. 
5.3.3 Statistical analysis 
 
All data were analysed using PASW Statistics 18.0.2 (Chicago, IL). Logistic regression was 
used to investigate candidate variables predictive of an abnormal MRI.  As even minor abnormalities 
may have clinical relevance to the individual child and to maximise our model’s predictive power, 
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major and minor abnormalities were combined for analysis as were normal and normal-variant 
categories. Based on previously reported clinical and demographic factors which may increase the 
risk for structural brain lesions (32;202), the following were investigated: age at CSE; seizure 
duration > 60 mins; seizure focality; continuous vs. intermittent CSE; seizure aetiology (PFS vs. non-
PFS); previous history of seizures or CSE; abnormal neurological examination at assessment; history 
of developmental delay pre-CSE; and results of previous neuroimaging. These were entered into a 
multivariable logistic regression analysis. Bootstrapping techniques were used to assess internal 
validity (203).  
Scaled cognitive scores were calculated for each patient who underwent neuropsychological 
testing at study entry and also at final follow-up, as described in Chapter 3 and t-tests were used to 
compare these scores between children with and without abnormal features on their MRI. 
5.4 Results 
5.4.1 MRI results 
 
Overall, 25/80 (31.2% patient scans showed some abnormal features. These were evenly 
split between major and minor abnormalities, as defined earlier.  All of the major abnormalities were 
found in children with acute, remote or acute on remote symptomatic CSE and only one child with 
PFS showed a minor abnormality. A full breakdown of findings by aetiological group is given in Table 
5-1 and detailed description of specific abnormalities found is given in Table 5-2). One child with PFS 
and no children with other forms of CSE met criteria for unilateral HIMAL and a further 3 children 
with PFS and one child with an unclassified episode of CSE met partial criteria. Including these 
children within the diagnosis, there were a significantly higher proportion of children with HIMAL in 
the PFS group compared to the other groups (9.1% vs. 2.1%, p = 0.029, Chi-squared). 
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 Normal Normal-variant 
Minor 
abnormality 
Major 
abnormality 
PFS (n=33) 30 (90.9%) 2 (6.1%) 1 (3.0%) 0 
Acute 
symptomatic CSE 
(n=3) 
1 (33.3%) 0 1 (33.3%) 1 (33.3%) 
Remote 
symptomatic CSE 
(n=7) 
0 0 2 (28.6%) 5 (71.4%) 
Acute on remote 
symptomatic CSE 
(n=14) 
4 (28.6%) 0 3 (21.4%)  7 (50.0%) 
Idiopathic 
epilepsy related 
CSE (n=8) 
7 (87.5%) 0 1(12.5%) 0 
Cryptogenic 
epilepsy related 
CSE (n=11) 
7 (63.6%) 0 4 (36.4%) 0 
Other CSE (n=4) 4 (100%) 0 0 0 
Total (n=80) 53 (66.3%) 2 (2.5%) 12 (15.0%) 13 (16.2%) 
Table 5-1: MRI findings by aetiology of CSE 
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Minor abnormalities  Major abnormalities 
Nonspecific focal white 
matter lesions 
3  
Previous hypoxic 
ischaemic injury at 
term 
3 
Delayed myelination 
and non-specific white 
matter lesions 
1  
Extensive 
malformation of 
cortical development 
1 
Labyrinthitis ossificans 1  
Porencephalic cyst 
with VP shunt in situ 
2 
Lack of white matter 
bulk 
4  
Mesial temporal 
sclerosis 
1 
Nonspecific diffuse 
white matter signal 
change 
2  Focal cortical dysplasia 1 
Septo-optic dysplasia 1  
Mature damage post 
meningitis 
2 
   
Periventricular 
leucomalacia 
secondary to preterm 
hypoxic ischaemic 
injury 
1 
   Tuberous sclerosis 1 
   
Bilateral basal ganglia 
signal change with 
overlying cortical 
atrophy suggestive of 
neurometabolic 
disease 
1 
Table 5-2: Description of MRI abnormalities found 
5.4.2 Risk Factors for an abnormal MRI 
 
Since not all children had previous CT or MRI, previous neuroimaging was not included in the 
regression model. Regression analysis showed abnormal neurological examination, continuous CSE 
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and non-PFS aetiology as factors predictive of an abnormal MRI. 10 repeated bootstrap analyses 
using 1000 samples each consistently identified these 3 factors as significant and others were not. 
Odds Ratios, B-values and their 95% Confidence Intervals are reported in Table 5-3. 
Predictive factor 
Abnormal 
MRI (%) 
p-value B 
95% confidence 
interval (B) 
Odds 
ratio 
Abnormal neurological 
examination at the time of 
MRI scan 
12 (92.3%) 0.001 5.249 3.959 – 424.134 190.460 
Non-PFS/Unclassified vs 
Prolonged febrile seizures 
24 (51.1%) 0.001 – 0.002 4.345 2.194 – 316.923 77.108 
Continuous vs. Intermittent 
CSE 
19 (40.4%) 0.001 - 0.004 3.399 1.240 – 390.450 29.947 
Developmental delay prior to 
CSE 
15 (62.5%) 0.442 – 0.495 0.682 -40.391 – 47.439 1.978 
Previous seizures 18 (37.5%) 0.716 – 0.786 -0.053 -50.912 – 97.662 0.949 
Previous CSE 9 (42.9%) 0.114 – 0.140 -1.545 -145.027 – 16.245 0.248 
Focal vs. Generalised onset 9 (39.1%) 0.854 – 0.904 -0.020 -52.063 – 45.551 0.980 
Seizure duration > 60 mins 
vs. Duration < 60 mins 
8 (22.2%) 0.032 – 0.053 -1.584 -162.625 – 1.134 0.205 
Age - 0.299 – 0.357 -0.135 -40.097 – 4.986 0.313 
Table 5-3: Clinical factors predictive of an abnormal MRI after CSE 
5.4.3 The implications of previous neuroimaging 
 
30 of the 80 children (37.5%) had head CT scan during their acute admission with CSE. CT 
scan was abnormal in 7 (23.3%). 4 of these were also abnormal on follow-up MRI. Lesions which 
appeared to resolve were minor and included cerebral oedema, white matter asymmetry and wide 
subdural spaces.  Of the remaining 23 children who had a normal acute CT scan,  four (17.4%) had an 
abnormal MRI within 13 weeks of their CSE –  3 minor and one major abnormalities . 17/49 (34.7%) 
children who did not have a CT scan had an abnormal MRI scan (Figure 5-1).  
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Figure 5-1: Flowchart of patients by previous CT result 
 27 of the children in our cohort had previous brain MRI before entry into our study. These 
had been performed for a variety of indications including investigation of developmental delay; 
previous unprovoked seizures; and acute meningitis. Repeat imaging after CSE allowed the detection 
of 5 minor abnormalities that had previously not been reported (Figure 5-2) although they were 
present on the original pre-CSE scans i.e. these were old lesions (consistent with a remote 
symptomatic aetiology) that did not represent new emergent findings and did not necessitate any 
change in treatment. No new major abnormalities were found in children with previous 
neuroimaging, although one patient who had previously been diagnosed as having cortical dysplasia 
was diagnosed as having tuberous sclerosis.   
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Figure 5-2: Flowchart of patients by previous MRI results 
5.4.4 Neuroimaging and cognition 
 
 Children with either minor or major abnormalities reported on their MRI scan had lower 
mean cognitive scores at their initial assessment, although these did not reach statistical 
significance. By 1 year post-CSE however, their cognitive scores dropped further whilst children with 
a normal MRI scan maintained their cognitive ability and this difference was statistically significant. 
Full details are given in Table 5-4. 
 Normal MRI Abnormal MRI p-value for difference 
Mean cognitive score 
1 month post-CSE 
91.06 (20.32) 76.11 (20.33) 0.056 
Mean cognitive score 
1 year post-CSE 
91.00 (18.17) 70.38 (17.65) 0.008* 
Table 5-4: Cognitive scores for children with normal and abnormal brain MRI 1 month and 1 year post-CSE 
5.5 Discussion 
 
It is known from previous studies that have used a mixture of CT and MRI that a high 
proportion of children with CSE have abnormal neuroimaging.  However, ours is the first study to 
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follow a cohort with complete MRI coverage and to systematically investigate clinical factors 
associated with an abnormal MRI.  The main findings are: over 30% of children will have brain MRI 
abnormalities detectable a median of 1 month following CSE, and clinical features can predict those 
children who are most likely to have structural abnormalities on MRI if it is performed as part of 
their follow up investigations. 
Our study found abnormalities on brain MRI in 31.3% (95% CI: 22.2 – 42.1%) of children with 
CSE. This is similar to the findings in a study looking at new onset CSE by Singh et al.(202), which 
reported a 30% yield of neuroimaging abnormalities based on combined CT/MRI in 144 children. 
Previous studies have reported that imaging children after a first unprovoked seizure has a yield of 
brain abnormalities of 13-32%(204-206), not accounting for seizure duration. As a high proportion of 
CSE is associated with an acute provoking factor(32), with the resultant possibility of associated 
structural brain injury, it is consistent that the yield of neuroimaging in CSE is at the upper end of this 
range. 
A recent meta-analysis designed to estimate the prevalence of incidental MRI findings in 
healthy people found overall rates of intracranial abnormalities of 2.7% (95% CI 1.57 – 4.08%)(207). 
Thus, the yield of abnormal features in 31% of our cohort of children with CSE, is substantially higher 
than that expected in a normal population without CSE and unlikely to represent incidental findings.  
The specific predictive factors for a MRI detected structural brain abnormality identified in 
the current study were having i) an abnormal neurological examination after CSE, ii) non-PFS CSE or 
iii) continuous CSE.   Thus, in deciding whether a child should have MRI following status epilepticus, 
we would suggest that these findings be taken into account.  We found no evidence that focality of 
the seizure, history of previous seizures or CSE, or duration of CSE were associated with 
abnormalities on MRI within 6 weeks after CSE and therefore suggest that these should be 
considered less important in the decision on whether an MRI is appropriate. Since the incidence of 
CSE is greatest in infants and younger children(32), the majority of children with CSE are unlikely to 
tolerate an MRI scan without some form of sedation or anaesthesia. These associated procedures do 
carry a risk(208), albeit a small one, (to the child) although the MRI itself is believed to carry minimal 
health risks. Therefore the risks and difficulties in obtaining a brain MRI in children following CSE 
need to be carefully weighed against the likely yield.  We found only one minor abnormality and no 
major abnormalities in the 33 children with PFS at 13 weeks post-CSE, giving an estimated yield of 
major abnormalities of 0-10.3% (95%CI). Thus although children with PFS make up a substantial 
proportion of childhood CSE and there are  concerns over their longer term risk of hippocampal 
damage(209), the majority of them will not have structural abnormalities on MRI during the 
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immediate follow-up period. Although previous reports have suggested an association between PFS 
and HIMAL (Lewis DV et al, FEBSTAT group, personal communication), and we found a greater 
number of children meeting HIMAL criteria in our PFS group the clinical implications of this remains 
uncertain(210).  
Our study did not consider the emergency management of CSE, so we are unable to 
comment on the use of head CT in the emergency department. None of the children in our study 
required emergency neurosurgical intervention, although there may have been children where this 
was an important possibility to exclude. CT performed in the acute situation appears to detect a 
number of acute abnormalities that do not persist and while a normal CT scan reduces the likelihood 
of an MRI abnormality, the predictive power of either a normal or an abnormal CT scan in isolation is 
similar to the clinical factors described earlier. Therefore a normal CT scan does not offer complete 
reassurance that there would be no pathology found on MRI.   
Although CT is more widely available in the acute situation, to detect acute causes of 
seizures (e.g. meningoencephalitis, venous sinus thrombosis), MRI is now the preferred imaging 
modality for epilepsy(73;211;212), due to its increased sensitivity in picking up remote symptomatic 
causes of seizures, such as cortical malformations(212).  In addition, MRI does not utilise ionising 
radiation,  to which children are more sensitive than adults(213;214). Although we found 
abnormalities in 5 children whose MRI scan were previously reported as normal elsewhere, their 
original pre-CSE MRI scans, on re-evaluation by the research team, were not normal and the 
abnormalities seen on repeat scans had already been present.  This would suggest that, in a child 
with a known abnormality on MRI or with otherwise identified remote symptomatic CSE, an episode 
of CSE by itself would not be sufficient reason to repeat the MRI.  It also suggests that CSE is unlikely 
to result in additional brain injury in children with pre-existing brain abnormalities.  
One limitation of this study is that, as previously discussed, our patient cohort may not be 
completely representative of the complete population of children with CSE. Our cohort contained a 
lower proportion of children with acute symptomatic (3.8% v 17.1%; 95%CI for difference 4.8-19.6%)  
or remote symptomatic CSE (8.8% v 16.5%; 95%CI for difference 2-15%) than the previous 
epidemiological study of CSE in North London(28) and compared to epidemiological studies of CSE in 
other populations(29;31). The reasons for this have been previously discussed in Chapter 4, however 
one implication is that the patients included in our study do not include those with the most severe 
medical conditions. As these are among the children most likely to have structural abnormalities on 
neuroimaging this makes our estimate of the yield a conservative one and inclusion of these children 
would not be expected to alter the overall conclusion.  
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It is difficult to comment on how the MRI findings affected the clinical management of these 
children, as responsibility for this remained with the referring hospitals. We did however find that an 
abnormal MRI scan was significantly associated with poorer cognitive outcome at 1 year. This 
suggests that the MRI findings detected were of functional significance to the children. Reports from 
each scan were provided to the responsible clinician looking after each child and our classification 
system was defined that any major abnormalities found would have implications for further 
management and prognosis, if found in a previously imaging-naïve child. It is also important to 
remember however that a normal MRI scan may provide reassurance to families.  
In this chapter we have discussed the clinical findings at MRI following CSE. Based on our 
findings, combined with those of previous studies, we suggest that MRI should be considered in the 
follow-up of children after an episode of CSE as a sizable proportion of children will have structural 
brain abnormalities.  The findings have the potential to provide important diagnostic and prognostic 
information as well as directing therapy. The children most likely to have an abnormal scan are those 
with a persistent abnormal neurological examination and those who have had a continuous seizure 
lasting longer than 30 minutes, while children who can be identified as having had a PFS are less 
likely to benefit from routine neuroimaging.   Whether CSE may lead to structural changes in the 
brain in the longer term, such as mesial temporal sclerosis will be addressed in the following 
chapters. 
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 CHAPTER 6: HIPPOCAMPAL VOLUMES 
 
6.1 Introduction 
 
Although MTS can be diagnosed by a skilled observer on visual inspection of suitable MRI 
sequences(215), reliable detection in a clinical setting requires a unilateral reduction in hippocampal 
volume of over 30%(116). In the previous chapter we established that only one of the children in our 
cohort had MTS on visual inspection of their MRI scan, and in that child it pre-dated their episode of 
CSE. As our hypothesis proposes that MTS is an acquired lesion, developing in children with 
previously normal hippocampi as a result of CSE-related damage, more sensitive techniques are 
necessary to detect precursor stages to clinical MTS. Hippocampal volumetry is one method of 
improving the sensitivity to subtle volume changes over simple inspection and has the additional 
advantage of allowing the quantitative measurement of longitudinal changes. In the interests of 
clarity, the results and discussion sections of this chapter will be organised into 4 sections: the first 
will relate to the assessments of normative hippocampal growth; the second to the cross-sectional 
analyses of hippocampal volumes; the third to the analysis of hippocampal asymmetry; and the 
fourth will concentrate on a longitudinal analysis of hippocampal growth.  
6.1.1 Technical aspects of volumetry 
 
The sensitivity of hippocampal volumetry to true changes in hippocampal volume will be 
limited by the accuracy of these measurements. While a variety of automated techniques for 
measuring hippocampal volumes have been developed(181;182;216;217), the majority of these 
have been designed to process healthy, adult subjects and perform less well in the presence of brain 
pathology(218) or in younger children(219;220). Therefore to date the gold standard remains 
manual tracing of the hippocampus and measurement of the resulting region of interest (ROI). 
Detailed descriptions of how to delineate the hippocampus have been given by a number of 
sources(183). While slight differences in anatomical landmarks and scanning sequences used 
between different studies(184), as well as idiosyncrasies of individual MRI scanners mean that 
absolute values for hippocampal volumes may not be comparable between studies, it has been 
shown that relative values can be obtained with good consistency from an individual centre using a 
well-defined method(185). 
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Although most of the widely accepted protocols predominantly use the coronal plane to 
define regions of interest, more recently simultaneous views of all 3 orthogonal planes has been 
reported to give increased accuracy and reproducibility(221). For the purposes of this study, a 
representative approach was adapted from the previously published literature (182;184;219;222-
226). Particular emphasis was placed on those studies that featured a paediatric population and that 
included measurements of inter/intra-rater reliability.   
6.1.2 Hippocampal growth 
 
One complication of working with a paediatric population is allowing for growth. Over the 
age range included in our study (1 month – 18 years), brain size as well as hippocampal volume 
would be expected to increase and then plateau as children reach their full adult growth. In order to 
compare children who will, of necessity be of varying ages and sizes, this effect needs to be 
accounted for. Because of the technical and ethical difficulty in obtaining MRI scans in normal 
children there have been few studies of normal hippocampal development, and normalised growth 
curves are not available. However those studies that have been performed indicate that growth is 
rapid in the first few years of life and slower or static thereafter: 
 Using a small sample of 6 children, aged between 14 and 60 months, who were having MRI 
for posterior fossa/spinal tumours, Obenaus et al(226) showed that hippocampal volume 
increases approximately linearly over this age range, and that intracranial volume is the 
most appropriate normalisation measure. 
 Between that ages of 4 and 18 years, Gogtay et al(227) found no significant increase in 
hippocampal volume with age in a longitudinal study of 31 healthy children, suggesting that 
the majority of hippocampal growth occurs before 4 years age. They did show alterations in 
localised hippocampal morphology with age, implying that developmental maturation may 
still be occurring, without significant changes in absolute volume.  
 Utsunomiya et al(224) studied 42 Japanese children aged from 3 weeks to 14 years with 
normal neurology who were having MRI scans for various clinical reasons but did not show 
any intracranial pathology. They showed an initial rapid growth phase in the first two years 
of life, followed by slower growth throughout the rest of childhood.  
 Similarly Knickmeyer et al(228) found a 13% increase in hippocampal volumes between the 
ages of 1 and 2 years in their cohort of 13 children using automated segmentation 
techniques. 
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 Another study of 50 children between 1 month and 15 years having MRI for various clinical 
reasons but without epilepsy and without macroscopic structural brain lesions by Pfluger et 
al(229) used a sigmoidal function to model hippocampal growth, but found that the initial 
slow phase of growth predicted from this function occurred during the pre-natal period. 
They also demonstrated initial rapid growth in the first 2 years of post-natal life with 
plateauing of growth thereafter.  
In order to assess the effect of CSE on hippocampal growth therefore, it will be necessary to 
construct a model of normal growth using our healthy control population. 
6.1.3 Objectives 
 
 The objectives of this part of our project are: firstly, to establish normal hippocampal 
volumes in a healthy control population and use this to construct a model of normal hippocampal 
growth; secondly to longitudinally measure hippocampal volumes in a cohort of children following 
CSE in order to establish any deviation in the normal growth trajectory associated with the episode 
of CSE; thirdly to ascertain the impact aetiology has on these factors. 
6.2 Methods 
6.2.1 Hippocampal volumetry 
 
Hippocampal volumetry was performed using the 3D-FLASH MRI sequence detailed 
previously. This sequence provided T1-weighted images with isometric voxels at a resolution of 
1mm3. MRIcro (Rorden, GeorgiaTech Centre for Advanced Brain Imaging) was used to re-orient and 
re-slice the 3D-FLASH images perpendicular to the long axis of the hippocampus. Each hippocampus 
was then manually segmented with a region of interest using MRIcroN (Rorden, GeorgiaTech Centre 
for Advanced Brain Imaging). 
The following anatomical rules were used to define the boundaries of the hippocampus 
(adapted from Hammers et al.(182)): 
1. The hippocampus was visualised in 3 orthogonal planes using MRIcroN and then this used to 
guide placement of the ROI. 
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2. Initial definition of the ROI was done on successive coronal slices. Once the posterior extent 
of the hippocampus was reached then axial and sagittal views were used to further refine 
the ROI. 
3. The anterior border of the hippocampus was defined as the most anterior coronal slice 
where the temporal horn starts to widen and comes to sit alongside the hippocampus 
4. The posterior border was taken to be the last coronal slice on which the fornix is visible 
separate from the crus. 
5. In the anterior section the amygdala was used to define the superior border of the 
hippocampus.  
6. Where visible the alveus was identified and used to define this border. More posteriorly the 
hippocampus was defined by its border with the lateral ventricle. 
7. The inferior border was taken to be variously the parahippocampal gyrus; uncal sulcus; 
interface of the prosubiculum and cornu ammonis; border between subiculum, and 
praesubiculum; or sulcus hippocampalis 
8. Medially the hippocampus was taken to be bordered by the parahippocampal gyrus or 
cerebrospinal fluid and laterally by the lateral ventricle or overlying white matter 
 The volume of each ROI was measured and recorded separately using MRIcroN and 
each ROI file saved for use in further processing steps. An example ROI is shown in Figure 6-1. 
 
  
Figure 6-1: Example hippocampal region of interest 
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6.2.2 Intracranial volume 
 
 Intracranial volume was calculated using the Brain Extraction Tool (BET) in FSL to remove the 
skull and overlying tissues from the 3D-FLASH images. The initial parameters used were: 
bet <input> <output> –f 0.6 –R –o 
The output image was then reviewed for errors and if the segmentation was inadequate 
then settings were adjusted to achieve an optimal result. For some children who were either below 
the age of 4 months at time of scan or who had significant structural abnormalities, such as previous 
ventriculo-peritoneal shunt insertion, BET was unable to fully remove the skull without also 
excluding significant portions of brain. In these cases the best achievable result was taken from BET 
and then the mask was manually adjusted in fslview.  
fslstats was then used to calculate intracranial volume (ICV) by summating all voxels in the 
segmented image using a threshold intensity of 30. 
6.2.3 Validation  
 
 Hippocampal measurements were performed independently by 2 different 
observers (MM and MY) on separate occasions, blinded to the clinical status of the child. As scans 
were collected over time, volume measurements were performed at different times, therefore at 
each point some previously measured scans were included to check for any drift in measurements. 
Each hippocampus therefore had between 2 and 4 measurements recorded by 2 different observers. 
Some drift was seen with the final batch of hippocampi measured, with lower age-adjusted 
hippocampal volumes reported by one observer and therefore increased CoV. These scans were 
therefore all reviewed and compared to previous segmentations. All hippocampi with overall CoV 
greater than 12.5%, representing substantial disagreement between observers, were chosen for re-
measurement and the initial ROIs discarded.  
ROIs were used to calculate inter/intra-rater reliability measurements for each 
hippocampus. An overall, inter-rater and intra-rater coefficient of variation (CoV) was calculated for 
each hippocampus and averaged over all the scans. A random subsample of 200/420 hippocampi 
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also had inter-rater overlap ratios (OvR)(230) and similarity indices (SI)(231) calculated to provide 
additional metrics for comparison (Figure 6-2).  
 
Figure 6-2:  Similarity Index and Overlap Ratio 
  
6.2.4 Statistical analysis 
6.2.4.1 Cross-sectional analysis 
 
 All measurements for each hippocampus were averaged to provide mean left and right 
hippocampal volumes for each MRI scan, which were used for this and subsequent analyses. Control 
hippocampal volumes were then plotted against age and ICV and step-wise linear regression was 
used to test for possible relationships between hippocampal volume, age, ICV and gender. Pearson’s 
correlation was used to test for a relationship between ICV and hippocampal volumes as well as ICV 
and ln(age). Cross-sectional analyses to compare each aetiological group (control children, children 
with PFC, children with symptomatic CSE and children with other CSE) at each time point were 
performed using univariate ANOVA with appropriate corrections for covariates. Post-hoc tests with 
Bonferroni corrections for multiple comparisons were used to compare volumes between each 
aetiological group-pair. 
6.2.4.2 Hippocampal asymmetry 
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 An asymmetry index (AI) was calculated for each scan according to the formula (where HV 
stands for hippocampal volume): 
 
 This was then compared between groups at each time point using a Kruskall-Wallis 1-way 
ANOVA and Mann-Whitney U to perform post-hoc comparison of individual pairs of groups. Moses 
extreme reactions tests were used to compare each patient group with controls to assess outliers. 
Bonferroni corrections for multiple comparisons were applied as appropriate. 
6.2.4.3 Longitudinal analysis 
 
To assess hippocampal growth, several models of normal growth were tested using 
linear/non-linear regression against control values. The model with the best fit was used to generate 
predicted hippocampal volumes for each patient. Predicted mean growth rates over the study 
period were also generated using the patient’s mean age and differentiating the model equation. 
Linear regression was then used to estimate the actual hippocampal growth in each patient over the 
study period and then the predicted growth was subtracted from this to give an estimate of the 
difference from expected growth seen. All patients who appeared to show lower than expected 
hippocampal growth were reviewed and had their hippocampi re-measured in order to improve the 
precision of the growth estimate. These repeat measurements were done by the original observers 
(MM and MY), blinded to the time point of each scan. Patients who showed an estimated 
hippocampal growth with the upper bound of the 95% confidence interval below zero  after this 
procedure were considered to have definite reductions in hippocampal volume over the study 
period. Linear and logistic regressions were used to explore the influence of baseline clinical factors 
on hippocampal growth. 
6.2.4.4 Hippocampal volumes and cognition 
 
The impact of hippocampal growth and volume on cognition was assessed using univariate 
linear regression to compare cognitive scores at baseline and 1 year to age-adjusted hippocampal 
size, ICV and hippocampal growth rates. Variables with p < 0.10 were then entered into a step-wise 
regression analysis, with criteria of p < 0.05 for entry and p > 0.10 for removal.   
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6.3 Validation studies and normative results 
6.3.1 Results 
6.3.1.1 Validation studies 
 
A summary of the different validation measures that were used to estimate reliability is 
given in Table 6-1. Overall reliability of hippocampal volume measurements was acceptable, with 
both inter/intra-rater CoV falling within the middle of the range of reported values from a sample of 
published studies (Table 6-2). Given the heterogeneous nature and young age of our cohort, this was 
considered acceptable to proceed with further analysis. 
Overall CoV Inter-rater CoV Intra-rater CoV 
(MY) 
Intra-rater CoV 
(MM) 
Similarity 
Index 
Overlap 
Ratio 
6.39% 6.27% 5.19% 7.88% 0.798 0.685 
CoV = standard deviation of volume measurements/mean volume 
Table 6-1: Overall, inter and intra-rater coefficients of variability for hippocampal volume measurements 
 
Study Number of scans Age range CoV SI OvR 
Jack et al (1990)(185) 10 Adults 8.7% - - 
Pfluger et al 
(1999)(229) 
50 1mth – 15 yrs 4.9% - - 
Pantel et al (2000)(221) 15 18-21 yrs - - 0.71 – 0.73 
Obenaus et al 
(2001)(226)  
5 1-5 yrs 13% - - 
Hammers et al 
(2008)(219) 
5 2-3yrs 9.0% 0.91 0.84 
Table 6-2: Previously reported inter-rater reliability measures 
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6.3.1.2 Normal hippocampal and intracranial volumes 
 
 Left and right hippocampal volumes and ICV appeared to have an exponential relationship 
with age in controls (Figure 6-3).  
 
Figure 6-3: Left/right hippocampal volumes (A) and intracranial volume (B) in healthy controls with age 
Both left and right hippocampal volumes were significantly correlated with ICV for controls 
(p < 0.001) and with ln(age) (p < 0.001), however only ICV emerged as an independent predictor on 
Figure 6-4: Left and right hippocampal volumes by ICV 
B 
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multivariable linear regression. Figure 6-4 shows left and right hippocampal volumes plotted against 
ICV with regression lines. We did not find a significant relationship between gender and 
hippocampal volume. 
There were significant differences in ICV at initial scan between each patient group (Figure 
6-5) after adjusting for age (p = 0.001). Post-hoc tests with Bonferroni correction for multiple 
comparisons showed that children with symptomatic CSE had age-adjusted ICV approximately 
110cm3 lower than controls (p = 0.030) and approximately 152cm3 lower than children with PFS (p = 
0.001) but were not significantly different from children with other CSE (p = 0.057). There were no 
significant differences in ICV between the other 3 groups. 
 
Figure 6-5: ICV by age for patients and controls at initial MRI scan 
  6.3.2 Discussion 
 
Accurately modelling hippocampal volume and growth is necessary to fully assess 
hippocampal volume changes post-CSE. Because technical variations in methodology between 
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studies can result in different absolute measurements of hippocampal volume, it is necessary to 
create a unique model for any given set of experimental conditions. Measurement of hippocampal 
volume in our control cohort enabled the creation of such a model for this study, allowing 
comparisons with normal hippocampal volume and growth to be conducted in subsequent analyses.  
Our findings that hippocampal volumes are proportional to intracranial volumes are similar 
to the conclusions of Obenaus et al(226). We also found that right hippocampal volumes were 
higher than left hippocampal volumes in the majority of children, again in line with earlier studies 
(229).  
Both ln(age) and ICV were found to strongly correlate with hippocampal volume, but when 
both were entered into the same model, only ICV remained predictive. ICV was therefore chosen for 
use as a covariate in the subsequent analysis due to its stronger association with hippocampal 
volume. As children with symptomatic CSE had a higher incidence of previous brain injury and 
structural abnormality, it was not surprising that this was reflected in a reduced ICV compared to 
controls. 
 Normal hippocampal growth rates have been shown to approximate an exponential curve in 
childhood (229) so an exponential model was used to fit a growth curve to our control data and 
generate expected growth rates for later comparison. It was further assumed that hippocampal 
growth over this age group is always positive (i.e. the hippocampus does not shrink in healthy 
children under the age of 16), which was in accordance with the growth rates predicted by our 
model. This meant that any definite loss of hippocampal volume or negative growth in patients 
within our cohort was considered abnormal.  
6.4 Comparison of mean hippocampal volumes 
6.4.1 Results 
6.4.1.1 Mean hippocampal volumes at 1 month 
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80 patients had MRI scans suitable for volumetry at their initial scan, a mean of 31.8 days 
post-CSE (median 29.5). These were compared with 31 healthy controls with no previous history of 
seizures. Figure 6-6 and Figure 6-7 show actual and predicted left and right hippocampal volumes for 
each aetiological group. Both left (p=0.023) and right (p=0.009) hippocampal volumes were 
significantly different between aetiological groups. Post-hoc analysis showed that children with 
symptomatic CSE had significantly smaller corrected-hippocampal volumes than controls bilaterally 
(Left p=0.023, mean difference 202 mm3; Right p = 0.008, mean difference 243 mm3) and smaller 
right hippocampal volumes than children with 
PFS (p = 0.034, mean difference 206 mm3). All other groups were not significantly different from 
each other. Results are summarised in Table 6-3 below. 
Group Mean left hippocampal volume 
(mm3) 
Mean right hippocampal volume 
(mm3) 
 
Controls 1977 (1890 - 2065) 2085 (1991 - 2180)  
PFS 1944 (1859 - 2028) 2048 (1956 - 2140)   
Symptomatic CSE 1776 (1674 - 1878) 1842 (1731 - 1953)  
Other CSE 1949 (1847 - 2051) 2044 (1933 - 2155)  
All hippocampal volumes are given for an adjusted ICV of 1191 cm3 
  = p < 0.05 
Table 6-3: Mean left and right hippocampal volumes at 1 month post-CSE 
  
 
Figure 6-6: Left hippocampal volumes at 1 month post-CSE 
 
 
Figure 6-7: Right hippocampal volumes at 1 month post-CSE 
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Figure 6-8 Left hippocampal volumes at 6 months post-CSE 
6.4.1.2 Mean hippocampal volumes at first follow-up scan 
 
50 patients had MRI suitable for hippocampal volumetry at the first follow-up period. This 
occurred a mean of 174.8 days post-CSE (median 169.5). As it was not possible to repeat MRI on our 
control group, the same measurements are used for comparison. 
Figures 6-8 and 6-9 show actual and predicted left and right hippocampal volumes for each 
aetiological group at first follow-up. Right hippocampal volumes were significantly different between 
groups (p= 0.005) whereas left hippocampal volumes were not (p=0.080). On post-hoc testing there 
was a trend for children with symptomatic CSE to have smaller left hippocampal volumes than 
controls (p=0.061, mean difference 210mm3) but this did not reach statistical significance. Right 
hippocampal volumes were significantly smaller in children with symptomatic CSE compared to both 
controls (p=0.010, mean difference 309mm3) and children with PFS (p=0.018, mean difference 
316mm3). There were no significant differences between the other groups. These results are 
summarised in Table 6-4 below. 
Group Mean left hippocampal volume (mm3) Mean right hippocampal 
volume (mm3) 
Controls 2062 (1970 - 2152) 2175 (2067 - 2284) 
PFS 1992 (1882 - 2102) 2182 (2050 - 2313) 
Symptomatic 
CSE 
1851 (1720 - 1982) 1866 (1710 - 2022) 
Other CSE 1975 (1839 - 2111) 2001 (1838 - 2163) 
All hippocampal volumes are given for an adjusted ICV of 1244 cm 3 
    = p < 0.05 
Table 6-4: Mean left and right hippocampal volumes at 6 months post-CSE 
 
Figure 6-9: Right hippocampal volumes at 6 months post-CSE 
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6.4.1.3 Mean hippocampal volumes at final follow-up scan 
 
49 patients had MRI suitable for hippocampal volumetry at the final follow-up period. This 
was performed a mean of 396.2 days post-CSE (median 391). Figures 6-10 and 6-11 show left and 
right hippocampal volumes at 1 year post-CSE. On the final follow-up MRI, Left hippocampal 
volumes showed a significant effect of group (p=0.036) whereas right hippocampal volumes did not 
(p=0.065). Post-hoc testing showed that children with symptomatic CSE continued to have smaller 
left hippocampi than control children (p=0.043, mean difference 224mm3) but that the difference in 
right hippocampal volume was not significant (p=0.105, mean difference 258mm3). These results are 
summarised in Table 6-5 below.  
Group Mean left hippocampal volume 
(mm3) 
Mean right hippocampal volume 
(mm3) 
 
Controls 2080 (1987 - 2172) 2190 (2068 - 2311)  
PFS 2057 (1944 - 2169) 2207 (2059 - 2354)  
Symptomatic CSE 1856 (1723 - 1989) 1932 (1757 - 2106)  
Other CSE 1953 (1810 - 2097) 2076 (1888 - 2264)  
All hippocampal volumes are given for an adjusted ICV OF 1255 cm3 
   = p < 0.05 
Table 6-5: Mean left and right hippocampal volumes at 1 year post-CSE 
 
Figure 6-10: Left hippocampal volumes at 1 year post-CSE Figure 6-11: Right hippocampal volumes at 1 year post-CSE 
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6.4.2 Discussion 
We found no evidence of group differences in either left or right corrected hippocampal 
volumes in children with PFS and healthy controls during the year following initial episode of CSE on 
cross-sectional analysis. This finding is in keeping with a previous cross-sectional follow-up study of 
children with PFS, which have also found no difference in mean left/right hippocampal volumes 
between children with PFS and controls (160). This implies that the population mean hippocampal 
volume on either side is not affected by PFS.  Our original hypothesis was that long term 
hippocampal damage is sustained in a proportion of children with PFS. This is not necessarily 
contradicted by this finding, as it is possible that the subset of children affected is not great enough 
to significantly alter the population mean, whilst there still being clinically significant volume loss in a 
small proportion of children. Further investigation of growth rates in individual patients was 
therefore carried out. 
Similar findings were apparent in children with other CSE, with no evidence of group 
differences in hippocampal volumes compared with controls.  
 Children with symptomatic CSE did have systematically smaller corrected hippocampal 
volumes on both left and right sides than healthy controls, although the statistical significance of the 
difference was borderline at some time points after Bonferroni correction for multiple comparisons. 
Given that these children also had significantly smaller ICV than controls and a high incidence of 
structural brain abnormalities, these findings need to be interpreted in context. Many of these 
children had severe neurological conditions and structural brain abnormalities both within and 
without the temporal lobe. It is difficult to conclude therefore that the reduction in mean 
hippocampal volume found was a direct result of CSE, as, apart from two patients with brain damage 
secondary to bacterial meningitis, the abnormalities were the result of insults that pre-dated the 
episode of CSE. Hence it is likely that the hippocampal changes found also pre-date the episode of 
CSE, and reflect an increased vulnerability to the preceding insult(s).  
6.5 Hippocampal asymmetry 
6.5.1 Results 
 Figure 6-12 shows the hippocampal asymmetry index at the initial scan and at each follow-
up and group values are summarised in Table 6-6. Kruskal-Wallis testing showed that there were 
significant differences in AI between the groups at the initial MRI (p=0.048) and at first follow-up 
(p=0.040) but not at the final MRI (p=0.286). Post-hoc testing with Bonferroni correction showed 
that this was primarily because children with symptomatic CSE displayed significantly greater AI at 
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initial MRI (p=0.011) and first follow-up (p=0.021) than children with other CSE. No patient groups 
showed a systematic difference in AI from controls, although there appear to be a number of 
outliers from the histograms.  
  Controls PFS Symptomatic 
CSE 
Other CSE 
Initial MRI Mean 0.082 0.074 0.129 0.058 
Median 0.080 0.051 0.091 0.046 
Range 0.017 – 0.191 0.002 – 0.290 0.003 – 0.588 0.001 – 0.249 
First follow-up 
MRI 
Mean - 0.092 0.148 0.053 
Median - 0.069 0.147 0.031 
Range - 0.006 – 0.263 0.005 – 0.503 0.004 – 0.316 
Final follow-
up MRI 
Mean - 0.097 0.182 0.085 
Median - 0.072 0.166 0.054 
Range - 0.014 – 0.279 0.010 – 0.583 0.001 – 0.350 
Figure 6-6: Summary statistics for hippocampal AI 
 Moses extreme reaction tests showed that extreme outliers were significantly more likely in 
children with PFS compared to controls at initial MRI (p=0.033) and first follow-up (p=0.002), but not 
at one year (p=0.079) and in children with symptomatic CSE at all 3 time points 
(p=0.001/0.010/<0.001). Excluding the one outlier described below, children with other CSE showed 
no increase in outliers at any time point. Histograms for each group at each time-point are shown in 
Figure 6-13, illustrating the differences in distribution of AI. 
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Figure 6-12: Hippocampal asymmetry index at A) 1 month B) 6 months and C) 1 year post-CSE 
97 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
 
  
Figure 6-13 
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Identified outliers with high AI on all 3 MRI scans included one patient with symptomatic CSE 
and a previous diagnosis of right MTS (AI at 1st/2nd/3rd scan: 0.588/0.503/0.583); and a patient with 
other CSE who had a prolonged first afebrile seizure at 8 years but no subsequent seizures (AI at 
1st/2nd/3rd scan: 0.249/0.316/0.350). MRI was reported as normal at all points and the patient was 
attending mainstream school and performed above the expected norms on cognitive testing at the 
beginning and end of the study.  
The 95th centile for AI in control children was 0.181, using this as a cut off, 2 children with 
PFS had a raised AI at their initial MRI scan, one child dropped out of the study after the initial scan 
and follow-up data was not available, the other child had a gradual reduction in AI to within the 
range for control children by the final follow-up. 3 children had an initially normal AI which then 
increased at the first follow-up point above 0.181. One of these was lost to follow-up at 1 year and 
the other two had subsequent reductions in AI at further follow-up, although one remained above 
the 95th centile. Finally a further 2 children with PFS had increases above the 95th centile at their final 
MRI scan, having previously had normal AI.  
Raised AI at any time point was not significantly associated with any identified clinical factors 
on step-wise logistic regression.  
6.5.2 Discussion 
 
Asymmetry indices are a powerful and sensitive way to detect unilateral MTS. By choosing a 
measure that is independent of laterality, assumptions of which side is affected are avoided. As 
demonstrated by the patient in our sample, MTS presents with high hippocampal asymmetry, and 
therefore we would expect evolving MTS to be accompanied by a rising AI. However interpreting 
isolated changes in AI is complicated as there are multiple mechanisms that may increase 
hippocampal asymmetry: increased growth in one hippocampus; failure of growth on one side with 
continued growth in the contra-lateral hippocampus; as well as a unilateral reduction in 
hippocampal volume. Bilateral changes will not be detected with this measure and therefore 
changes in AI need to be interpreted carefully in the context of other clinical and radiological 
information. 
There is a trend for increased hippocampal AI in children with symptomatic CSE compared to 
control children, but this does not reach statistical significance at any time point. Furthermore this 
disappears if the single patient with established MTS is excluded from the analysis. However there 
are significant increases in the tails of the distribution at all time points when compared to controls, 
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which remain even when this patient is removed. This suggests that any increase in mean AI is 
primarily driven by an increase in the number of patients at the extreme end of the distribution and 
not just by the occurrence of one case of MTS in our sample. Indeed 6/24 (25%) children with 
symptomatic CSE had an AI above the 95th centile for controls at 1 year. 
A previous study of 14 children with PFS by our group found an increase in the extremes of 
distribution of hippocampal AI 4-8 months after PFS, with 5 children having AI above the 95th centile 
for controls (46). Similarly in the present study children with PFS were also found to have a 
significant increase in the tails of the distribution for hippocampal AI compared to controls at 1 
month and 6 months post-PFS, however by 1 year this was no longer apparent, although 3/21 (14%) 
children continued to have hippocampal AI above the 95th centile for controls.  
Reviewing the children with PFS who had raised AI at any point, it was apparent that in 3/7 
(43%) cases the increase in AI was transient and normalised with time. Only one of these seven 
children displayed significant hippocampal volume loss (as discussed in Section 6.6) and they all had 
normal hippocampal volumes. Increases in AI were mostly due to either increased growth on one 
side or normal growth on one side with static/slower growth on the other. In the 3 cases with 
subsequent normalisation of AI, the affected side then caught up. Further follow-up was not 
available on the other 4 cases, so the subsequent trajectory of these patients is unknown; there 
were no patients with raised AI across 2 or more time points. Given the evidence that AI can 
normalise on subsequent re-measurement, this needs to be interpreted with caution and may not 
alone be sufficient evidence to diagnose evolving MTS; however given the normal growth rates of 
healthy control children at this age, even static growth of one hippocampus is potentially significant. 
 
  
100 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
 
6.6 Hippocampal growth 
6.6.1 Results 
6.6.1.1 Normal hippocampal growth 
 
 Hippocampal growth was calculated separately for left and right hippocampi using control 
data. Different regression models were tested against the data and this is presented in Figure 6-14 
and 6-15. An exponential model was chosen as the best fit for the data both from theoretical and 
observational criteria. Values for the constants in the model were derived using non-linear 
regression and are presented with their estimated standard errors (Table 6-7). 
Model: HV = 1000*(a – (a-b)*exp(-c*age)) 
 a S.E. b S.E. c S.E. 
Left 2.26562 0.06876 0.71187 0.29298 1.18510 0.39590 
Right 2.37331 0.07888 0.84182 0.33414 1.17949 0.45688 
HV = hippocampal volume; S.E. = Standard Error 
Table 6-7: Regression models for left and right hippocampal volumes 
 The derivative of this model was then used to calculate expected growth rates for each 
patient, using their mean age over the study period. Overall, no aetiological group had statistically 
significant deviation from the predicted growth rate over the study period; however this does not 
exclude MTS being an uncommon outcome of CSE as originally hypothesised. Therefore the growth 
rates in individual patients were studied in more detail. 
In order to minimise the standard errors (S.E.) around our estimates of hippocampal growth 
rates, especially those estimated from only 2 MRI scans, individual patients who showed large 
reductions in hippocampal volume were reviewed and their hippocampi re-measured, with the 
observers blinded to the child’s clinical status or the time point the scan was taken at. The aim of 
this was to improve the precision of our measurements of hippocampal volumes, and hence our 
growth rate estimates. Those remaining patients who had an estimated rate of change of 
hippocampal volume with the upper limit of the 95% confidence interval below zero, were defined 
as showing definite hippocampal volume loss. 
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Figure 6-14: Left hippocampal volume by age in healthy controls 
 
HV = hippocampal volume; a, b and c are the constants in the model equations 
 
 
Figure 6-15: Right hippocampal volumes by age in healthy controls 
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6.6.1.2 Hippocampal growth in children with PFS 
 
 26 children with PFS had repeat imaging. Of these 10 successfully underwent MRI on two 
occasions and 16 attended and tolerated MRI at all 3 time-points. The remaining 7 children with an 
initial scan declined or failed to tolerate further imaging. There was no significant difference in age, 
seizure duration, seizure semiology or previous medical history between children who attended for 
1, 2 or 3 scans. Hippocampal volumes over time of each patient are plotted in Figure 6-16 (left 
hippocampus) and 6-17 (right hippocampus) along with the predicted normal growth curve 
generated from control data and the estimated growth rates are shown in Figure 6-18. Overall the 
mean growth rate did not differ from that predicted from the control model for either hippocampus. 
Hippocampal growth did not correlate with any seizure-associated variables (seizure duration, 
focality, continuous vs. intermittent) on linear regression for either hippocampus. 
 3 children appeared to have a unilateral reduction in left hippocampal volume over the 
study period, one had a reduction in right hippocampal volume and one child had a bilateral 
reduction in hippocampal volumes (red lines on Figure 6-16/6-17). All had generalised tonic-clonic 
convulsions continuously for at least 30 minutes as part of their PFS. Further clinical details are 
summarised in Table 6-8.  
Patient 
ID 
Age at CSE 
(years) 
Duration 
(min) 
Previous seizure 
history 
Seizure 
recurrence 
Hippocampal changes Number 
of scans 
16 4.56 69 No previous seizures No further 
seizures 
Decrease in right 
hippocampal volume: 
240mm
3
/yr 
3 
17 2.96 45 2 previous febrile 
convulsions, 1 
episode PFS 
2 further PFS Decrease in left 
hippocampal volume:  
215mm
3
/yr 
2 
119 1.21 60 2 previous febrile 
convulsions from 6 
months age 
1 further short 
febrile convulsion 
Decrease in left 
hippocampal volume: 
197mm
3
/yr 
2 
151 1.61 105 No previous seizures No further 
seizures 
Small bilateral 
decreases in 
hippocampal volume: 
left 67 mm
3
/yr; right 
178 mm
3
/yr 
3 
225 2.89 30 2 previous febrile 
convulsions 
No further 
seizures 
Decrease in left 
hippocampal volume: 
660mm
3
/yr 
2 
Table 6-8: Children with hippocampal volume loss following PFS 
 A further two children were found to have static or very slow hippocampal growth, at an age 
where our model predicted large increases in hippocampal volume. These are not included in Table 
6-8 as they did not show absolute volume losses. 
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6.6.1.3 Hippocampal growth in children with symptomatic CSE 
 
 17 children with symptomatic CSE were available for analysis, 13 children had 3 scans 
available and 4 had 2. The remaining 7 children with an initial scan declined or failed to tolerate 
further imaging. There was no significant difference in age, seizure duration, seizure semiology or 
previous medical history between children who attended for 1, 2 or 3 scans, although there was a 
tendency for more of the older children to re-attend. Hippocampal volumes over time of each 
patient are plotted in Figure 6-19 (left hippocampus) and 6-20 (right hippocampus) along with the 
predicted normal growth curve generated from control data and the estimated growth rates are 
shown in Figure 6-21. Hippocampal growth did not correlate with any seizure-associated variables 
(seizure duration, focality, continuous vs. intermittent) on linear regression. 
 One patient, with known right sided TLE-MTS had decreases in both left and right 
hippocampal volumes and a further 4 children had unilateral decreases in either left or right 
hippocampi (Blue lines on Figure 6-19/6-20). Further clinical details are given in Table 6-9. 
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Patient 
ID 
Age at CSE 
(years) 
Duration 
(min) 
Previous seizure history Focal Continuous Clinical 
information 
Medication Seizure 
recurrence 
Hippocampal 
changes 
No of 
scans 
9 5.68 30 6 previous short febrile 
seizures 
No No Ex-prem 26/40 
Previous IVH 
Developmental 
delay 
None No further 
seizures 
Decrease in left 
hippocampal volume 
292mm
3
/yr 
3 
113 10.10 215 3 neonatal seizures No Yes Ex-prem, 24/40 
Previous IVH 
Developmental 
delay 
Carbamazepine Started on 
medication, 
no further 
seizures 
Decrease in right 
hippocampal volume 
550mm
3
/yr 
3 
128 4.27 110 Absence seizures since 6 
months age, 10 prior 
episodes of CSE 
No No Known 
developmental 
delay with acute 
febrile illness 
Topiramate 5 absence 
seizures 
Decrease in left 
hippocampal volume 
252mm
3
/yr 
3 
175 3.31 45 Neonatal seizures and then 
5 seizures over past 3 
months 
No No Left occipital 
infraction from 
neonatal sepsis 
and haemorrhage 
Phenytoin, 
Sodium 
Valproate 
Weekly 
short clonic 
seizures 
Decrease in right 
hippocampal volume 
544mm
3
/yr 
2 
205 7.36 30 8 previous CPS Yes Yes Right MTS None Monthly 
CPS 
Bilateral decreases in 
hippocampal volume: 
left 360mm
3
/yr; right 
185mm
3
/yr 
3 
CPS: Complex partial seizures  
IVH: Intraventricular haemorrhage 
MTS: Mesial Temporal Sclerosis 
Table 6-9: Children with hippocampal volume loss following symptomatic CSE 
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6.6.1.4 Hippocampal growth in children with other CSE 
 
 17 children with other CSE had repeat imaging. 10 attended for all 3 MRI scans and 7 were 
imaged twice. The remaining 6 children with an initial scan declined or failed to tolerate further 
imaging. There was no significant difference in age, seizure duration, seizure semiology or previous 
medical history between children who attended for 1, 2 or 3 scans, although there was a tendency 
for more of the older children to re-attend. Hippocampal volumes over time of each patient are 
plotted in Figure 6-22 (left hippocampus) and 6-23 (right hippocampus) along with the predicted 
normal growth curve generated from control data and the estimated growth rates are shown in 
Figure 6-24. Hippocampal growth did not correlate with any seizure-associated variables (seizure 
duration, focality, continuous vs. intermittent) on linear regression for either hippocampus. 
1 child had a bilateral decrease in hippocampal volume over the study period and one child 
had a unilateral decrease in right hippocampal volume. 2 children had a large decrease in right 
hippocampal volume and a smaller decrease in left hippocampal volumes, although the confidence 
intervals surrounding the growth rate of the left hippocampus in both children contained both 
positive and negative values. A further child showed bilateral decreases in hippocampal volumes, 
but the confidence intervals again contained both positive and negative values. Children showing 
decreases are highlighted in red in Figure 6-22/6-23. Further clinical details are given in Table 6-10. 
There was also one child under 1 year of age, who presented with CSE due to cryptogenic epilepsy 
and recurrent febrile and afebrile seizures who showed low growth of both hippocampi compared to 
that predicted by our control model at that age. This child was later found to have a SCN1a mutation 
and continues to have difficult to control seizures and an increasing cognitive deficit. 
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Patient 
ID 
Age at 
CSE 
(years) 
Duration 
(min) 
Previous seizure history Focal Continuous Clinical 
information 
Medication Seizure 
recurrence 
Hippocampal changes No of 
scans 
12 6.34 45 1 previous unprovoked focal 
seizure 
Yes No Idiopathic 
epilepsy 
None Recurrent 
episode of CSE 
Decrease in left 
hippocampal volume 
860mm
3
/yr, right 
286mm
3
/yr 
2 
47 15.44 103 Daily seizures for past 1 ½ years No No Cryptogenic 
epilepsy 
Sodium 
valproate 
Topiramate 
Daily recurrent 
seizures, 
myoclonic and 
generalised tonic-
clonic 
Decrease in left 
hippocampal volume 
360mm
3
/yr, right 
130mm
3
/yr 
3 
88 5.10 30 Previous PFS followed by 2 
subsequent simple febrile 
convulsions 
No Yes Idiopathic 
epilepsy 
Phenytoin 
Carbamazepine 
No further 
seizures 
Decrease in right 
hippocampal volume 
174mm
3
/yr 
2 
124 0.86 80 3 previous febrile and afebrile 
seizures 
No No Cryptogenic 
epilepsy 
SCN1a mutation 
Sodium 
valproate 
Topiramate 
Breakthrough 
seizures when 
unwell 
Reduced growth of both 
hippocampi 
3 
199 9.83 47 None Yes Yes Unprovoked 
new onset CSE 
None 1 further possible 
seizure 
Bilateral decrease in 
hippocampal volume: left 
410mm
3
/yr; right 
685mm
3
/yr 
3 
202 8 90 1 previous febrile convulsion, 
previous cluster of clonic 
seizures 
Yes No Cryptogenic 
epilepsy 
Sodium 
valproate 
None Bilateral decreases in 
hippocampal volume: left 
442mm
3
/yr; right 
1017mm
3
/yr 
2 
Table 6-10: Children showing hippocampal volume loss following other CSE 
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6.6.1.5 Predictive factors for hippocampal volume loss 
 
 Linear regression did not show any significant association between hippocampal growth 
(left/right) and a number of clinical factors, including: seizure duration (p = 0.150/0.425); focal vs. 
generalised CSE (p = 0.253/0.124); continuous vs. intermittent status epilepticus (p = 0.941/0.742); 
previous history of CSE (p=0.150/0.096);and number of previous seizures (p=0.948/0.541). Each 
factor was entered individually into the regression model (p-values quoted) and in all 2-factor 
combinations, with no significant associations being found. Logistic regression was also performed 
using a significant decrease in hippocampal volume as the outcome measure and the same factors as 
predictors, and similarly failed to show any significant associations. 
 Regression analysis was repeated on the PFS subgroup alone and showed that the number 
of previous febrile seizures had a significant association with left hippocampal growth (p < 0.001; B = 
-76.68; 95%CI: -111.16 - -42.20) and that children who showed a definite decrease in hippocampal 
volume were also more likely to have previous febrile seizures (p = 0.051, OR 1.75; 95%CI: 1.00 – 
3.06). No associations were found with other clinical factors. Subgroup analysis of the other groups 
did not reveal any significant associations (p-values all > 0.1 on univariate linear and logistic 
regression). 
 Seizure recurrence during the follow-up periods was also not associated with a definite 
decrease in hippocampal volume, but there was a borderline association between hippocampal 
volume loss and repeated CSE (p=0.079, OR: 4.61 95%CI 0.84 – 25.5).  
6.6.2 Discussion 
 
Many attempts to evaluate hippocampal volume changes following CSE have relied on 
single-time point cross-sectional data (45;47;160).  This presents inherent limitations when 
considering a quantity that is changing over time. Analysis of data at any single time point is unable 
to detect progressive changes in hippocampal volume over time and may cause misleading 
extrapolations from a single outlying measurement. Since our initial hypothesis linking CSE and TLE-
MTS presupposes that the changes occurring in the hippocampus are progressive in nature, 
longitudinal measurements and analysis of hippocampal volumes are essential to detect volume 
changes over time.  
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Only two studies to date have reported longitudinal measurements of hippocampal volumes 
after CSE in children (46;159). In both these studies, which only considered children with PFS, initial 
hippocampal volumes were measured within 3-5 days of the initial episode of CSE, with follow-up 
measurements a number of months-years later. It is known that patients imaged within this acute 
period show increased hippocampal volumes, thought to be attributable to hippocampal oedema 
(232). Because of this our group previously interpreted a fall of 203mm3 in mean corrected 
hippocampal volumes in children with PFS between initial MRI scan and follow-up at 4-8 months 
post-CSE as the result of the resolution of this initial oedema, as hippocampal volumes at follow-up 
were not significantly different from control values(46). Provenzale et al(159), despite taking initial 
measurements at a similar time point, had a longer period of follow-up spanning 2-23 months post-
CSE and reported absolute falls of 715-1217mm3 in uncorrected hippocampal volumes in 3/11 
children along with persistent abnormal T2 signals, and smaller reductions in a further 2 children. 4/5 
of these children had recurrent unprovoked seizures and 2 were diagnosed with TLE. All 5 of these 
children were interpreted as having MTS. The relatively high drop-out rate from their original cohort 
of 38 children along with generous diagnostic criteria may explain the relatively high rate of MTS 
(45.5%) reported in their study. 
6.6.2.1 Hippocampal growth following PFS 
 
In this current study, we found 5/26 (19.2%; 95%CI: 8.5-37.9%) patients with PFS, to have 
definite hippocampal volume loss, defined as a rate of change of hippocampal volume with the 
upper bound of the 95% confidence interval below zero, in the 6-12 months following CSE. Growth 
rates for two of our patients are based on 3 serial hippocampal measurements, and 3 patients only 
attended for the initial scan and one follow-up. Only one of these 5 patients (ID: 16) was amongst 
those identified as having increased hippocampal AI in Section 6.5. The others had symmetrical 
hippocampi on their initial MRI and AI remained within normal limits at all times. The reason for AI 
remaining normal, despite volume loss was that in the 4 children with unilateral volume loss, it was 
the larger hippocampus at initial scan that lost volume and then became the smaller hippocampus. 
Since AI is independent of laterality, this did not cause an increase in AI. This may also be reflective 
of the fact that these reductions in hippocampal volume did not, in general take these patients 
outside of the range of our control cohort, as can be seen in Figure 6-15/6-16.  
The children with PFS with volume loss form a heterogeneous group. There were no obvious 
clinical characteristics to set these children apart from the rest of the cohort at initial presentation. 
3/5 had a history of previous febrile convulsions, 2 quite severe (1 had multiple PFS; the other had 
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recurrent FC from the age of 6 months). While 2 children have had recurrent seizures, including a 
further episode of CSE in one child, these have all been associated with an acute febrile illness and 
none of these children have developed unprovoked seizures or received a diagnosis of epilepsy.  
One fact that is apparent is that MTS is not an important cause of PFS. None of our patients 
meet the criteria for MTS and none had hippocampal abnormalities visible on their initial MRI scan. 
However a sizeable proportion of children do display loss of hippocampal volume following PFS, 
which could be interpreted as a sign of longer-term hippocampal injury, and a potential precursor to 
MTS. It is difficult to draw firm conclusions about the proportion of children who will develop MTS, 
as it cannot be assumed that children with volume loss in the first year following PFS will necessarily 
progress further to clinical MTS. None of our cohort has developed unprovoked seizures to date and 
further follow-up is needed to determine if those children with volume loss do progress to MTS-TLE. 
However as progressive volume loss would appear to be a prerequisite for a normal hippocampus to 
transform into a sclerosed one, it seems biologically implausible that those children who are not 
showing signs of altered hippocampal growth will go on to develop MTS as a result of this episode of 
PFS if no signs of this process are detectable in the first year. This would place 19% as a plausible 
maximum proportion of children that are at risk of developing MTS. That this is not significantly 
different from the proportion of children reported by Provenzale et al(159), particularly if the two 
patients in their study who showed less than a 1% decline in volume are disregarded, despite our 
more intensive follow-up and more stringent diagnostic criteria, suggests that this is a genuine effect 
with longer term clinical significance.  
From our limited sample, it is not possible to extract clinical predictors that could help 
determine which children are at risk, as our study was not powered fully to perform such subgroup 
analysis given the numbers enrolled. The lack of association between hippocampal growth and any 
of the seizure-associated variables that were tested, suggests that there may not be a simple 
relationship between seizure severity and hippocampal damage. In spite of previous studies pointing 
towards an association between febrile seizure duration and MTS-TLE(162) we did not find an 
association between duration of CSE and hippocampal volume loss, albeit all the children in our 
cohort had a seizure duration of over 30 minutes by definition. We did find an association between 
volume loss in children with PFS and the number of previous febrile seizures that they had sustained. 
This raises the possibility that “multiple hits” are required for PFS to cause lasting hippocampal 
damage. Some supporting evidence for this hypothesis has come from animal models of PFS, in 
which animals with pre-existing cortical lesions were found to be much more vulnerable to 
developing epilepsy after an induced PFS(233). Alternatively, certain combinations of the factors 
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that cause certain children to react to febrile illnesses with a PFS may also be responsible for 
hippocampal volume loss, with the episode of PFS perhaps being a trigger for this. Further data is 
needed to draw a definite conclusion, especially longer-term follow-up.  
6.6.2.2 Hippocampal growth following non-PFS CSE 
 
Volume loss is not limited to children with PFS: 5/17 (29.4%; 95%CI: 13.3-53.1%) patients 
with symptomatic CSE and 5/17 (29.4%; 95%CI: 13.3-53.1%) patients with other CSE also had 
hippocampal volume loss during the study period, a higher proportion than the children with PFS.  
As well as having lower mean hippocampal volumes than the other groups and more 
extreme asymmetry, a sizeable proportion of children with symptomatic CSE demonstrate significant 
hippocampal volume loss after CSE. While only one patient in our cohort had clinical MTS, the 
hippocampus is known to be selectively vulnerable to a variety of neurological insults, including 
hypoxic injury (234;235) and brain injury associated with preterm birth (236). It can be seen from 
Figure 6-17/6-18 that all but one of the children showing volume loss had low initial hippocampal 
volumes compared to controls so it is likely that these hippocampi have sustained previous injury. 
Although there is relatively little known about the effects of additional neurological insults in people 
with pre-existing structural abnormalities, animal models have shown that pre-existing neuronal 
injuries or abnormalities can cause increased vulnerability to further insults(237;238). Therefore for 
these children to lose volume after CSE may not be unexpected. An alternative explanation is that 
the original injuries have caused long term disruption of hippocampal growth, resulting in small 
hippocampi that continue to shrink with age. The time gap between any initial brain injuries and the 
rate of hippocampal volume loss seen following CSE suggest that this is unlikely to have been a 
continuous process since initial injury, but long term damage with a more insidious time course does 
remain a possibility.  
The 5/17 children with other CSE who showed definite volume loss all had modest bilateral 
losses and all received a diagnosis of epilepsy either before study entry (4/5 children) or shortly 
afterwards (1/5 children). Studies of adult patients with newly diagnosed epilepsy have shown that a 
proportion will show significant hippocampal volume loss if longitudinal MRI is performed (239;240). 
This has been shown to occur in both focal and generalised epilepsy, with studies by Salmenpera et 
al(239) and Liu et al(240) both finding that between 10-20% of adults with newly diagnosed epilepsy 
show decreases in hippocampal volume on longitudinal MRI. The decreases demonstrated are 
relatively modest and were not been shown to be related to any particular epilepsy syndrome, 
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seizure type or seizure frequency. Neither were they shown to lead to MTS. This effect is similar in 
magnitude and frequency to that displayed by our cohort. It seems reasonable to conclude that 
there may be a similar pathological process at work and that this is likely to be related to the 
underlying epilepsy, rather than the episode of CSE alone.  
 
6.7 Hippocampal volume and cognition 
6.7.1 Results 
 
 Predicted hippocampal volumes were calculated using the model generated in Section 6.3.7 
and these were used to generate corrected hippocampal volumes. A similar process was used to 
calculate corrected ICVs, with a linear model of the form ICV = a+b*ln(age) being used to generate 
predicted ICV. Left and right corrected hippocampal volumes were then averaged for each scan to 
generate a mean corrected hippocampal volume. Linear regression was then used to investigate the 
relationship between hippocampal volumes, ICV, growth rates and cognitive outcome at 1 month 
and at 1 year.  
 Mean corrected hippocampal volumes at initial scan showed a strong correlation with the 
composite cognitive score at initial assessment (p= 0.002) and at final follow-up (p=0.006), as was 
corrected ICV (p=0.001/0.001; initial assessment/follow-up). Neither initial nor follow-up cognitive 
scores showed a significant correlation with left (p=0.465) or right (p=0.740) hippocampal growth 
rates. When both ICV and mean hippocampal volume were entered into a step-wise linear 
regression model, only corrected ICV remained in the final model for both initial and follow-up 
cognitive scores.  
6.7.2 Discussion 
 
 Both baseline age-corrected ICV and hippocampal volume was correlated with cognitive 
scores at baseline and after 1 year. Modelling with step-wise linear regression showed that ICV was 
the stronger predictor for initial and follow-up cognitive scores. Since we have previously shown that 
ICV and hippocampal volume are tightly correlated, this suggests that the overall level of brain 
development or injury is the primary determinant of cognitive outcomes after CSE and that this 
masks any contribution from specific hippocampal injuries, hence little predictive power is added by 
including hippocampal volume into a model of cognitive scoring.  
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6.8 Conclusion 
 
We have demonstrated that around 20-30% of children go on to have definite hippocampal 
volume loss in the year following CSE. In comparison to previous studies of hippocampal volume 
after CSE, we have achieved a more intensive and more complete follow-up, as well as including 
different aetiologies of CSE other than PFS. This has shown that volume loss after CSE is not limited 
to PFS, but occurs with equal, if not greater frequency in other forms of CSE. The characteristics of 
this volume loss appear to differ by CSE aetiology and we hypothesise that this is because of 
differing causes and consequences.  
The most pronounced effects are in children with symptomatic CSE. These children have 
pre-existing brain injury, including hippocampal injury and it is likely that this plays an important part 
in determining the response to CSE. We hypothesise that children with pre-existing injuries are more 
vulnerable to the deleterious effects of CSE on the hippocampus, and this can be seen in the 
increased proportion of children with symptomatic CSE showing hippocampal volume loss and 
increasing asymmetry following CSE.  
Children with CSE in the context of idiopathic or cryptogenic epilepsy appear to show 
bilateral hippocampal volume losses, with no increase in asymmetry. We hypothesise that this is 
associated with the underlying epileptic condition and is not related to the development of MTS. 
Finally, children with PFS show no signs of pre-existing hippocampal injuries, and the 
majority show normal growth and hippocampal volumes following CSE. Around 20% will show signs 
of long term hippocampal injury after PFS, as evidenced by a unilateral loss of hippocampal volume 
over time. We hypothesise that some number of these will progress to MTS and start exhibiting 
spontaneous seizures. There may also be more subtle forms of hippocampal injury that occur 
following PFS, as evidenced by the number of children who showed a transient rise in hippocampal 
AI and/or reduced hippocampal growth, without actual loss of volume. Animal models of MTS show 
cell death and hippocampal volume loss as an early feature (53) following CSE, suggesting that 
although we have shown evidence of some degree of hippocampal injury, the induction of further 
hippocampal damage, at a time so remote from the initial episode of CSE may be less likely, though 
this will only become evident with longer-term follow-up of our cohort.  
In the following chapters we will explore the use of diffusion tensor imaging to provide 
further information about brain changes following CSE, both within the hippocampus and in other 
brain regions.  
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Chapter 7: Hippocampal DTI 
 
7.1 Introduction 
 
 As previously described, diffusion tensor imaging is a technique that provides information 
about the preferential diffusion of water molecules within living tissue. DTI can identify 
abnormalities in the micro-architecture of the brain (174;175)and is increasingly being used in the 
assessment of structural pathology in the brain in both clinical and experimental research (241;242). 
It is proposed that by being sensitive to changes in tissue microstructure, DTI can enable the 
detection of subtle brain abnormalities that are not observed using conventional MRI techniques.  
In patients with established TLE-MTS there have been several reports of changes in MD and 
FA in the affected hippocampus(186-191), raising the possibility that DTI may provide an additional 
method of tracking hippocampal changes post-CSE and aid in detecting precursor stages to TLE-MTS. 
Diffusion abnormalities have been reported in the peri-ictal phase(243;244) and in the first 1-3 days 
following CSE using diffusion weighted imaging (DWI)(245), but no investigations using DTI have 
been reported.  
7.2 Validation studies 
 
7.2.1 Rationale 
 
Although there is increasing interest in whole brain analyses of these parameters, using 
automated tools such as voxel-based morphometry(195) and tract-based spatial statistics(196), 
which will be considered in Chapter 8, selective measurement of diffusion metrics, such as MD and 
FA within specific brain areas using a region/volume of interest (ROI) based approach remains 
important.  
However, even in brain structures where ROI placement should be easier than would be 
expected in the hippocampus, ROI placement is a non-trivial problem. The appearance of anatomical 
boundaries and landmarks on MD or FA maps is often unfamiliar and can be difficult to ascertain. 
Diffusion scans are also of a lower spatial resolution and typically have a lower signal-to-noise 
ratio(246) than conventional anatomical scans with greater sensitivity  to susceptibility artefacts 
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associated with the echo planar imaging readout required for bulk motion insensitivity necessary for 
DTI. There is furthermore, no agreed standard for hippocampal ROI placement, and a variety of 
different methods have been reported throughout the literature. Some manual methods that have 
been used in published studies (186-191;247;248) are listed in Table 7-1: 
Wieshmann et al. (1999)(188) Hippocampus manually delineated using b0 image 
Assaf et al (2002)(186) 4x8mm ROI placed on MD map 
Muller et al (2006)(247) 3X4mm ROI placed on b0 image 
Thivard et al (2005)(187) Hippocampus manually delineated using MD map 
Salmenpera et al (2006)(189) Elliptical ROI drawn on 4 consecutive slices on b0 image 
Kimiwada et al (2006)(190) Hippocampus manually delineated using b0 image 
Knake et al (2009)(191) 4mm diameter spherical ROI placed on b0 image 
Hong et al (2010)(248) 3.3 mm diameter spherical ROI placed on b0 image 
b0 = Reference image without diffusion weighting 
Table 7-1: Published methods of hippocampal ROI placement 
As mentioned in Chapter 2, methodological differences between some of these studies have 
led to different conclusions as to the types and magnitude of FA changes seen in TLE-MTS, although 
there is broad agreement that MD tends to increase. Preliminary validation studies were therefore 
performed to investigate different methods of hippocampal ROI placement and optimise the 
method chosen for subsequent studies. 
 
7.2.2 Methods  
 
7.2.2.1  MRI sequences 
 
 Diffusion-weighted echo planar imaging was used to acquire 19 axial slices, 2.5mm thick, 
using the following parameters: TR = 96 ms, TE = 2700 ms, acquisition matrix 96x96, in-plane 
resolution 2.5x2.5 mm. Diffusion-weighting was performed along 20 non-collinear directions using 
maximum b values of 1000s/mm2. One acquisition with no diffusion-weighting (b0 image) was 
included with each set of diffusion-weighted sequences. The scan was repeated three times to 
improve SNR and the data merged together without averaging. MD and FA maps were then 
generated from this data using TractoR as mentioned in Chapter 3.  
 These maps as well as the b0 image were used for all the studies described below. 
Hippocampal ROIs drawn on the 3D-FLASH images from the volumetry study as described in Chapter 
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6 were also used. All images were manually inspected for motion artefact and any unsuitable images 
were excluded from the analysis.  
7.2.2.2Validation cohort 
 
Ten sample patient scans and 6 healthy controls were chosen randomly from those children 
in our cohort who tolerated the DTI sequences. The patient group consisted of 4 boys and 6 girls 
with ages ranging from 0.93 - 15.82 years, and a mean age of 4.00 years. The group of healthy 
controls consisted of 4 boys and 2 girls, aged between 2.27 – 9.77 years with a mean age of 4.74 
years. The controls chosen for this study were all healthy volunteers with no known neurological or 
developmental problems.  
7.2.2.3 Manual ROI placement 
 
 FSL (http://www.fmrib.ox.ac.uk/fsl/, FMRIB, Oxford University) was the primary software 
package used for this analysis: fslview was used to visualise the MD/FA/b0 maps as a 3-D dataset and 
to manually delineate the ROI; mean MD and FA values within the generated ROI were then 
measured using fslstats. 
As there is no current gold standard for defining ROIs in the hippocampus, four methods of 
ROI placement were chosen for comparison, adapted from the manual methods that have been 
previously described (Table 6-1) as well as a semi-automated method that involved first drawing an 
ROI on a high resolution T1-weighted image and then registering this onto the MD and FA maps. 
 In order to create an ROI the following methods were used: 
 
Method 1) The MD map was loaded into MRIcron and the entire hippocampus manually 
delineated as far as was ascertainable. Landmarks that were used to identify 
the hippocampus included the lateral ventricle and chroidal fissure. 
Method 2) The b0 images were loaded into MRIcron and the entire hippocampus 
manually delineated as far as was ascertainable using similar landmarks as 
Method 1. 
Method 3) The slice with the largest cross-section through the anterior third of the 
hippocampus was identified on a coronal view and a fixed size ROI of 3x2 
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voxels was placed into the hippocampus on the MD map on two consecutive 
coronal slices. 
Method 4) The hippocampus was defined using the 3-D FLASH dataset and this was 
then co-registered to the FA map. The technique used is described below. 
 
 Sample images of ROIs created by each method are given in Figure 7-1: 
 
Each method was then used to generate an ROI for each hippocampus and the mean MD 
and FA values within the ROI recorded. This was then repeated by the same observer at least 48 
hours after the first run. This generated two MD and two FA values for each method in each 
hippocampus.   
 
Following this a similar comparison was performed to determine the optimum size for the ROI in 
Method 3. The following sized ROIs were placed into the hippocampus in MRIcron (Figure 7-2): 
Figure 7-1: Example ROIs for each method of ROI placement 
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1) 1 voxel 
2) 2x2 voxels on one coronal slice 
3) 2x2 voxels on two consecutive coronal slices 
4) 3x2 voxels on two consecutive coronal slices 
5) 3x2 voxels on three consecutive coronal slices 
6) 3x3 voxels on three consecutive coronal slices 
 
These were similarly repeated after 48 hours and the MD and FA values compared using the 
coefficient of variability. 
 
7.2.2.4 Coregistration 
 
Method 4 used the hippocampal ROIs created on 3D-FLASH images that were used to measure 
hippocampal volumes described in Chapter 6. Each subject had left and right hippocampi outlined as 
a ROI using the 3D-FLASH sequences in MRIcron as previously described.  
The FA maps were then co-registered to the 3D-FLASH images using the non-linear co-
registration tools in FSL (249) (FNIRT). The resulting warp-field was inverted and used to map the 
ROIs from the 3D-FLASH images onto the FA maps, which are in the same image space as the MD 
and b0 maps. The mean MD and FA values within each ROI were calculated in similar fashion to the 
ROIs created from the other methods using fslstats.  
 
  
Figure 7-2: Increasing ROI sizes used for Method 3. Each cube represents one voxel. 
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7.2.2.5 Qualitative assessment 
 
Each ROI was viewed in FSLview by an experienced paediatric neuroradiologist (Dr WK 
Chong) who had not been involved in drawing them. They were viewed and overlaid onto MD, FA 
and b0 maps. Each ROI was agreed to lie within the hippocampus as far as was ascertainable from 
visual inspection by the same neuroradiologist.  
 
7.2.2.6 Statistical analysis 
 
As described above, two MD and FA measurements were obtained for each method in each 
hippocampus. Since precision is not easily comparable across individuals, especially when the value 
being studied may vary, these two values were used to calculate the CoV separately for a method in 
each subject and then averaged across patients. This was performed separately for MD and FA.  
The CoV from each hippocampus was then averaged across all patients to generate a mean CoV 
for each of the four methods. The range and standard deviation of all voxel values within each ROI 
was also calculated and likewise averaged across all patients for each method. 
PASW 18.0 (Chicago, IL) was used to test for differences in CoV between each of the four 
methods of ROI placement with a Kruskal-Wallis test. Repeated Mann-Whitney U tests with 
Bonferroni correction for multiple comparisons were used to compare pairs of methods individually. 
Likewise Univariate ANOVA was used to compare the mean range and standard deviation of MD/FA 
values within each ROI across each of the 4 methods. The cut-off for significant values was taken as 
p < 0.05.  
7.2.3 Results 
 
7.2.3.1 Estimation of reliability 
 
There was no significant difference between the CoV values obtained for patients and for 
controls for either MD or FA overall, therefore these were pooled for further analysis. There were 
significant differences in CoV for both MD and FA (p < 0.001) between methods. The results from 
comparisons between individual methods are given in Figures 7-3 & 7-4 and Table 7-2. 
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Figure 7-3; Mean coefficient of variation for MD measurements for each placement method 
Figure 7-4: Mean coefficient of variation for FA measurements for each placement method 
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Method CoV (MD) % (s.d.) CoV (FA) % (s.d.) 
Method 1 Hippocampus outlined on MD map 1.399 (1.304) 7.318 (7.325) 
Method 2 Hippocampus outlined on b0 map 7.082 (6.623) 13.362 (12.797) 
Method 3 3x2x2 voxel ROI placed on MD map 1.571 (1.576) 5.692 (6.231) 
Method 4 Hippocampus outlined on T1-weighted 
image and transformed onto FA map 
0.939 (0.939) 2.701 (2.037) 
Table 7-2: Comparison of different methods of ROI placement 
After adjusting for multiple comparisons, Methods 3 and 4 were found to be significantly 
better than Method 2 for MD and FA measurements (p <0.001). Method 1 was also significantly 
better than Method 2 for FA measurements (p <0.001) but not for MD measurements. Although it 
did not reach statistical significance Method 4 gave lower CoV values for both MD and FA 
measurements than Methods 1 and 3.  
7.2.3.2 Varying ROI size 
  
The results of varying the size of the ROI in Method 3 are shown in Figure 7-5 and 7-6. There 
was a significant effect of ROI size on mean CoV (p < 0.001). The smallest CoV was obtained for a 
2x2x2 voxel ROI for MD measurements and a 3x2x3 voxel ROI for FA measurements. The lowest CoV 
obtained by this method was still greater than that from Method 4 (dotted line in Figure 7-5/7-6). 
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Figure 7-5: Coefficient of Variation for MD measurements by ROI size 
Figure 7-6: Coefficient of Variation for FA measurements by ROI size 
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7.2.3.3 Variance within each ROI 
 
While the CoV values for MD or FA measurements did not significantly differentiate 
Methods 1, 3 and 4, there were differences in the actual MD and FA values reported. Univariate 
ANOVA with post-hoc analysis and Bonferroni correction for multiple comparisons was used to 
compare mean MD/FA values and the range of MD/FA values within each ROI across methods. 
Method 4 (co-registration of ROI from the T1-weighted scan) gave consistently higher values for MD 
(p < 0.001) and lower values for FA (p < 0.001) across all the hippocampi studied (Table 7-3). There 
were also differences in the standard deviation and range of MD/FA values within each ROI 
according to the method used to draw that ROI (Table 7-4). Method 4 produced ROIs with a 
significantly higher standard deviation (p < 0.001) and range (p < 0.001) of MD values within them 
compared to either of the other two methods. Considering FA values, Method 1 showed the greatest 
range and variance of voxel values within each ROI compared to either Method 3 (p < 0.001) or 
Method 4 (p = 0.006).   
 Mean MD value (mm/s) (s.d.) Mean FA value (s.d.) 
Method 1 (ROI on MD map) 0.9161 x 10-3 (0.0428) 0.1472 (0.0343) 
Method 3 (Fixed size ROI) 0.9101 x 10-3 (0.0520) 0.1391 (0.0342) 
Method 4 (Co-registered ROI) 0.9860 x 10-3 (0.0496) 0.1262 (0.0124) 
Table 7-3: Mean MD and FA values for Methods 1, 3 and 4 
 Mean s.d. of 
MD 
Mean MD 
range (mm/s) 
Mean s.d. of 
FA 
Mean FA 
range 
Method 1 (ROI on MD map) 0.07242 x 10-3 0.29406 x 10-3 0.05501 0.23588 
Method 3 (Fixed size ROI) 0.07941 x 10-3 0.25971 x 10-3 0.04052 0.13679 
Method 4 (Co-registered ROI) 0.13430 x 10-3 0.70916 x 10-3 0.04372 0.20383 
Table 7-4: The range and standard deviation of MD and FA reported from voxels within each ROI 
 
7.2.4 Conclusion 
 
It is apparent from our validation study that a significant increase in the reliability of 
hippocampal MD and FA measurements is possible by optimising the method of ROI placement. 
Method 2 appears to be significantly less reliable than the others and should not be recommended, 
despite its use in previous studies of the hippocampus (188;190). Method 2 was therefore not 
considered further in the more detailed ROI analysis.  
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Examining the values reported from individual voxels within each ROI, we found that firstly, 
there is a large range of MD and FA values measured within any individual ROI. Secondly, the 
variation in FA values between voxels is proportionally much greater than that for MD. The range of 
MD values from individual voxels within each ROI for Method 4 was significantly higher than that for 
Method 1 or 3 (p < 0.001). This means that the voxels within each ROI created by Method 4 contain 
a larger range of MD values than those created by Method 3 or Method 1. In particular, they contain 
more voxels with higher MD values. They also contain a larger range of FA values than ROIs created 
by Method 3, but these values are, on average, lower. The most likely explanation is that Method 4 
suffers from partial volume effects through inclusion of edge voxels that contain a proportion of the 
surrounding cerebrospinal fluid (CSF) as well as hippocampus. Increased MD and decreased FA 
measurements would be expected if this was the case (250;251).  
In contrast ROIs created by Method 1 have similar mean MD and FA values to those from 
Method 3 but a much higher range of FA values within each ROI. As there are some very high (over 
0.4) FA values recorded using Method 1 one possible interpretation of this is extension of the ROI 
outside the hippocampus and into adjacent white matter tracts, with the partial volume effect from 
CSF acting to offset the alterations in mean values. 
The final decision of which method to use must take into account many different considerations. 
Our results show that the most reproducible measurements can be obtained by delineating an ROI 
on a high resolution anatomical scan and co-registering this to the diffusion data (Method 4), 
although Methods 1 and 3 are not significantly less reproducible and remain viable alternatives. 
Both Method 1 and Method 4 attempt to cover the entire hippocampus, whereas Method 3 only 
samples from a portion of the hippocampal head. Therefore Method 3 will not be sensitive to 
changes occurring elsewhere in the hippocampus that do not affect the head. If this is considered 
likely then one of the other methods should be preferred. However because of its limited coverage, 
Method 3 is less susceptible to partial volume effects, as it avoids edge voxels, therefore if there is 
an a priori reason to believe changes may be limited to or maximal in the hippocampal head then 
there may be advantages to using this. 
If Method 3 is used, then the size of the ROI matters; if the ROI is too small or too large then the 
CoV starts to increase. There appears to be a trade-off with smaller ROIs enabling more accurate 
placement within the hippocampus and avoiding partial volume effects. On the other hand larger 
ROIs are  less susceptible to noise as they are able to average the signal over a larger number of 
voxels. For any individual set of scanning parameters and anatomical structure we suggest that there 
is an optimal size for an ROI. For this cohort the optimum appeared to be between 8 and 12 voxels.  
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Of the methods that provide whole hippocampal coverage, then Method 4 appears to be 
preferable to Method 1. Both will suffer from partial volume effects on edge voxels, but it seems 
likely that Method 1 carries a greater risk of sampling outside the hippocampus altogether due to 
the low resolution of the diffusion maps. By using the MD map to define an ROI, to be subsequently 
used to measure MD values, Method 1 also introduces another potential confounding factor. Using 
the high resolution T1-weighted images to define the hippocampus, as in Method 4 avoids both of 
these issues. It may also allow more sampling of the hippocampal body and tail, as this area is 
difficult to define using the MD maps alone (since at this resolution it will be only 1-2 voxels in cross-
section).  
Of the methods tested in this study, Methods 3 and 4 seem to be the methods of choice. Both 
give a CoV comparable or lower than those reported previously (247;252;253) and are therefore 
viable options for use in clinical studies. For our further analysis, Method 4 was preferred due to its 
lower variability and greater coverage of the hippocampus. 
 
7.3 Hippocampal DTI following CSE  
 
7.3.1 Aims 
 
Having established a reliable method for measuring MD and FA within the human 
hippocampus, this present study aimed to use this technique to investigate hippocampal MD and FA 
following CSE. The objective was to use diffusion metrics to track hippocampal changes occurring 
post-CSE and identify potential biomarkers for TLE-MTS. We hypothesised that CSE will lead to 
increases in MD and decreases in FA in patients with CSE compared to healthy controls in patients 
that are at risk of developing MTS.  
7.3.2 Methods 
7.3.2.1 MRI sequences 
The same MRI sequences were used as described in 7.2.2.1. 
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7.3.2.2 ROI placement 
All measurements were taken using Method 4 described above in 7.2.2.4. This was applied 
to all patient scans who tolerated the DTI sequences and hippocampal MD/FA measurements 
recorded as described. Each hippocampus was measured at least once by two separate observers.  
7.3.2.3 Statistical analysis 
 
Measurements for each hippocampus were averaged to provide mean left and right 
hippocampal MD/FA for each MRI scan. Hippocampal MD and FA were plotted against age for 
control subjects and tested for possible dependencies with Spearman’s Rank correlation and linear 
regression. Cross-sectional analysis was then performed between aetiological groups and controls at 
each time-point using univariate ANOVA with appropriate corrections for covariates. Bonferroni 
post-hoc tests were used to compare each aetiological group with controls individually. 
Spearman’s Rank correlation was used to test the age dependency of MD in each 
aetiological group after removal of obvious outliers. Correction for multiple comparisons was not 
performed in order to maintain the sensitivity of a negative result.  
Linear regression was performed to estimate the rate of change of left and right 
hippocampal MD and FA in each child over time in a similar manner as described in Chapter 6 for 
estimating hippocampal growth rates. A standard error was estimated from each linear regression 
and values greater than 1.96 S.E. above zero were reported as significant increases in MD. Similarly 
for FA, values greater than 1.96 S.E above or below zero are reported as significant increases or 
decreases in FA over time respectively. 
Univariate ANOVA, t-tests and χ-squared tests were used as appropriate to test for 
differences in the effects of clinical factors on the rates of change of MD/FA. MD/FA measurements 
and rates of change were also compared with cognitive scores using linear regression with age 
correction as appropriate. 
7.3.3 Subjects 
 
 25 control subjects and 56 patients tolerated DTI at their initial scan and were entered into 
this analysis. A detailed breakdown of patient numbers for each aetiological group is given in Table 
7-5. 
132 | P a g e  T h e  c o n s e q u e n c e s  o f  c h i l d h o o d  c o n v u l s i v e  s t a t u s  
e p i l e p t i c u s  
 
 Controls PFS Symptomatic CSE Other CSE 
Initial MRI 25 30 19 17 
6 month follow-up - 18 12 13 
1 year follow-up - 19 15 9 
Table 7-5: Number of patients tolerating DTI by group 
7.3.4 Normal changes in MD and FA 
7.3.4.1 Results 
 
 Hippocampal MD on both sides in healthy controls showed a clear age dependency, with a 
sharp decrease in MD in the first few months of life followed by a steady slower decline thereafter 
(Figure 7-7). One control subject was excluded from further analysis as an outlier (left and right 
hippocampi circled in red on Figure 7-7). Linear regression showed a strong linear relationship 
between MD and ln(age). The regression coefficients and p-values are given in Table 7-6.  
 Regression coefficient 
(10-3mm3/s/ln(years)) 
95% confidence 
interval 
p-value 
Left hippocampus  (1.027) -0.032 -0.052 –  -0.012 0.003 
Right hippocampus (1.031) -0.042 -0.060 – -0.024 <0.001 
Table 7-6: Regression coefficients for MD vs. ln(age) in control subjects 
 
Figure 7-7: Graphs showing hippocampal mean diffusivity against age (A) and log-transformed age (B) in control subjects 
(Red circles show outliers excluded from the regression analyses) 
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In contrast, our control cohort did not appear to show a relationship between age and 
hippocampal FA on either side (Figure 7-8). There was no significant correlation between FA and age 
or ln(age) with linear regression. 
 
Figure 7-8: Hippocampal fractional anisotropy against age in control subjects 
 
7.3.4.2 Discussion 
 
 Previous studies of MD and FA in normal populations have shown that they continue 
to develop as children grow older, with reductions in MD and increases in FA being seen with 
increasing age(254), although few studies have been able to look closely at children between 1 and 3 
years of age. Our study is unique in including such a broad age range of children, from 1 month up to 
16 years and therefore exact comparison with previous studies of normal development, which 
typically contain a larger number of children in a more tightly constrained age range, is difficult. The 
timing and magnitude of MD/FA changes alters between brain regions and is thought to reflect the 
differential rates of maturation of different brain structures(255). In addition there have been no 
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longitudinal studies performed that specifically look at the normal development of MD/FA within the 
hippocampus. 
The control hippocampal FA values reported in this study are lower than those reported in 
previous studies on adults (186;187;189), which have typically reported mean control FA values of 
0.15-0.23. In the one study of children with TLE (190), hippocampal FA values of 0.17 – 0.25 were 
reported in healthy controls, with a mean of 0.21. By contrast FA in our control sample was between 
0.10 - 0.16, with a mean of 0.12. Children are known to have lower FA values across a number of 
brain areas than adults; FA increases with age as their brains mature (255-257). The very young 
nature of our control group, with a mean age of 4.14 years, meant that lower absolute FA values 
would be expected compared to either adult studies or the previous report of hippocampal MD/FA 
in children by Kimiwada et al.(190), which included control children with a mean age of 11.0 years. 
Furthermore, the signal-to-noise ratio (SNR)of the particular MRI sequences used to calculate FA 
have a large effect on the absolute values obtained, with increased SNR leading to lower FA(258). As 
the majority of previous studies used relatively fewer repetitions and diffusion directions, while 20 
non-co-linear diffusion directions, were used in this study, each repeated 3 times and averaged, the 
improved SNR obtained by this DTI sequence provides a further factor causing lower absolute FA 
values.  
It is apparent that, despite efforts to optimise the methodology used to measure 
hippocampal MD/FA, this remains difficult. Unmeasurable errors, such as partial volume effects 
mean that there is a greater degree of uncertainty over the measurements, and it is difficult to be 
certain if this is the reason we were unable to detect a significant relationship between age and 
hippocampal FA in control children or if there is truly no age effect in our cohort. 
 
7.3.5 Cross-sectional mean MD and FA after CSE 
7.3.5.1 Results – mean MD 
 
There was a significant effect of group on MD at 1 month post-CSE for both left (p < 0.001) 
and right (p = 0.007) hippocampi after correcting for age. There was a significant interaction 
between aetiology and age (p=0.007), Post-hoc analysis with correction for multiple comparisons 
showed that children with symptomatic CSE had significantly higher hippocampal MD than controls 
on both left (p = 0.001, mean difference 0.13x10-3mm2/s) and right (p<0.001, mean difference 
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0.11x10-3mm2/s) sides.  However, neither of the other groups had significantly different MD values in 
the hippocampus from controls. 
At 6 months post-CSE children with symptomatic CSE continued to have significantly higher 
MD than controls (p=0.022, mean difference 0.04 x10-3mm2/s , left; p=0.002, mean difference 
0.09x10-3mm2/s, right). At 1 year post-CSE this difference was still present, but did not reach 
significance on the left (p=0.317, mean difference 0.04x10-3 mm2/s) though it remained significant on 
the right (p=0.015, mean difference 0.07x10-3mm2/s) hippocampal MD.  
Summaries of hippocampal MD at each time-point are given in Table 7-7. p-values represent 
difference from control subjects. 
Group Mean adjusted left 
hippocampal MD (10
-3 
mm
2
/s) 
p-value Mean adjusted right 
hippocampal MD (10
-3
mm
2
/s) 
p-value 
1 month post-CSE (MD is evaluated at ln(age)=0.92) 
Controls 1.001 (0.959 - 1.043)  0.993 (0.960 - 1.027)  
PFS 1.005 (0.967 - 1.043) NS 1.000 (0.970 - 1.031) NS 
Symptomatic CSE 1.131 (1.083 - 1.178) 0.001* 1.106 (1.069 - 1.144) < 0.001* 
Other CSE 1.047 (0.995 - 1.099) NS 1.026 (0.985 - 1.068) NS 
6 months post-CSE (MD is evaluated at ln(age)=1.05) 
Controls 0.993 (0.978 - 1.009)  0.987 (0.961 - 1.013)  
PFS 1.004 (0.986 - 1.022) NS 1.013 (0.982 - 1.044) NS 
Symptomatic CSE 1.034 (1.012 - 1.056) 0.022* 1.074 (1.036 - 1.111) 0.002* 
Other CSE 1.020 (0.999 - 1.042) 0.284 1.002 (0.965 - 1.039) NS 
1 year post-CSE (MD is evaluated at ln(age)=1.17) 
Controls 0.988 (0.962 - 1.014)  0.982 (0.952 - 1.012)  
PFS 0.977 (0.948 - 1.006) NS 0.982 (0.949 - 1.015) NS 
Symptomatic CSE 1.030 (0.997 - 1.062) 0.317 1.058 (1.020 - 1.095) 0.015* 
Other CSE 0.996 (0.953 - 1.040) NS 0.999 (0.950 - 1.049) NS 
Figures in brackets represent 95% confidence intervals 
p-values quoted represent differences from control means with Bonferroni correction for multiple comparisons  
*statistically significant at p < 0.05 NS: Not statistically significant 
Table 7-7: Age-adjusted hippocampal mean diffusivity compared with control values 
7.3.5.2 Results – mean FA 
 
There were no significant differences detected in hippocampal FA between each aetiological 
group at 1 month or 6 months post-CSE. At 1 year post-CSE there was a significant effect of aetiology 
on FA in the left hippocampus (p = 0.001) but not right (p = 0.289). Post-hoc analysis with correction 
for multiple comparisons showed that children with symptomatic CSE had significantly reduced left 
hippocampal FA compared to children with PFS (p = 0.008) and a trend towards lower FA than 
control children (p = 0.051). No significant effect was seen in the right hippocampus.  
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7.3.5.3 Discussion 
 
 Children with symptomatic CSE were found to have higher hippocampal MD than controls. 
While this did not reach statistical significance after correction for multiple comparisons for the left 
hippocampus at 12 months follow-up (Table 7-7), left hippocampal MD was significantly higher in 
children with symptomatic CSE than controls at one month and also at 6 months post-CSE. This is in 
keeping with the reductions in hippocampal volume demonstrated in Chapter 6 and is similarly likely 
to represent the effect of the previous neuronal injury or abnormality. It is difficult to attribute this 
to a direct effect of CSE given the high proportion of this group who had widespread pre-existing 
structural abnormalities.  
 Children with PFS or other CSE did not differ systematically from controls in hippocampal 
MD, again similar to the previous analysis of hippocampal volumes. 
No significant differences were found in hippocampal FA, which may be a result of the 
natural variation in hippocampal FA at this age masking any individual alterations.  
While, as previously discussed, there have been a number of studies showing increases in 
hippocampal MD and possible reductions in FA in established MTS in both adults(186-189;191) and 
children(190), it is unknown whether this is an early or late change in the course of the disease. Only 
one of the children in our cohort had clinical evidence of MTS and this child had hippocampal MD on 
the affected side much greater than any of the other children in this study (Figure 7-11). No children 
developed MTS over the course of this study, therefore it not surprising that we did not find 
significant alterations in hippocampal MD or FA except in the group of children with pre-existing 
neuronal damage/abnormality (symptomatic CSE). This would point towards the increase in MD and 
decrease in FA being a relatively late change in the evolution of seizure-associated neuronal injury.  
 
7.3.6 Developmental changes in MD 
7.3.6.1 Results 
 
Graphs of left and right hippocampal MD against ln(age) for each aetiological group at each 
time point are shown in Figure 7-9. The dotted lines represent the predicted values from control 
measurements.  
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Figure 7-9: 
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After removal of outliers (circled in red on Figure 7-9), Spearman’s Rank Correlation was 
performed on each patient group at each time point in order to test the relationship between age 
and MD within each group. Bootstrapping using 1000 random samples with replacement was used 
to generate 95% confidence intervals for ρ. The results are given in Table 7-8 with uncorrected p-
values. 
 
 Left Right 
 ρ (95% CI) p-value ρ (95% CI) p-value 
Controls -0.429 (-0.739 - -0.003) 0.037* -0.568 (-0.822 - -0.162) 0.004* 
1 month post-CSE  
PFS -0.323 (-0.631 - 0.103) 0.081 -0.354 (-0.681 - 0.104) 0.055 
Symptomatic CSE -0.730 (-0.914 - -0.378) 0.001* -0.522 (-0.895 - -0.007) 0.032* 
Other CSE -0.750 (-0.894 - -0.472) 0.001* -0.598 (-0.814 - -0.163) 0.011* 
6 months post-CSE  
PFS -0.172 (-0.711 - 0.422) 0.494 0.160 (-0.306 - 0.636) 0.526 
Symptomatic CSE -0.813 (-0.983 - -0.355) 0.001* -0.564 (-0.915 - 0.218) 0.090 
Other CSE -0.637 (-0.885 - -0.138) 0.019* -0.773 (-0.981 - -0.139) 0.005* 
1 year post-CSE  
PFS -0.418 (-0.748 - 0.039) 0.075 -0.407 (-0.685 - --0.028) 0.084 
Symptomatic CSE -0.349 (-0.782 - 0.310) 0.221 -0.203 (-0.861 - 0.605) 0.527 
Other CSE -0.700 (-1.000 - 0.077) 0.036* -0.933 (-1.000 - -0.568) <0.001* 
* p < 0.05 (uncorrected values) 
Table 7-8: Correlations between MD and age in children following CSE 
 Unlike the control group, children with PFS did not show a significant correlation between 
age and MD at any time point; children with symptomatic CSE also did not show a significant 
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correlation between age and hippocampal MD at 1 year post-CSE, although they did before this time 
point; children with other CSE showed significant correlations at all points.  
7.3.6.2 Discussion 
 
 Although hippocampal MD was strongly correlated with age in control subjects, and this 
remained true for children with other CSE, this was not the case for children with PFS, who did not 
show a significant relationship between age and MD at any time point. 
 Similar findings were noted in a previous study of children with PFS by Scott et al(232), 
which investigated a cohort of 14 children 4-8 months after PFS. They found that the children with 
PFS did not show an age dependency of hippocampal MD, whereas MD in control subjects was 
strongly correlated to log10(age). We have now shown that this remains a consistent finding up to 1 
year post-CSE, and that it appears to only occur in children with PFS, as opposed to those with other 
types of CSE: children with epilepsy-related and other non-symptomatic CSE displayed a strong age 
dependency of hippocampal MD at all stages and, while children with symptomatic CSE did not show 
such a strong correlation at their final follow-up scan, the large number of outlying measurements 
that were excluded from the correlation analysis suggest that in many cases the hippocampus was 
involved in the underlying pathology as has previously been discussed.  
 The rate of change of MD is greatest during the first 2 years of life, and decreases thereafter, 
therefore the strongest correlations should be found in younger children. This makes the lack of age 
dependency in the children with PFS, who were the youngest of all the groups, more striking.  
 For this to be a seizure-related effect, an age-dependant effect of PFS on hippocampal MD 
would have to be hypothesised, such that younger children show a decrease in hippocampal MD 
following PFS, whereas older children show an increase. However, given that children with other 
forms of CSE are not so affected, this seems biologically implausible. One alternative hypothesis 
would be that hippocampal MD develops differently in children with PFS: i.e. there is a 
developmental abnormality in children with PFS, likely caused by genetic factors, such as have been 
shown to play an important role in susceptibility to febrile seizures(259). This would imply that brain 
maturation is different in some children, rendering them susceptible to having prolonged seizures 
with certain febrile illnesses. This difference in developmental trajectory is then expressed as a lower 
hippocampal MD at a younger age and a subsequent failure of hippocampal MD to then reduce at 
the child gets older. 
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 This effect appears to be specific to children with PFS, as children with epilepsy-related and 
other, non-symptomatic forms of CSE continued to show a strong age dependency at all time-points. 
We would therefore suggest that this represents evidence to support the hypothesis that there is a 
transient developmental abnormality in children with PFS rather than an effect of CSE.  
7.3.7 Changes in MD and FA over time 
 
7.3.7.1 Changes in MD over time 
 
Serial plots of MD in individual children are shown in Figure 7-10, 7-11 and 7-12. Children 
who showed significant decreases in hippocampal volume (Chapter 6) are highlighted in red/light 
blue. 
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Figure 7-10: Hippocampal MD in children with PFS 
Numbers in red refer to patient identifiers 
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  Figure 7-11: Hippocampal MD in children with symptomatic CSE 
Numbers in black on graph refer to patient identifiers 
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Figure 7-12: Hippocampal MD in children with other CSE 
  
Numbers in red refer to patient identifiers 
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The change in hippocampal MD over time was estimated in each child using similar 
methodology as that described in Chapter 6 to estimate hippocampal growth rates. There was no 
significant effect of aetiological group on the rate of change of hippocampal MD after adjusting for 
age, although there was a trend for children with PFS to show smaller rates of reduction in MD than 
either of the other groups (Univariate ANOVA, p=0.063). Of the 50 children who had serial DTI 
enabling longitudinal analysis, 6 showed a significant increase (defined as >1.96 S.E. above 0) in 
hippocampal MD over the course of their follow-up. 4 of these were children with prolonged febrile 
seizures and 2 were children with other CSE. Their details are summarised in Table 7-9, of note all 
but one child had subsequent recurrent seizures (whether febrile or otherwise) during the follow-up 
period, although the numbers were too small for formal statistical analysis. 
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Patient 
ID 
Age at 
CSE (yrs) 
Duration 
CSE (mins) 
Previous seizure 
history 
Focal Continuous Clinical information Medication Seizure 
recurrence 
Hippocampal 
changes 
2 3.72 32 4 previous SFS N Y PFS N 2 further SFS Large bilateral 
increases in MD 
7 1.32 40 None N N PFS N None Bilateral increases 
in MD 
17 3.13 45 4 previous SFS, 1 
previous PFS 
N Y PFS N 2 further PFS Increase in right MD 
and decrease in left 
hippocampal 
volume 
56 1.20 40 None Y N PFS N 1 further SFS Small increase in 
left MD 
47 15.5 100 Daily seizures N N Cryptogenic epilepsy VPA, TPM Daily myoclonic 
jerks 
Bilateral increases 
in MD and 
decreases in 
hippocampal 
volume 
121 1.70 45 2 previous 
afebrile seizures 
Y N Idiopathic epilepsy VPA Continuing 
seizures every 
1-2 months 
Small increase in 
right MD 
SFS: Short febrile seizure (<30 mins duration) 
PFS: Prolonged febrile seizure 
VPA: Sodium Valproate 
TPM: Topiramate 
Table 7-9: Clinical details of patients showing increases in hippocampal mean diffusivity following CSE
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7.3.7.2 Changes in FA over time 
  
Serial plots of FA in individual children are shown in Figure 7-13, 7-14 and 7-15. Children who 
showed significant decreases in hippocampal volume (Chapter 6) are highlighted in red/light blue. As 
there was no significant difference between left and right hippocampal FA rates of change over time 
(paired t-test, p =0.760), rates of change were averaged for comparison. There was no significant 
effect of aetiology on the rate of hippocampal FA change (Univariate ANOVA, p = 0.309), but those 
children with recurrent seizures did show greater reductions in FA than those who did not have 
subsequent seizures (2-sample t-test; -0.002/year vs. -0.031/year, p = 0.044).   
 28/50 children with longitudinal FA measurements showed decreases in hippocampal FA 
greater than 1.96 standard errors over the study period and 13/50 showed increases greater than 
1.96 standard errors. There were no children who showed a significant decrease on one side and an 
increase in the contralateral hippocampus. Again, there was no significant difference between 
aetiological groups in the proportion of children showing either a decrease (Fisher’s exact test, p = 
0.270) or increase (Fisher’s exact test, p=0.919) in hippocampal FA, however a significantly greater 
proportion of those showing decreases in FA had recurrent seizures (Chi-squared, p=0.044).  
Numbers are summarised in Table 7-10. 
 Number Decreases in hippocampal FA Increases in hippocampal FA 
A
e
ti
o
lo
gi
ca
l 
gr
o
u
p
 
PFS 23 10 (43.5%) 6 (26.1%) 
Symptomatic CSE 14 10 (71.4%) 3 (21.4%) 
Other CSE 13 8 (61.5%) 4 (30.8%) 
Recurrent seizures 26 18 (69.2%) 5 (19.2%) 
No further seizures 24 10 (41.7%) 8 (33.3%) 
Table 7-10: Children showing decreases and increases in hippocampal FA following CSE 
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Figure 7-13: Hippocampal Fractional anisotropy in children with PFS 
Numbers in red refer to patient identifiers 
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Figure 7-14: Hippocampal FA in children with symptomatic CSE 
Numbers in black on graph refer to patient identifiers 
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Figure 7-15: Hippocampal FA in children with other CSE 
 
Numbers in red refer to patient identifiers 
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7.3.7.3 Discussion 
  
 Looking more closely at changes in individual children, we know that hippocampal MD 
decreases with age in normal children. The same was true for the majority of our patient cohort, 
who also showed decreasing MD with age. Only 6 children showed a significant increase (>1.96 S.E. 
above 0) in hippocampal MD over the course of the study. This was bilateral in 3 and unilateral in 3 
and occurred predominantly in children with PFS (4/6) or cryptogenic or idiopathic epilepsy (2/6) 
with further seizures following their episode of CSE. Only 1 child had had no subsequent seizures 
during the follow-up period and they showed the smallest increase in MD. There also appeared to be 
an effect of seizure recurrence on changes in FA, with those children with recurrent seizures showing 
a significantly greater decline in FA over the study period. This suggests that a small proportion of 
children will show increases in MD and decreases in FA following CSE, changes suggestive of an 
evolving hippocampal injury that may be a precursor to TLE-MTS, and that subsequent seizure 
activity may play an important part in this evolution.  
Figure 7-16 summarises the relationship between changes in MD, FA and hippocampal 
volume. Interestingly the children showing abnormal MD/FA trajectories were not necessarily the 
same children who showed loss of hippocampal volume. This raises the possibility that the 
pathological processes occurring following CSE can be separated; with neuronal reorganisation, 
causing changes in MD/FA not necessarily dependant on the neuronal cell loss that is thought to 
underlie volume loss. Since the hippocampus in established MTS has been shown to display both 
neuronal cell loss(112) and signs of structural reorganisation such as gliosis, mossy fibre sprouting 
and neurogenesis(260) it may be that both processes need to be activated in order for MTS to occur. 
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7.3.5 Cognitive outcome 
7.3.5.1 MD/FA and cognition 
 
 Mean hippocampal MD and FA at each time point, were tested against cognitive scores at 1 
month and at 1 year. No significant correlations were found. There were likewise no significant 
correlations between the rate of change in MD and either cognitive score.  
 There was however a significant association between both initial and final cognitive scores 
and the rate of change in FA, with greater increases in FA being associated with improved cognitive 
scores at both 1 month (p = 0.005) and 1 year (p = 0.041).  The association with cognitive scores at 1 
month remained even after adjusted ICV was added into the model (p = 0.008) but disappeared by 1 
year (p = 0.221). 
7.3.5.2 Discussion 
Given that we have previously shown that the most important determinants of cognitive 
outcome appear to be overall ICV and the presence/absence of structural abnormalities, the finding 
that greater rates of increase in hippocampal FA were associated with improved cognitive scores 
needs to be interpreted carefully. FA is thought to reflect the microstructural organisation of the 
brain and has previously been shown to increase as the brain develops (255;261). Increases in FA are 
therefore thought to represent maturation of brain structures and increased organisation.  
Figure 7-16: Venn diagram summarising the numbers of children with changes in 
hippocampal MD, FA and/or volume 
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One possibility may be that greater increases in hippocampal FA are related to or indicative 
of improved neurodevelopment and therefore lead to improved cognitive outcomes. However, as 
the relationship between the rates of increase of hippocampal FA over the study period was 
stronger for the initial cognitive scores rather than final ones, there are some problems with this 
interpretation. An alternative explanation is that it is the better cognitive ability at study entry that 
provides an improved substrate for subsequent neurodevelopment and therefore leads to larger 
increases in hippocampal FA over the study period. Since initial and final cognitive scores are 
correlated, there would then be a residual association between the rate of increase in FA and 
cognitive outcome 1 year post-CSE. Some evidence for this may come from the fact that if age-
adjusted ICV is added to the model as well then while there remains a significant association 
between the rate of FA change and the initial cognitive score, this is no longer significant at 1 year 
post-CSE.  
7.4 Conclusion 
 
 In this chapter we have shown that despite developing a reproducible and reliable method 
of measuring hippocampal MD and FA, measurement remains problematic. We were able to 
demonstrate a proportion of children displaying abnormal trajectories in DTI metrics following CSE, 
with some children showing increases in MD and others decreases in FA, suggestive of those 
changes seen in MTS. Since these are not the same children that were demonstrated in Chapter 6 to 
show loss of hippocampal volume post-CSE, apart from 2 children who showed volume loss, 
increases in MD and decreases in FA (Figure 7-16), we speculate that there may be separate 
processes at work, all of which are required for the development of clinical TLE:MTS.  
We have also shown that children with PFS do not show the normal relationship between 
age and hippocampal MD in contrast to healthy controls and children with other CSE. One plausible 
explanation for this is that there is a developmental abnormality in children with PFS leading to 
different trajectories in the development of neuronal organisation and that this is one of the factors 
that renders them vulnerable to having PFS at this age. 
 The focus of our study so far has been on the hippocampus, because of its central role in 
MTS. However it is well recognised that MTS is rarely limited to the hippocampus. In the subsequent 
chapter we will expand our focus and investigate broader changes in the rest of the brain following 
CSE. 
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Chapter 8: Tract-based Spatial Statistics 
 
8.1 Introduction 
 
 In the previous two chapters we have focussed on hippocampal changes following CSE, 
looking both at hippocampal volume measurements and DTI metrics. We have shown that there are 
progressive losses of hippocampal volume in a proportion of children post-CSE and that this occurs 
in CSE of any aetiology. 
There is a body of evidence that MTS is not limited to the hippocampus but often affects 
other, extra-hippocampal structures (262;263). Animal studies have suggested that several other 
cortical and subcortical regions are affected by CSE, in addition to the hippocampal changes seen 
(54;264). In addition CSE in humans has been associated with widespread changes in cortical grey 
matter(265) and subcortical white matter tracts(266;267). It is likely therefore that any initial 
damage sustained in an episode of childhood CSE is not restricted to the hippocampus but rather 
that pathological changes elsewhere in the brain may play an important part in the pathogenesis of 
TLE-MTS. The aim of this chapter is to consider structural brain changes outside of the hippocampus. 
  As using an ROI based approach for whole brain analysis is time consuming and difficult to 
standardise for multiple brain regions, an automated, whole-brain analysis technique, tract-based 
spatial statistics (TBSS) was used to investigate MD and FA changes following CSE across the entire 
white matter skeleton. The results from the TBSS investigations were then cross-validated using 
manual ROI-based measurements of MD/FA in selected white matter tracts.  
8.1.1 Tract-based Spatial Statistics 
  
Tract-based Spatial Statistics (TBSS) (196) is an operator independent, automated technique 
for performing whole-brain analysis of diffusion data. It relies on the identification of a common 
white matter skeleton, containing orientation independent information about the major white 
matter tracts from subjects’ FA maps.  
This has several advantages over other automated techniques for the comparison of DTI-based 
metrics, such as voxel based morphometry (VBM) or traditional manual techniques involving ROI 
placement. Unlike manual ROI placement, it allows analysis of the entire white matter skeleton and 
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avoids having to make a priori assumptions about the likely location of white matter differences. 
Since it is not operator dependent, it also avoids subjective errors of ROI placement. In contrast to 
VBM-style approaches, TBSS does not require perfect alignment between images as location 
information is summarised by projection onto the common white matter skeleton, hence it may be 
less prone to inaccuracies caused by mis-registration(196). Altering the size of the smoothing kernel 
used in VBM can drastically alter the results of the analysis, especially when processing DTI 
data(268), as TBSS does not require smoothing of the image, this removes a further element of 
subjectivity.  
Previous use of TBSS in patients with TLE has shown decreases in FA in several white matter 
tracts including the anterior corpus callosum, parahippocampal gyrus and temporal gyri(269) and so 
there are reasons to believe that white matter abnormalities may be present following PFS. 
8.1.2 Region of interest analysis 
 
 Although TBSS will identify areas along the white matter skeleton where there is a significant 
deviation in FA or MD from a control population , it does not provide information as to the 
magnitude of such differences, nor is it able to take into account of longitudinal information. It is 
useful therefore to combine TBSS analysis with an independent approach to quantitative 
measurements of DTI metrics. To this end a region of interest was placed in the genu of the corpus 
callosum on each scan in order to quantitate the MD/FA changes in this region. The genu was 
chosen out of all the tracts where differences were shown on the initial TBSS analysis because its 
large size and anatomy allowed consistent placement of an ROI. The mean MD/FA were also 
calculated across the entire white matter skeleton  This allows cross-validation of the results from 
the TBSS analysis, as well as providing a quantitative insight into how these metrics are changing 
across time points. 
8.2 Methods 
 
 As these automated techniques rely on accurate transformation of MRI images from 
disparate subjects into a common image space (co-registration) in order to allow like for like 
comparisons, this analysis was restricted to comparison of children with PFS with healthy controls in 
the same age range. The reasons for this were three-fold.   Firstly the heterogeneous nature of the 
other two patient groups and specifically the high incidence of structural brain abnormalities in 
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children with non-PFS CSE (as discussed in Chapter 5) meant that accurate co-registration was not 
possible using standard tools.  Secondly the time taken to perform the analysis rises exponentially 
with the number of subjects therefore this was restricted in order to complete this within a 
reasonable time period.  Finally, limiting the number of different comparisons performed reduces 
the probability of a type-I error 
8.2.1 TBSS 
 
TBSS was performed using standard scripts contained within the FSL software package (249). 
Using the FA maps generated during the previous study, all subjects' FA data were aligned into a 
common space using the nonlinear registration tool FNIRT(270). As the age range of our subjects 
precluded using a standard target image, TBSS was used to perform a search for the most 
representative image in our cohort and each subject was then aligned to that image. Finally that 
image is affine-transformed into 1x1x1mm MNI52 space and the same transformation applied to all 
of the other subjects. This was done separately for each time-point. Visual inspection of each subject 
was then used to check the validity of the registration and any subjects where the registration had 
not worked were removed from the analysis.  
Next, the mean FA composite image was created by averaging all the warped FA images and 
thinned to create a mean FA skeleton which represents the centres of all tracts common to the 
group using a threshold of FA > 0.2. Each subject's aligned FA data was then projected onto the 
mean FA skeleton. A similar transformation was applied to each subjects’ MD data and both datasets 
were analysed using voxelwise cross-subject statistics.  
The randomise tool from FSL was used to perform voxel-wise permutation-based 
nonparametric two-sample permutation tests(271) with 5000 permutations on the aligned white 
matter skeleton to look for significant differences in MD or FA between children with PFS and 
healthy controls. Threshold-free cluster enhancement(272) was used to detect significant clusters of 
voxels and correct for multiple comparisons. Gender, age and ICV were entered as covariates and 
coded as nuisance variables. The results were stored as statistical maps with p < 0.05 taken as the 
level of significance.  Results were visualised as colour-coded masks thresholded at p <0.05 and 
superimposed on the mean FA map and skeleton. Localisation of differences was performed with 
the aid of a reference white matter atlas. 
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Each of these stages was repeated for each time point, thus 3 separate TBSS analyses were 
made comparing patients at each time point with controls. As the age of the patients was changing 
at each time point, control subjects were chosen from our cohort to approximately match the age 
range of the patients at each time point, so each comparison was made to a different, albeit 
overlapping set of control subjects.  
8.2.2 Region of interest analysis 
 
  The genu of the corpus callosum was chosen for the region of interest analysis. Since 
defining the entirety of a specific white matter tract using manual methods is not possible from a 
structural MRI scan(273), a small, fixed-size ROI (similar to Method 3 from Section 7.2.2.3) was 
placed within the centre of the genu using the co-registered T1-weighted image as this provided the 
best contrast for white matter visualisation without confounding FA measurements.  
 A 3x2x2 voxel ROI was placed within the genu of the corpus callosum. This was defined as 
the most anterior coronal slice where the two halves of the corpus callosum meet in the midline. A 
3x2 voxel ROI was drawn on this slice and the slice immediately posterior to it (Figure 8-1). 
 The mean white matter skeleton generated during the TBSS analysis was also saved and 
used as an ROI to measure the mean MD and FA over the entire skeleton in each subject.  
  fslview was used for image visualisation and ROI placement. fslstats was then used 
to calculate the mean MD and FA within each ROI. 
 Univariate ANOVA was used to compare MD/FA within each ROI between control and 
patient groups at each time point. Age, ICV and gender were entered as co-variates to mimic the 
TBSS analysis. Adjusted MD/FA values were determined after correction for age/ICV. Spearman’s 
Figure 8-1: Example ROI placed in the genu of the corpus calllosum 
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rank correlation with Bonferroni correction for multiple comparisons was used to explore the age 
dependencies of both MD and FA within each ROI. 
8.3 Results 
 
 29/33 children with PFS had imaging suitable for use in this analysis. The remaining 4 
children did not tolerate the DTI sequence and so were excluded.  18 children from the control 
group tolerated DTI and were in a suitable age range. The numbers of children with PFS at each time 
point and their ages are summarised in Table 8-1. 
 Number Mean age (years) Median age 
(years) 
Age range 
(years) 
Controls 18 2.76 2.45 0.62 – 5.47 
Patients 1 month post-PFS 29 2.06 1.86 0.85 – 4.61 
Patients 6 months post-PFS 17 2.40 2.25 1.19 – 5.01 
Patients 1 year post-PFS 19 2.99 2.90 1.76 – 5.45 
Table 8-1: Age ranges and numbers of children at each time point 
 For the TBSS analysis the control group was split into three overlapping cohorts to 
approximately match the age range of the patients at each time point. The numbers of children and 
ages for each control cohort are given in Table 8-2. 
 Number Mean age (years) Age range (years) 
Controls for 1 month group 15 2.24 0.62 – 4.28 
Controls for 6 months group 12 2.95 1.69 – 5.25 
Controls for 1 year group 14 3.31 1.69 – 5.47 
Table 8-2: Age ranges for control group at each time point 
8.3.1 TBSS   
8.3.1.1Fractional Anisotropy 
The results of the TBSS analysis comparing FA between patient and control groups are shown in 
Figure 8-2 and 8-3. There were widespread reductions in FA at 1 month post-CSE in multiple white 
matter tracts. These reductions were largely still present at 6 months post-CSE. However by 1 year 
post-CSE there were no longer any significant differences between patients and controls. A summary 
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of the tracts found to be involved at each time point is given in Table 8-3. There were no areas found 
with significantly higher FA in patients than controls at any time point. 
In order to ascertain if these reductions were an artefact due to the selection of the control 
groups, the analysis was repeated comparing patients at each time point against the entire control 
group. Reductions were still apparent at 1 and 6 months post-CSE and the regions affected did not 
appear to differ to any great extent. 
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Major white matter tracts showing decreases in FA 
Anterior thalamic radiation (left + right) 
Inferior fronto-orbital fasciculus (left + right) 
Anterior corona radiata (left + right) 
Genu of the corpus callosum 
Body of the corpus callosum 
Splenium of the corpus callosum 
Internal capsule 
External capsule 
Inferior fronto-occipital fasciculus (left + right) 
Uncinate fasciculus (left + right) 
Table 8-3: White matter tracts showing significant decreases in FA at 1 and 6 months post-PFS 
8.3.1.2 Mean Diffusivity 
 
 There were no significant differences in MD along the white matter skeleton found between 
patients and controls at any time point. 
8.3.2 Regions of Interest 
 
 Mean values for FA within the genu of the corpus callosum and over the entire FA skeleton 
for each of the groups are given in Table 8-4. FA within the genu was significantly lower in patients 
than controls 1 month post-PFS (p=0.006). It then increased at 6 months post-PFS, but was still 
significantly below control values (p=0.042) before appearing to normalise by 1 year post-PFS. FA 
values over the entire TBSS skeleton were also significantly below control values at 1 month (p = 
0.012) and 6 months (p = 0.021) post-PFS, but had normalised by 1 year post-PFS.  
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 Mean FA adjusted for age, ICV and gender (95%CI) 
 Genu p-value Mean skeleton p-value 
Controls 0.648 (0.649 – 
0.718) 
 0.367 (0.356 - 0.378)  
Patients 
1 month 
post –PFS 
0.607 (0.577 – 
0.637) 
0.006* 0.346 (0.338 - 0.355) 0.012* 
Patients 
6 months 
post –PFS 
0.618 (0.579 – 
0.656) 
0.042* 0.345 (0.334 - 0.356) 0.021* 
Patients 
1 year 
post –PFS 
0.676 (0.638 – 
0.715) 
1 0.360 (0.349 - 0.370) 1 
p-values represent significance levels for differences from control values and are adjusted for multiple comparisons 
* p < 0.05 after Bonferroni correction for multiple comparisons 
Table 8-4: Mean adjusted FA within ROIs and comparison with control values 
 Mean values for MD within each ROI for each of the groups are given in Table 8-5 below.  
 Mean MD adjusted for age, ICV and gender within each ROI (95% CI) 
 Genu p-value Mean skeleton p-value 
Controls 0.989 (0.930 – 1.048)  0.897 (0.881 - 0.913)  
Patients 1 
month post 
–PFS 
1.017 (0.966 – 1.068) 1 0.905 (0.892 - 0.918) 1 
Patients 6 
months 
post –PFS 
1.000 (0.935 – 1.065) 1 0.911 (0.894 - 0.927) 0.726 
Patients 1 
year post –
PFS 
0.954 (0.890 – 1.019) 1 0.892 (0.876 - 0.908) 1 
p-values represent significance levels for differences from control values and are adjusted for multiple comparisons 
Table 8-5: Mean adjusted MD within ROIs and comparison with control values 
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8.4 Discussion 
8.4.1 MD and FA changes following PFS 
 
Widespread reductions in FA were detected in multiple white matter tracts following PFS 
using TBSS analysis. These changes were apparent at 1 month post-PFS, and remained until at least 6 
months post-PFS. However, by 1 year they appeared to have resolved. Manual region of interest 
analysis also showed similar reductions in FA in the genu, with gradual normalisation over time, as 
did analysis over the entire white matter skeleton. No differences in MD were detected using TBSS 
and, this was also the case using the ROI analyses.  
8.4.2 Methodological comparisons 
 
 Comparison of different methods of measuring white matter FA and MD is important, as 
neither TBSS nor an ROI-based approach can truly be held as a “gold standard”. There was good 
concordance between the results of the TBSS and the ROI analysis. Manual ROI placement is subject 
to problems with reproducibility as discussed in Chapter 7.2, which is a potential source of Type II 
error, and this has been commented on by other research groups(274;275); TBSS, although it avoids 
any subjective bias from ROI selection and placement relies on automated co-registration 
techniques  can be difficult to assess and validate. That concordant results have been achieved using 
these different techniques allows greater confidence to be placed on these findings. 
8.4.3 Interpretation 
 
 Apart from isolated case reports (158;266;276), there have been no studies looking at 
diffusion metrics following CSE to date, and none have used whole brain analysis techniques such as 
TBSS. Those cases that have been reported in the literature have shown acute changes in cortical 
grey and sub-cortical white matter on DWI, with a reduced apparent diffusion coefficient (ADC). 
These acute MRI changes have generally been observed to resolve on follow-up imaging by 1 month, 
although the majority of the cases reported have had residual neurological problems with associated 
chronic MRI changes. These reports therefore represent the most severe extreme outcomes of CSE 
and cannot be taken as being representative of the general population, nor can they prove causality. 
They do show, however, that permanent neurological alterations can occur following CSE, and 
changes in DWI and ADC form part of the acute response to CSE. No reports of reductions in FA 
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following CSE have been reported, however FA is rarely measured in a clinical context and the one 
study that did calculate FA(158) only reported FA values from the fornix, which remained constant. 
A number of more systematic DTI studies have taken place in patients with established TLE, 
which are summarised in Table 8-6.  These studies have used a mixture of manual ROI 
measurements, VBM and TBSS to compare various diffusion metrics in patients with TLE (both with 
and without MTS) and controls. There have been consistent reports of reduced FA in portions of the 
corpus callosum, external capsule, ipsilateral temporal lobe and frontal white matter tracts.  
Study Method Patient group Summary of findings 
Arfanakis et al 
2002(263) 
Manual ROI 15 patients with 
TLE 
Reduced FA in external capsule and 
posterior corpus callosum 
 
Thivard et al 
2005(187) 
SPM-DTI 
Manual ROI 
35 patients with 
TLE:MTS 
Reduced FA in corpus callosum and 
ipsilateral temporal stem. Increased MD 
in ipsilateral temporal lobe 
Gross et al 2006(277) Manual ROI 11 patients with 
TLE:MTS 
Reduced FA in genu of corpus callosum 
and external capsule. Increased MD in 
genu, splenium and external capsule 
Focke et al 2008(278) TBSS/VBM 33 patients with 
TLE:MTS 
Reduced FA in ipsilateral temporal lobe, 
external capsule, temporal lobe white 
matter and frontal white matter tracts 
Riley et al 2010(279) TBSS 12 patients with 
TLE 
Reduced FA in ipsilateral anterior and 
mesial temporal lobe, cerebellum and 
contralateral frontoparietal lobe 
Afzali et al 2011(269) TBSS 19 patients with 
TLE (seizure-
free) 
Reduced FA in ipsilateral temporal lobe, 
anterior corpus callosum, external 
capsule and frontal gyri 
Table 8-6: DTI studies of patients with TLE 
None of our cohort of 29 children with PFS has a diagnosis of epilepsy, nor do they show any 
visible clinical changes on MRI or gross neurological abnormalities, as previously discussed in 
Chapter 5. It is then perhaps not surprising that our findings differ from previous reports of patients 
with established TLE or case reports of CSE. While reductions in FA were found in all of the areas 
highlighted in previous studies of TLE, children with PFS showed more dramatic FA reductions across 
many more portions of the white matter skeleton compared to the limited regional changes that 
have been reported in TLE. Unlike the case reports of CSE, they did not display focal abnormalities 
on DWI or increases in ADC/MD, but as the mean time of our first scan was 1 month post-CSE, any 
acute changes would have been expected to have resolved.  
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The predominant changes reported post-CSE have been increases in hippocampal 
volume(46), T2 hyper-intensities(159) and increases in ADC(266), all of which have been linked with 
transient and self-resolving oedema(46;232). If the reductions in FA are a direct effect of the PFS and 
represent seizure-related neuronal damage, then as FA remains reduced past the time when the 
acute oedematous changes are expected to resolve, it would appear to represent a longer term 
disruption of white matter, with a slower time-course to resolution. Reductions in FA may represent 
other aspects of this initial injury that cause more long lasting impairments of white matter integrity, 
such as a degree of myelin breakdown or axonal degeneration (174;280) and therefore recovery of 
FA may lag behind the other measures. That it does recover may be a reflection of the resilience of 
the developing brain or the relatively mild nature of any PFS associated injury, and suggest that 
neuronal repair and reorganisation following PFS is by and large a successful process, although as 
demonstrated in Chapter 6, failure to detect differences at a group level does not necessarily 
exclude the possibility that there may be a proportion of individuals in which changes do not resolve. 
However given the time course of FA reductions noted on ROI analysis, there may be 
alternative explanations that are also biologically compelling: there are reasons to believe that the 
reductions in FA may not represent seizure-associated neuronal injury, but rather may be a transient 
developmental stage in children with a predisposition to PFS.  
Febrile seizures are most common between the ages of 6 months-5 years, with a peak 
incidence at 18 months(281). They are also known to have a large genetic component to their 
aetiology(282). Furthermore epidemiological data shows that if children who had one PFS have a 
further febrile convulsion, it is likely to also be prolonged(283), reflecting a possible underlying 
predisposition to prolonged seizures. The implications of this are that children who suffer a PFS are 
highly likely to have pre-existing abnormalities that predispose them to have a prolonged seizure in 
response to a febrile illness and that these abnormalities are likely to have a genetic basis. It is 
possible that this increased susceptibility is related to aberrant white matter development, and it is 
this that is causing the global reductions in white matter FA. As children grow and develop, their 
susceptibility to febrile seizures decreases and it may be expected that any associated structural 
abnormality will also normalise - i.e. that the abnormality predisposing these children to PFS 
represents an aberrant developmental stage that normalises with age. If this is the case, then as the 
children in our cohort were a year older by the end of the study and all were over 18 months in 
chronological age, then the normalisation of FA values taking place during this time should represent 
an end to their risk of further febrile seizures.  
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8.4.4 Conclusions 
 
In this chapter, we have shown that there are widespread reductions in FA detected 
following PFS and that these are still present at 6 months post-PFS, but normalise by 1 year post-PFS. 
We have advanced two possible explanations for these observations:  namely that they may 
represent longer term seizure-induced injury, with subsequent healing and normalisation; 
alternatively that they represent an aberrant developmental phase that is related to these children’s 
susceptibility to PFS and that subsequently normalises as their risk of febrile seizures decreases. 
Both of these hypotheses would provide a plausible explanation for the data presented in this 
chapter, however further data will be required to determine which should be preferred.  
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 CHAPTER 9 - DISCUSSION 
 
 The aim of this thesis has been to explore the structural and functional consequences of 
childhood CSE in the first year post-CSE. In this concluding section I will attempt to draw together 
the separate strands of evidence that have been presented in the separate preceding chapters and 
set out the conclusions that we have drawn as to our original hypotheses. I will also discuss the 
potential limitations of our study and suggest improvements that could be made to address these in 
the future. Finally I will advance some suggestions for future research to build on the findings of this 
study. 
9.1 CSE and structural brain abnormalities 
  
 One of the initial findings to come out of this study was an estimate of the incidence of 
structural brain abnormalities in children with CSE. 31.2% of the children in this study were found to 
have an abnormality on MRI following their episode of CSE, although it seems clear that the majority 
of these predate the seizure and are likely to represent causes rather than outcomes of CSE. This is a 
similar proportion to that reported in previous studies of neuroimaging after CSE(202), although this 
is the first reported cohort to have complete MRI coverage. It was also possible to demonstrate that 
abnormalities picked up on CT in the acute situation differ from those detected by MRI. 
 Of note no children with PFS were found to have clinically significant abnormalities on their 
initial MRI scan and none had evidence of pre-existing MTS. This implies that detectable, pre-existing 
hippocampal damage is not a significant cause of PFS and that children with PFS have grossly normal 
hippocampi at the time of CSE. 
9.2 Hippocampal injury following CSE 
 
One of the primary aims of this thesis was to investigate hippocampal injury following CSE and 
specifically any link between PFS and the development of MTS. To this end detailed measurements 
of hippocampal volume were made in children over the initial year following an episode of CSE. A 
pre-requisite for the development of MTS is a loss of hippocampal volume and we found that 20-
30% of children show evidence of hippocampal volume loss in the year following CSE. This is the first 
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study to demonstrate hippocampal volume loss in an unselected cohort of children with CSE and is 
an important first step to quantifying the risk of developing TLE-MTS following CSE.  
The proportion of children showing volume loss was not significantly different between 
aetiological groups, showing that hippocampal injury following CSE is not limited to PFS, but can 
occur with all types of prolonged seizures. There are qualitative differences in the pattern of injury 
between children with CSE of different aetiologies, with unilateral damage being more common in 
PFS and bilateral damage in other CSE. We hypothesise that the consequences of this injury may 
differ as TLE-MTS is usually a lateralised condition.  
Volume loss is not the only marker of hippocampal damage, and another change that has been 
reported in TLE-MTS is an increase in hippocampal MD. Evidence of increases in hippocampal MD 
was found in a smaller proportion of children, not all of whom showed significant volume loss. The 
majority of these children had PFS, although overall numbers were too small for formal statistical 
analysis. Increases in hippocampal MD would be consistent with developing MTS and it is possible 
that the disassociation with hippocampal volume loss indicates separate pathological processes at 
work. If both are necessary for the development of TLE-MTS then the increased incidence of the 
latter in PFS may explain the association between TLE-MTS and PFS but not other forms of CSE.  
DTI changes were associated with an increased incidence of recurrent seizures (both febrile and 
afebrile) over the follow-up period, and there was a borderline association between volume loss and 
the number of previous febrile seizures, so it may be that further episodes of seizure activity play an 
important part in the evolution to MTS.  
9.3 Developmental abnormalities in children with PFS 
 
 It is recognised that febrile seizures show an extremely strong familial inheritance, with 
studies estimating the heritability at around 65-75%(284;285). Likewise animal models and genetic 
linkage studies have demonstrated the contribution of individual genes to febrile seizure 
susceptibility(259). As seizures, including febrile seizures are a neurological phenomenon, it seems 
reasonable to assume that the genetic contribution to febrile seizure susceptibility is modulated via 
an effect on brain structure and/or development. There is therefore reason to believe that, although 
children who are classified as having a PFS were believed to be neurologically and developmentally 
normal prior to their episode of CSE, there may in fact be subtle differences in brain structure and/or 
neuronal connectivity. We have previously reported on functional differences in the form of 
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impaired cognitive function and impaired performance on specific tests of hippocampal memory in 
children with PFS compared to healthy controls and to population norms, both at 1 month post-PFS 
and persisting at 1 year(173).  
 Since the occurrence of febrile seizures and PFS is age limited, the underlying abnormalities 
may likewise be transient and normalise as the child grows older. Two findings from our study lead 
us to believe that this may be the case: 
 Firstly we found widespread reductions in FA compared to healthy controls across the white 
matter skeleton in children following PFS. These reductions persisted at 6 months post-PFS but were 
no longer apparent at 1 year. While this could represent a long-lasting, but ultimately transient 
seizure effect, we believe that it is more plausible that this represents abnormal white matter 
development in children with PFS that normalises as the susceptibility to febrile seizures wanes.  
 Secondly in most children hippocampal MD decreases with increasing age, however this age 
dependency is not apparent in children with PFS, unlike healthy controls or those with other forms 
of CSE. This finding would be consistent with children with PFS having a different developmental 
trajectory. While only limited conclusions can be drawn from a negative result, this finding would be 
consistent with a developmental abnormality in children with PFS rather than a seizure-related 
insult.  
9.4 Cognitive changes post-CSE 
 
We have previously reported impaired cognitive function in children with CSE, both at 1 
month post-CSE and persisting at 1 year(173). Children with PFS had better outcomes than children 
with symptomatic or other CSE, but were still under-performing compared to both healthy controls 
and population norms.  
Since children with an abnormal MRI had significantly reduced cognitive outcome, a large 
part of the cognitive impairment in children with symptomatic CSE is likely to be attributable to 
structural brain abnormalities, which largely pre-date the episode of CSE. The importance of this was 
further demonstrated by volumetric analysis, which showed that while both hippocampal volume 
and overall intracranial volume were predictive of cognitive outcome, intracranial volume was the 
stronger predictor, suggesting that is the overall condition of the brain that is the primary 
determinant rather than any specific injury, whether CSE-induced or not.   
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9.5 Limitations 
 
There are a number of weaknesses in our current study that set limits on the strength of the 
conclusions that can be drawn.  
The most important limitation of this study was the lack of longitudinal assessment of our 
control group. Ideally serial cognitive assessment and imaging would have been done on the control 
group as well as our patient cohort to enable a direct comparison with normal growth and 
development. However, given the difficulty of performing MRI in this age group, it was not feasible 
to repeat these investigations in our control group.  Repeating the general anaesthesia for those 
children who were having MRI for clinical reasons would not have been appropriate. Repeating an 
MRI scan on those controls that had their MRI during natural sleep after one year would have 
required additional sedation. It may have been possible to repeat imaging on the older children who 
were able to tolerate an awake scan, but this would not have covered the age range most of interest 
to us in this study and was not judged worthwhile to attempt on only a small proportion of our 
control group.  
The lack of longitudinal data on a control population limits the comparisons that are possible 
with patient groups. For longitudinal measurements, such as hippocampal growth rates, we have 
been restricted to indirect comparisons with an estimated model of normal growth. While this is a 
valid technique, and has resulted in the detection of significant differences, direct comparison with a 
control group may offer greater statistical power and robustness.  
Cross-sectional comparisons have also involved the serial comparison of a changing patient 
population against a static control group. While the children contained in our control cohort have 
been adjusted to match the age range of patients at each time point, we recognise that this may be 
prone to bias and therefore it is difficult to be completely certain that the differences that have been 
found on sequential cross-sectional analyses are not due to a developmental process taking place in 
patients, but which does not show up in our static control sample. Since the majority of our cross-
sectional analyses found no difference between patients and controls, the practical impact of this 
may be limited for this study. 
A further limitation was the large proportion of children who were notified to us with CSE 
but did not take part in the study, whether for clinical reasons or because of parental reluctance. 
While every effort was made to recruit as representative a sample of children as possible, inevitably 
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we were not able to collect full details from those children who were either not willing or not able to 
attend GOSH to take part in the study and therefore it is not possible to completely exclude other 
unknown areas of bias in our cohort. From the details available to us the clinical characteristics of 
participants did not differ significantly from non-participants except in the aetiology of CSE, as 
previously discussed in Chapter 3. This does limit the applicability of our findings to children with the 
most severe acute or previous neuronal injuries, who were underrepresented in our cohort, but in 
these children the severity of the injury would be expected to overwhelm any additional significance 
of CSE itself.  
Although the duration of CSE did not appear to have a significant effect on any of the 
parameters measured in this study, it remains a possibility that seizure duration is important but 
that a ceiling effect is seen at 30 minutes. Assessment of this would require the recruitment of a 
cohort of children with brief seizures for comparison, alongside the existing group of healthy 
controls. 
9.6 Future directions 
 
 This current study has provided important information about the consequences of childhood 
CSE; nevertheless, some questions remain unanswered. Given the initial abnormalities identified 
during this study, extended follow-up of this cohort of children over the following 10-15 years will be 
necessary to answer the ultimate question of which, if any, go on to develop clinical TLE-MTS. We 
hope to repeat the clinical, neuroimaging and cognitive assessments in these children after a 
suitable time period of at least 10 years. This will help to resolve which of our speculations as to the 
nature of hippocampal injury post-CSE are correct and which are not. In the meantime further 
relevant information will be produced from an extended 8 year follow-up of a previous cohort of 
children with CSE that is being collected by other members of our research group. 
 Further analysis of the data available from this cohort of children also has the potential to 
provide more valuable answers and clarification of some of the hypotheses generated from this 
thesis. The use of techniques such as tractography to further probe the white matter changes 
identified following PFS in Chapter 8 would allow further delineation of the magnitude and time-
course of these changes.  
 In addition, if the speculation about underlying developmental abnormalities in children 
with PFS is correct, it is possible that not all children with these abnormalities will encounter the 
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required environmental triggers to have a PFS. Similar abnormalities may be present in children at 
risk of developing PFS, such as siblings or those with a strong family history of febrile seizures. 
Investigation of these children may be of benefit in exploring whether similar developmental 
abnormalities are present independent of the initiating factor of CSE and identify the role of the 
seizure itself in the pathology previously identified. Investigation of genetic factors and associating 
these with structural or functional brain changes may also help to elucidate the underlying 
pathology behind PFS.  
  
9.7 Conclusion 
 
In conclusion, through the analysis of this unique cohort of children, a number of important 
findings have been discovered: 
 31.2% of children with CSE have structural abnormalities on their MRI scan 
o The majority of these are pre-existing abnormalities and clinically significant 
abnormalities are rare in children with PFS 
 Children with symptomatic CSE have reduced hippocampal volumes and increased 
hippocampal MD compared with controls and children with other forms of CSE 
 Long term hippocampal damage, as represented by hippocampal volume loss, 
occurs in 20-30% of children following CSE and is not restricted to children with PFS 
 Decreases in FA are found across multiple white matter tracts in the months 
following PFS and appear to resolve by 1 year 
 There may be developmental abnormalities in the evolution of hippocampal MD in 
children with PFS 
Over the course of this thesis we have shown that hippocampal injury following CSE is not 
just associated with PFS and that brain abnormalities following PFS are not just limited to the 
hippocampus. Rather both concepts need to be widened to include the risk of hippocampal injury in 
non-PFS CSE and the presence of other developmental abnormalities found in children with PFS.  
 Changes in metrics such as hippocampal growth, mean diffusivity and fractional anisotropy 
following CSE may also herald pathological changes within the hippocampus and are likely to play a 
part in the evolution of MTS. However, while we have demonstrated that such changes occur in 
almost a third of children, the ultimate significance of these changes will only be apparent with 
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further follow-up of our cohort. It does appear that the development of MTS may be a multi-step 
process and that recurrent seizures or CSE may play a role.  
 Subtle cognitive impairments and developmental abnormalities found in children with PFS 
suggest that these children are not entirely normal compared to healthy controls, and that this likely 
pre-dates the episode of CSE. Whilst the development of TLE-MTS remains a concern, attention also 
needs to be paid to the underlying problem that renders these children susceptible to PFS and the 
potential ramifications of this. 
 
Of our original hypotheses, we have shown that: 
1. Children with symptomatic CSE do indeed have worse structural and clinical 
outcomes than children with other forms of CSE 
2. Hippocampal injury following CSE however, does not appear to be specifically 
associated with PFS, but occurs across all forms of CSE 
3. While cognitive performance was associated with hippocampal volume, overall 
ICV appeared to be a stronger predictor and the degree of volume loss did not 
appear to be predictive of cognitive outcomes. 
Further investigation of the link between CSE, MTS and eventual clinical as well as cognitive 
outcomes will hopefully answer many of these questions. This study has provided important 
evidence that long term hippocampal damage does occur following CSE and that children with PFS 
display significant abnormalities that are likely developmental in origin. Extended follow-up from this 
and other similar cohorts should aid in drawing definitive conclusions about the likelihood of 
developing TLE-MTS following childhood CSE as well as the significance of the other abnormalities 
presented as part of this thesis. 
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 APPENDIX A: LIST OF PARTICIPATING HOSPITALS 
 
 Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH 
 Barnet Hospital, Wellhouse Lane, Barnet, Herts EN5 3DJ 
 Chase Farm Hospital, The Ridgeway, Enfield, Middlesex EN2 8JL 
 Chelsea & Westminster Hospital, 369 Fulham Road  London SW10 9NH 
 Central Middlesex Hospital, Acton Lane, Park Royal,  London NW10 7NS 
 Evelina Children’s Hospital, Westminster Bridge Road, London, SE1 7EH 
 Hammersmith Hospital, Du Cane Road , London W12 0HS 
 Hillingdon Hospital, Pield Heath Road, Uxbridge, UB8 3NN 
 Homerton University Hospital, Homerton Row, London E9 6SR 
 King George Hospital, Barley Lane, Ilford IG3 8XE 
 Newham University Hospital, Glen Road, Plaistow, London E13 8SL 
 North Middlesex University Hospital, Sterling Way, London N18 1QX 
 Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ 
 Queen’s Hospital, Rom Valley Way, Romford, Essex RM7 0AG 
 Royal Free Hospital, Pond Street, London NW3 2QG 
 Royal London Hospital, Whitechapel Road, Whitechapel, London E1 1BB 
 St George’s Hospital, Blackshaw Road, Tooting, London SW17 0QT 
 St Mary’s Hospital, Praed Street, Paddington  London W2 1NY 
 University College Hospital , 235 Euston Road , London NW1 2BU 
 Watford General Hospital, Vicarage Road, Watford, Herts WD18 0HB 
 Whipp’s Cross Universiyt Hospital, Whipps Cross Road, London E11 1NR 
 The Whittington Hospital, Magdala Avenue, London, N19 5NF 
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 APPENDIX B: MRI PROTOCOLS 
 
Scan sequence for children under 2 years of age 
Duration 
(mins) 
Sequence  No. slices Echo time (ms) Repeat 
time (ms) 
Thickness Gap Matrix Field of view Flip Inversion 
time 
05:34 3dFLASH 1 slab (176 
slices) 
4.94 11 1mm 20% (0.2mm) 224x256 256x224 15 0 
06:04 T2 MAPS 
Relaxometry 
1 16 echoes from 
22ms to 352ms 
2400 5 - 150x256 210x157.5 180 - 
03:19 T2 DESTIR 
AXIAL 
22 14 6170 4 40% (1.6mm) 216x320 200x200 150 130 
03:19 T2 DESTIR 
CORONAL 
22 14 6170 4 40% (1.6mm) 216x320 200x200 150 130 
06:27 TIR Coronal 20 68 7000 5 10% (0.5mm) 192x256 200x200 150 350 
12:96 3x20 DTI 45 89 6300 2.5 mm none 96x96 240x240 N/A  
01:04 DWI 19 96 2700 5mm 30% (1.5 mm) 128x128 230x230 - - 
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Scan sequence for children over 2 years of age 
Duration 
(mins) 
Sequence No. slices Echo time (ms) Repeat 
time (ms) 
Thickness Gap Matrix Field of 
view 
Flip 
 
Inversion time 
05:34 3dFLASH 1 slab (176 
slices) 
4.94 11 1mm 20% (0.2mm) 224x256 256x224 15 0 
06:04 T2 MAPS 
Relaxometry 
1 16 echoes from 
22ms to 352m 
2400 5mm - 150x256 210x157.5 180 - 
03:13 Axial TSE T2 25 101 4920 4mm 40% of 4mm 
= 1.6mm 
245x384 220x175.3 150 - 
03:13 Coronal TSE 
T2 
25 101 4920 4mm 40% of 4mm 
= 1.6mm 
245x384 220x175.3 150 - 
08:08 3DFLAIR 176 Slices 353 6000 1mm none 256x256 256 150 2200 
12:96 3x20 DTI 45 89 6300 2.5 mm none 96x96 240 N/A -  
01:04 DWI 19 96 2700 5mm 30% (1.5 mm) 128x128 230 - - 
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 APPENDIX C: SEDATION PROTOCOL 
 
Patient Preparation 
 
All patients must: 
 Have hospital notes 
 Be weighed 
 Have local anaesthetic cream applied 
 Be fasted: 4 hours for food/milk, 2 hours for clear fluids / breast milk 
 Have baseline observations recorded inc. SpO2 
 A metal check must be completed 
 A full patient assessment should be conducted to establish suitability for sedation 
 Sleep deprivation should be encouraged 
 
Ward patients must be accompanied by a parent / guardian AND a ward nurse 
 
General Protocol 
 
 Small infants under 5 kgs = feed and wrap 
 Co-operative children of any age: may be persuaded to lie still without sedation, please seek 
the assistance of play therapist 
 Children with severe developmental delay, behavioural difficulties, OR over the age of 8 may 
need a GA 
 All other patients should be considered for sedation 
 
Sedation Medications 
 
Under 5 kgs  -Nil, feed and wrap 
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5-15 kgs  -Chloral Hydrate 100mg/kg (max 1 g) 
12-20 kgs -Triclofos 100mg/kg (max 2 g) + Alimemezine 2mg/kg (max 60 mg) 
20 kgs +  -Triclofos 100mg/kg (max 2g) + Alimemizine 2 mg/kg (max 60 mg) 
 
Intravenous ‘Top-Up’ 
 
To be considered if oral sedation is not effective after 45-60 minutes 
IV Diazemuls 1mg/kg (max dose 20mg) 
[Given slowly, in increments] 
 
Sedation Reversal 
 
Flumazenil 10-20 mcg/kg 
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 APPENDIX D: PUBLICATIONS ARISING FROM THIS THESIS 
 
Published research papers: 
1. Management of convulsive status epilepticus in children. Yoong M, Chin RF, Scott RC. Arch 
Dis Child Educ Pract Ed. 2009 Feb;94(1):1-9. 
2. The role of magnetic resonance imaging in the follow-up of children with convulsive status 
epilepticus. Michael Yoong, Rodica Mardari, Marina Martinos, Christopher Clark, Kling 
Chong, Brian Neville, Richard Chin, Rod Scott. Developmental Medicine & Child Neurology - 
Early online publication Jan 2012 http://dx.doi.org/10.1111.j.1469-8749.2011.04202.x.  
Abstracts: 
1. “Hippocampal growth following childhood convulsive status epilepticus” M Yoong, MM 
Martins, CA Clark, RFM Chin, RC Scott DMCN 54:S1 58 2012 
2. “The Developmental Profiles of Children Following CSE” Martinos M, Yoong M, Scott RC, de 
Haan M Epilepsia 50:288 2009  
3. “Measuring diffusion tensor parameters in the human hippocampus: region of interest 
placement" Yoong M, Martinos M, Clark CA, Chin RF, Scott RC. In Proceedings of the ISMRM 
17th Scientific Meeting & Exhibition, Honolulu, USA 
4. “Hippocampal volume is reduced in children with other forms of convulsive status 
epilepticus compared to children with prolonged febrile seizures.” Yoong M, Martinos M, 
Clark CA, Chin RF, Scott RC. Abstracts from the 9th European Congress on Epilepsy Epilepsia 
June 2010 Volume 51 Supplement s4: 138 
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